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General summary 
Multiple myeloma (MM) is a plasma cell cancer where, despite the major therapeutic advances, still 
the majority of patients relapse and develop a non-responsive disease. Consequently, there’s an 
urgent need for the development of new treatments. In the bone marrow microenvironment of MM 
patients most of the immune cells are numerically and functionally impaired, such as the invariant 
natural killer T (iNKT) cell. iNKT cells are unconventional lipid antigen reactive T cells bearing an 
important role in anti-tumor immunity. Mechanisms behind their deficiency still remain enigmatic 
and controlling iNKT cell activity has been challenging so far, affecting their implications in 
immunotherapy. Therefore, we aimed to unravel and overcome possible mechanisms causing iNKT 
cell deficiency in MM. 
We were the first to reveal the leptin – leptin receptor (LR) axis as an important iNKT cell-mediating 
pathway in MM and anti-tumor immunity. Progressive increase of leptin serum and LR expression 
levels were observed on iNKT cells during MM progression, both in human disease and the 5T33MM 
model. Functional analyses proved leptin to profoundly inhibit the iNKT cell functionality in vitro and 
in vivo. iNKT anergy, a major drawback in iNKT-based therapies, was strongly alleviated by blocking 
LR signaling and an almost complete tumor protection in the 5T33MM model was observed when 
iNKT cells were stimulated in presence of a LR antagonist. Finally, by means of intravital microscopy, 
we provided for the first time a detailed time course of iNKT cell dynamics in response to α-GalCer. In 
the second part of the PhD project, the implication of checkpoint molecule PD-1, in mediating iNKT 
cell deficiency and deficiencies in mucosal-associated invariant T (MAIT) cells, another invariant T cell 
subset, was evaluated. Not only iNKT cells but also MAIT cells proved to be numerically and 
functionally impaired in MM, a novel observation that hasn’t been reported before. Moreover, we 
discovered MAIT cell deficiency to be correlated with reduced iNKT cell numbers in MM patients. 
MAIT cells showed poor activation by α-GalCer-stimulated iNKT cells, illustrating a dysfunctional 
interaction between MAIT and iNKT cells. Remarkably, elevated PD-1 levels were found on both iNKT 
and MAIT cells. Treatment with a combination of PD-1 blockade and iNKT stimulation was able to 
significantly rescue the functionality of iNKT and MAIT cells and conferred superior tumor protection 
in the 5T33MM model. 
To conclude, the work presented here uncovers new promising ways to enhance the anti-tumor 
function of iNKT cells by restoring them from their state of anergy in MM. The results are 
groundbreaking in the fight against cancer, as they reveal a new form of cancer immunotherapy, 
potentially shining a light on future therapeutic avenues for aggressive cancers with currently limited 
treatment options as well. 
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Algemene samenvatting 
Multipel myeloom (MM) is een plasmacel kanker waarbij, ondanks de grote therapeutische 
vooruitgang, de meeste patënten nog steeds hervallen door ontwikkeling van resistentie aan huidige 
therapieën. De nood aan nieuwe geneesmiddelen voor de behandeling van MM is bijgevolg groot. 
Binnen de MM beenmerg micro-omgeving zijn de meeste immuuncellen functioneel deficiënt, 
waaronder ook de invariante natural killer T (iNKT) cel. iNKT cellen zijn niet conventionele lipid 
antigeen reactieve T cellen met een belangerijke rol in anti-tumor immuniteit. In MM zijn ze echter 
sterk gereduceerd in aantal, alsook functioneel defect. De ongekende mechanismen achter hun 
deficiëntie en het controleren van de iNKT cel activiteit in MM blijft tot op heden een grote uitdaging 
en een obstakel in hun gebruik als immmunotherapie. Bijgevolg hadden we tot doel om de mogelijke 
mechanismen die leiden tot iNKT cel deficiëntie in MM te ontrafelen en te overwinnen.  
Als eerste onthulde we de leptine - leptine receptor (LR) as als een belangrijke iNKT cel-gemedieerde 
pathway in MM en in anti-tumor immuniteit. We toonden, zowel in het 5T33MM muismodel als in 
MM patiënten, een progressieve stijging van zowel serum leptine als LR expressie levels aan op iNKT 
cellen. Functionele analyses bewezen dat leptine de iNKT cel functionaliteit zowel in vitro als in vivo 
sterk inhibeerde. iNKT anergie, een grote problematiek in iNKT gebaseerde therapieën, werd ook 
sterk opgeheven door blokkade van de LR signalisatie. Het gebruik van een LR antagonist in 
combinatie met iNKT stimulatie leidde tot een spectaculaire tumorprotectie in het 5T33MM model. 
Tot slot, konden we door middel van intravitale microscopie, voor het eerst een gedetaileerd 
tijdsverloop van de iNKT-celdynamiek als reactie op α-GalCer visualiseren. In het tweede deel van dit 
doctoraatsproject werd de implicatie van checkpoint molecule PD-1, in iNKT cel deficiëntie alsook bij 
de mucosaal-geassocieerde invariante T (MAIT) cel, een andere invariante T cel, in MM bekeken. 
Naast iNKT cellen bleken ook MAIT cellen in MM deficiënt te zijn in aantal en functie. Bovendien was 
de MAIT cel deficiëntie gecorreleerd met de gereduceerde iNKT cel aantallen in MM patiënten. MAIT 
cellen vertoonden een verminderde activatie door α-GalCer-gestimuleerde iNKT cellen, wat wees op 
een dysfunctionele interactie tussen MAIT en iNKT cellen. Opmerkelijk, waren de PD-1 levels op 
zowel de MAIT als iNKT cellen verhoogd. Combinatie van PD-1 inhibitie en iNKT stimulatie leidde tot 
een significant herstel van de iNKT en MAIT cel functionaliteit en resulteerde in een superieure 
kankerbescherming in het 5T33MM model. 
In conclusie, tonen we in dit werk nieuwe veelbelovende manieren aan om de anti-tumorale iNKT 
functionaliteit in MM te verbeteren door hun anergische toestand te herstellen. De resultaten zijn 
baanbrekend in de strijd tegen kanker, aangezien ze een nieuwe vorm van kankerimmunotherapie 
onthullen, die ook een hoopgevende therapeutische optie kan vormen voor andere aggressieve 
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1. Multiple myeloma 
Multiple Myeloma (MM), also known as Kahler’s disease, is an incurable monoclonal B cell 
malignancy that develops in the bone marrow (BM)1. MM accounts for approximately 1% of all 
cancers and is the second most prevalent hematologic malignancy after non-Hodgkin lymphoma2,3. 
This uncontrolled accumulation of terminally differentiated plasma cells in the BM is characterized by 
an overproduction of monoclonal antibodies (mAb) in the serum and/or urine, also known as M-
proteins or paraproteins. Immunoglobulins (Ig) G and Ig A are the two most common types of 
paraproteins detected in MM patients. Moreover, other major clinical manifestations such as bone 
lesions, kidney failure, anemia, hypercalcemia and a high risk of infections further typically 
characterize this disease1,4. 
More common in men than in women, MM is twice more present in the African-American 
populations compared to Caucasians. However, the reason of this uneven race and sex distribution is 
still unknown5. In Europe, the MM incidence is 4,5 to 6,0 per 100.000 each year with a mortality rate 
at 4,1 per 100.000. In Belgium around 600 people are diagnosed each year. The median age at 
diagnosis is situated between 60-65 years6. Also obese people (BMI >30), people with the Acquired 
immune-Deficiency Syndrome (AIDS) and persons with a familial history of lympho-hematopoietic 
cancers appear to be more prone to develop MM7–9.  
Almost all of the MM patients evolve from an asymptomatic pre-malignant stage called monoclonal 
gammopathy of undetermined significance (MGUS), which is present in around 3% of the population 
above 50. The progress to the MM stage happens at a rate of 1% per year. MGUS is an asymptomatic 
condition where less than 10% clonal plasma cells are found in the BM, where paraproteins can be 
detected in the blood and/ or the urine (<3g/dL) but in absence of any end-organ damage and 
further clinical signs of MM5. In certain patients, even a more advanced intermediate stage, named 
smoldering multiple myeloma (sMM) can be observed10. The risk of progression from sMM to 
symptomatic MM is 10% per year and is influenced by the underlying cytogenetic type of the disease. 
Patients with t(4;14) translocation, 17p deletion, and 1q amplification appear to have a higher risk of 
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2. The pathogenesis of multiple myeloma 
2.1 The normal plasma cell in the bone marrow niche 
MM cells represent the malignant equivalent of terminally differentiated, long-lived plasma cells12. 
The development of normal B cells from pluripotent hematopoietic stem cells which differentiate 
into pro-B cells occurs in the BM. Subsequently, rearrangements of the light- and heavy chain Ig 
genes occur, which results in the maturation of pro-B cells into naive B lymphocytes. Afterwards, the 
cell leaves the BM to migrate as mature B cell towards the secondary lymphoid tissues. Due to 
antigenic stimulation in the germinal center of the lymph nodes a differentiation of the mature B 
cells into short-lived plasma cells or centroblasts takes place. They then develop into centrocytes and 
undergo somatic hypermutations and isotype switching resulting in the generation of B cells or 
plasmablasts that secrete high affinity antibodies. Thereafter, plasmablasts migrate back to the BM 
where they differentiate into non-dividing, long-lived plasma cells12,13. 
A specific BM niche is required for the long-term survival of normal plasma cells. Plasma cells need 
stromal feeder cells and an assortment of cytokines to survive. CXCR4 and its ligand stromal derived 
factor-1 alpha (SDF-1α) expressed on BM stromal cells (BMSCs) are important regarding the homing 
of plasma cells towards the BM, the plasma cell survival and Ig production14. Moreover, BMSC also 
express IL-6 that through upregulation of anti-apoptotic proteins such as myeloid cell leukemia 
sequence 1 protein (MCL-1) seems to be crucial for the long term survival of the plasma cells15. The 
transformation of a normal plasma cell to a malignant MM cell involves a process of subsequent 
oncogenic events occurring due to genetic alterations12. 
2.2 The homing of myeloma cells in the bone marrow niche 
One of the key features of MM is the “homing” to the BM. Different studies indicated that MM cells 
home to the BM through a process called endothelial migration, generally used for the 
transendothelial migration of normal leucocytes. In this process the first step includes the adhesion 
of MM cells to endothelial cells which is possible through the expression of multiple adhesion 
molecules. MM cells are known to express integrins which help in the adhesion to endothelial cells 
that leads to an arrest of the MM cells. These integrins include the very late antigen 4 (VLA-4) and 
the lymphocyte function-associated antigen-1 (LFA-1)16. In addition, our group demonstrated the 
involvement of CD44v10 in the endothelial cell adhesion. After integrin-mediated arrest, chemokine 
receptors present on MM cells and their ligands in the BM microenvironment promote the migration 
and selective homing of the MM cells17. The different chemokine receptors and ligands that were 
identified to participate in this process include CXCR4 with the ligand SDF-1α, C-C chemokine 
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receptor (CCR)-1 and CCR5 with ligand macrophage inflammatory protein 1α (MIP-1α), CCR2 with 
ligand monocyte chemotactic proteins (MCP-1, 2, 3) and CXCR3 with its ligand interferon gamma-
induced protein 10 (IP10)18–21.  
Subsequently, there is the transmigration through the BM endothelium and the subendothelial 
basement membrane. MM cells possess a strong invasive capacity. Through secretion of matrix 
metalloproteinase (MMP)-2, -9 and urokinase-type plasmininogen activator (uPA), MM cells are able 
to degrade the extracellular matrix and the basement membrane, consequently helping them to 
invade and transmigrate into the BM22. Moreover, the bone marrow constitutes a hypoxic 
environment and hypoxia has been shown to benefit MM cell invasion in the BM23. 
2.3 (Epi)genetics and cellular heterogeneity in multiple myeloma 
2.3.1 Genetic alterations  
MM is known to be a heterogeneous disease characterized by intra-tumor heterogeneity on the 
genetic and cellular level. Chromosomal aberrations, translocations and mutations are commonly 
seen in MM. The genetic alterations can contribute to plasma cell immortalization (primary events) 
or disease progression (secondary events). Several primary genetic defects, being hyperdiploid or 
non-hyperdiploid events, are observed in MGUS and MM and are considered to initiate MM 
development24,25. Hyperdiploid MM cells are defined by multiple trisomies of odd chromosomes (3, 
5, 7, 9, 11, 15, 19 and 21) and are present in 50% of the MM patients26,27. The other half has non-
hyperdiploid MM cells of which the majority has chromosomal translocations. This constitutes 
rearrangements of Ig heavy chain promotors to an oncogene, subsequently resulting in the 
overexpression of that oncogene. The chromosomal translocations can be categorized in three 
groups. The cyclin D group represents the first group and consists of 18% of the MM patients and 
targets cyclin D1 [t(11;14)], cyclin D2 [t(12;14)] or cyclin D3 [t(6;14)]24,28. Secondly, the 
musculoaponeurotic fibrosarcoma (MAF) group, present in approximately 8% of the MM cases, the 
translocations result in the overexpression of MAF [t(14;16)], MAFA [t(8;14)] or MAFB [t(14;20)]. The 
third group covers about 15% of the MM patients and implies the overexpression of the MM SET 
domain (MMSET) and the fibroblast growth factor receptor 3 (FGFR3) as a result of t(4;14). The 
chromosome 13 deletion (del13) can be an additional oncogenic event. Also, secondary 
translocations and mutations have been involved in MM progression and include deletion of 
chromosome 17p, gain of chromosome 1q and loss of chromosome 1p or chromosome 13/13q, MYC-
upregulations, inactivation or mutations of p53-PTEN and NRAS, BRAF and KRAS mutations but also 
inactivation of cyclin-dependent kinase inhibitors CDKN2A and CDKN2C25,29–35. Different components 
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of the NF-κB pathway were found to be mutated and possibly contribute to MM progression and 
drug resistance36,37. 
2.3.2 Epigenetic alterations 
It is now widely accepted that besides genetic aberrations, epigenetic abnormalities are important 
for the initiation and progression of cancer, including MM. Epigenetic modifications constitute 
changes in the pattern of gene expression that are mediated by mechanisms other than alterations in 
the primary nucleotide sequence. Most of the epigenetic mechanisms described in cancers such as 
MM, have been found to include DNA methylation, histone modifications and miRNA38.  
 DNA methylation 
DNA methylation can be defined as the covalent addition of a methyl-molecule on the 5' cytosine 
residue preceding a guanine residue in so called CpG dinucleotides. This reaction is catalyzed by DNA 
methyltransferases (DNMT) and uses S-adenosyl-L-methionine as a methyl donor39. In cancer, the 
global DNA hypomethylation of repetitive sequences, such as Alu and LINE-1 repeats, gene bodies 
and intergenic regions has been observed and were shown to be responsible for genomic instability, 
transposon activation, proto-oncogene activation and loss of normal imprinting patterns. 
Additionally, site specific CpG hypermethylation of gene promotors were found to result in gene 
silencing. This has been shown for genes involving cell cycle regulation, cell invasion, growth factor 
signaling, DNA repair, immune modulation and the regulation of apoptosis38. In line with this, global 
hypomethylation of the LINE-1 and Alu repetitive elements was observed in MM patients compared 
to healthy subjects40. Furthermore, global methylation levels of repetitive sequences decreased upon 
disease progression and were linked with poor prognosis41,42. Moreover, hypomethylation of LINE-1 
was found to be associated with genomic alterations such as translocations in chromosome 14 and 
deletions of chromosome 13q, suggesting that hypomethylation of repetitive elements increases the 
vulnerability to genomic instability41. In another study, methylation patterns were associated with 
specific cytogenetic subgroups, such as translocations (e.g. t(4;14) ) and a hyperdiploid state42. 
Interestingly, genome wide DNA methylation profiling revealed that in MM, hypomethylation of 
genes occurs in early MM disease and further increase upon disease progression, while 
hypermethylation of genes seemed to be a limited event43. Even though considered as an infrequent 
event, hypermethylation of genes seems to be associated with the progression of MGUS to MM42. 
Namely, multiple studies have revealed, during the analysis of cell lines and primary MM cells, loci-
specific hypermethylations of genes involved in the regulation of apoptosis, cell cycle, DNA repair, 
osteogenesis, Wnt signaling, signal transduction, tumor suppression, hormone and growth factor 
signaling, cell adhesion, coagulation, hypoxia signaling, transcriptional repression, regulation of 
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translation and transcription factors as extensively reviewed in 44,45. Methylation of genes including 
SPARC, BNIP3, DAPK, RARβ, EGLN3, DLC-1, CDH-1, DCC, TGF-βR2, CD9 and p16 were also found to be 
related to a poor prognosis in MM46–53. The mechanisms of aberrant DNA methylation in MM are still 
unclear but are probably associated with altered expression levels or activity of DNA 
methyltransferase (DNMT) enzymes, as well as mutations in accessory proteins and promotor 
sequences44. 
 Histone modifications  
Histone modifications are the result of a complex interplay between different molecules referred to 
as chromatin modifying proteins that are subdivided in “writers”‖, “readers”‖ and “erasers”54. 
Writers are enzymes catalyzing the actual modification (histone acetyltransferases, HATs) while 
readers are proteins containing certain domains that recognize the different types of modifications. 
Erasers consist of enzymes that are removing histone modifications and belong to the group of 
histone deacetylases (HDACs). Thus, histone modifications recruit, in a context dependent manner, 
specific protein complexes consisting of different writers, erasers and chromatin accessory proteins. 
Thereby, they orchestrate various functions related to chromatin including transcription, DNA repair, 
chromatin structure and DNA replication54,55. The most studied modifications that play a key role in 
chromatin biology constitute acetylation, methylation and phosphorylation. Diverse mutations and 
translocations involving “writers”‖, “readers”‖ and “erasers”‖ of histone marks have been 
demonstrated to induce alterations in the pattern of histone modifications in cancer56. To our 
knowledge, little is known about aberrations of histone modifications in MM. So far, the best 
documented example in MM is the translocation t(4;14) which leads to overexpression of MMSET 
(NSD-2), a histone methyltransferase, in approximately 15% of the MM patients57. MM cells with 
t(4;14) showed higher levels of H3K36me2 (di-methylation of histon H3K4) and lower levels of 
H3K27me3 (tri-methylation of histon H3K4) compared to non-t(4;14) MM cells58. Gene expression 
profiling revealed that MMSET regulates genes involved in the p53 pathway, apoptosis, cell cycle 
regulation, DNA repair and adhesion and knockdown of MMSET could negatively affect survival and 
adhesion of MM cells58,59. Genes upregulated by MMSET overexpression displayed the H3K36me2 
histon mark without the repressive H3K27me3 histon mark. In contrast, silenced genes were 
enriched for the repressive histon mark H3K27me3 and depleted of H3K36me258. In relation to gene 
silencing, we discovered a set of under-expressed genes enriched for the histon mark H3K27me3 in 
MM patient samples compared to normal subjects60. Pharmacological intervention with histone 
methylation inhibitors (HMTi) or the histone deacetylase inhibitors (HDACi) led to re-expression of 
these silenced genes and impaired the survival of MM cells both in vitro and in vivo60. Related to the 
H3K27 histon mark, another member Bmi-1, was shown to be upregulated in MM cells compared to 
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normal plasma cells. On the functional level, Bmi-1 negatively regulates the expression of the pro-
apoptotic gene Bim and thus functions as an oncogene. Knockdown of Bmi-1 decreased survival of 
MM cells by upregulation of Bim, what demonstrates its potential as a target for epigenetic 
therapy61. Lastly, mutations in WHSC1L1 (NSD-3), MLL1-3 and in the histone demethylase UTX 
(removes histon mark H3K27me) have been described in MM patients. The importance of these 
mutations in MM still needs to be resolved62,63. To our knowledge, no reports on aberrant HDAC 
functions in MM have been published yet. Nevertheless, HDACi in MM has been extensively studied 
as a therapeutic approach, as described below in section 4.3. 
 microRNA expression 
microRNAs are non-coding RNAs that can silence specific target genes through degradation of mRNA 
or inhibition of translational repression64. Few studies demonstrated a dysregulation of miRNA 
expression in MM cells and this was shown to be associated with genetic abnormalities, such as IgH 
translocations, deletions and hyperdiploidy in human primary MM cells65. Deregulated miRNAs 
including miR-15, miR-16, miR-21, miR-106b, miR-19a and 19b, as well as miR-181a and b were 
detected in MM patients and modulated critical genes associated with MM pathogenesis, suggesting 
the involvement of abnormal miRNAs in MM66. 
2.3.3 Cellular heterogeneity 
Aside from (epi)genetic variations, there is the cellular and phenotypical heterogeneity that is adding 
an extra level of complexity to MM. Different subpopulations exist in MM which differ in clonogenic 
potential, phenotype, maturation state, gene expression and response to therapy67–69. Normal 
mature plasma cells express high levels of CD38, CD138 and to a lesser extent CD19. MM cells lack 
CD19 expression and their expression of CD38 and CD138 varies. Variable expression of CD45, CD20, 
CD27 and CD117 is seen in MM, while CD56, CD28 and CD33 expression levels are generally 
increased70. The characterization of the different subpopulations is still an active study domain for 
many researchers. Several clonogenic subpopulations have been observed and seem to include cells 
with both a B and plasma cell phenotype. The relationship between CD138 expression and the MM 
propagating capacity is the most studied. Research performed by Matsui et al. demonstrated the 
presence of CD138-B cells in patient’s samples and MM cell lines. A higher clonogenic potential and 
Ki67 expression could be observed for these cells compared to the typical CD138+ plasma cells. Also 
the cancer stem cell marker aldehyde dehydrogenase was higher expressed on the CD138-plasma 
cells67. Studies performed by our group in the 5TMM mouse model (for information about the model 
see section 6 of the general introduction) demonstrated that the tumor-initiating potential is not 
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only CD138 dependent. CD138-cells were also less sensitive to treatment both in vitro and in vivo69. 
Therefore, it is of major interest to target both CD138-and CD138+ plasma cells in MM pathogenesis. 
 
2.4 The bone marrow microenvironment in multiple myeloma 
The BM is the perfect microenvironment where various cross-talks occur between MM cells and the 
different BM compartments. Close interactions with the cellular components of the BM, including 
endothelial cells, osteoblasts, osteoclasts, adipocytes and immune cells, confer survival and growth 
to MM cells and induce angiogenesis, bone destruction, drug resistance and immune escape, 
ultimately leading to relapse (Figure 1)71. 
2.4.1 Cytokines and adhesion molecules in multiple myeloma 
MM cells and the BM microenvironment are linked by complex interactions mediated by soluble 
factors and adhesion molecules through a network of autocrine, paracrine and adhesion-mediated 
signals. They promote MM cell survival and proliferation through four major pathways, being the 
mitogen-activated protein kinases/ extracellular signal-regulated kinases (MAPK/ERK), janus kinase 
and signal transducers and activators of transcription (JAK/STAT), the phosphatidyl-inositol 3 kinase 
(PI3K/Akt) and the NF-κB pathway. A summary of the main cytokines and adhesion molecules is 
described below71,72. 
 Cytokines: IL-6 and IGF-1 
IL-6 is an important factor for the growth and survival of MM cells and high serum levels are 
correlated with poor prognosis. IL-6 is secreted by cells of the BM microenvironment including 
fibroblasts, osteoblasts, monocytes, BMSCs and even MM cells themselves73. Other growth factors 
such as IL-1β, vascular endothelial growth factor (VEGF), TNFα, transforming growth factor beta 
(TGF-β), fibroblast growth factor (FGF) as well as adhesion of MM cells to fibroblasts and the 
upregulation of CD40 can stimulate the expression and secretion of IL-6. Several signaling pathways 
are activated when IL-6 binds to the receptor on MM cells and consequently stimulate different 
mechanisms contributing to MM pathology. The JAK/STAT3 pathway activated by IL-6 upregulates 
the anti-apoptotic proteins Bcl-XL and Mcl-1 which results in the stimulation of MM survival, while 
the MAPK/ERK pathway triggers the proliferation of MM cells73–75. The IL-6 activated MAPK pathway 
stimulates both survival and proliferation by inhibiting cell cycle inhibitors p21 and p2773,76. 
Another crucial factor in MM is the insulin-like growth factor 1 (IGF-1) which is locally produced by 
fibroblasts and osteoblasts73,77. Aberrant expression of its receptor can be found on MM cells in 
association with poor prognosis78. When IGF-1 binds to its receptor, survival and proliferation signals 
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are promoted through activation of the NF-κB and the MAPK/ERK pathway78. IGF-1 can cause 
phosphorylation and leads to the inhibition of pro-apoptotic proteins (i.e. Bcl-2-associated death 
promoter) as well as downregulation of BIM expression79,80. Cell cycle progression can be promoted 
by degradation of the cell cycle inhibitor p2781. Also the sensitivity of MM cells regarding anti-MM 
drugs can be decreased by IGF-177,82,83. Our group was able to demonstrate the therapeutic relevance 
of targeting the IGF-1/ IGF-1 receptor axis, by using an IGF receptor-1 inhibitor picropodophyllin 
(PPP). Tumor growth as well as angiogenesis was inhibited by PPP and a prolonged survival was 
observed in the 5T33MM and the 5T2MM murine model (see section 6 for detailed info about the 
models) and synergistic anti-MM effects were seen combining PPP with a Bcl-2 mimetic (ABT-737) or 
a histone deacetylase inhibitor (LBH589)84–87. 
 Adhesion molecules 
Aside from the different growth factors described above, a lot of adhesion molecules such as 
syndecan (CD138), CD44, CD51, CD54, CD56, VLA-4, -5 and 6, LFA-1, neural adhesion molecule 
(NCAM) mediate cell-cell contact with BMSCs. This results in the direct and indirect activation of the 
signaling cascades already mentioned above. MM cell adhesion to fibronectin also contributes to cell 
adhesion-mediated drug resistance (see section 5.2), mediated by integrins, and leads to an 
increased DNA repair and stimulation of anti-apoptotic pathways88,89. 
2.4.2 Bone marrow stromal cells in multiple myeloma 
Bone marrow stromal cells (BMSCs) are not fully differentiated stem cells and mainly consist of 
fibroblast, adipocytes and myeloid-derived suppressor cells (MDSCs). They closely interact with MM 
cells promoting MM disease progression and resistance. BMSCs communicate with MM cells and the 
extracellular matrix in the BM, through secretion of cytokines, extracellular vesicles and cell-cell 
contact, such as type I collagen and fibronectin via syndecan 1 and VLA-4 on MM cells and VCAM-1 
via VLA-4 on MM cells or through intercellular adhesion molecule-1 (ICAM-1) via mucin-1 antigen 
(MUC-1) and LFA-1 on MM cells, inducing cell adhesion-mediated drug resistance90. This cross-talk 
activates different pathways resulting in the upregulation of cell cycle regulating proteins and anti-
apoptotic proteins. MM–BMSCs interactions principally trigger the NF-κB pathway and IL-6 secretion 
by BMSCs which in turn enhances the paracrine production and secretion of IL-6 and VEGF by MM 
cells73,91. The Notch pathway is switched on too, which also induce IL-6, IGF-1 and VEGF secretion and 
stimulates the MM cell proliferation and survival73,92. Moreover, BMSC from MM patients were 
shown to express several pro-angiogenic molecules, such as VEGF, basic-fibroblast growth factor 
(bFGF), angiopoietin 1 (Ang-1), transforming growth factor (TGF)-β, platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF) and interleukin-1 (IL-1)73,93.  
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Similar to solid tumors, BMSCs are known to be able to change into cancer-associated fibroblasts 
(CAFs) in the presence of MM cells. CAFs comprise a heterogeneous population displaying 
phenotypes similar to those of myofibroblasts (derived from quiescent fibroblasts that have 
undergone activation during tissue remodeling in wound healing, fibrosis). They actively participate 
in tumor growth and metastasis by production of cytokines and chemokines, and the release of pro-
inflammatory and pro-angiogenic factors, creating a more supportive microenvironment. CAFs 
express α-smooth muscle actin, fibroblast-specific protein-1, fibroblast activation protein and 
platelet-derived growth factor receptor-β94. Frassanito et al. were the first to demonstrate increased 
CAF numbers in MM patients compared to patients in remission or MGUS patients95. 
Recent research demonstrated that interaction between BMSCs and MM cells not only occur through 
cytokines or MM - BMSC cell contact but also through extracellular micro-vesicles or exosomes. They 
form a class of membranous vesicles secreted by different cell types in the extracellular 
microenvironment and mediate long-and short-distance communication through stimulation of 
target cells. They were recently identified as a novel mechanism for intercellular transfer of genetic 
information in the form of miRNA in clonal plasma cell disorders such as MM96,97. Additionally our lab 
described that BMSC-derived exosomes mediate bortezomib drug resistance and induce MM 
survival97. 
2.4.3 Endothelial cells and angiogenesis in multiple myeloma 
Angiogenesis is a frequent cause of tumor growth, tumor invasion and metastasis in cancer and also 
in hematological malignancies such as MM98,99. It consists of a multi-step process where new vessels 
are formed from pre-existing vasculature, i.e. capillaries. This process is possible due to interactions 
between endothelial cells, the extracellular matrix and the secretion of soluble pro-and anti-
angiogenic factors by surrounding tissues. Briefly, the different steps in the process include 
perivascular detachment of existing vessels, endothelial cell proliferation, matrix degradation, 
endothelial cell migration and formation of new vasculature. Of course, angiogenesis also occurs in 
healthy individuals but in a controlled way, while for pathological angiogenesis, like in MM, these 
different cellular events are dysregulated99. 
In MM, angiogenesis was shown to be correlated with disease activity99. A switch in favor of the pro-
angiogenic path was observed during disease progression in the 5T2 murine model (for preclinical 
models see section 6) and appeared to be dependent on the downregulation of CD45 and the VEGF 
production in MM cells100. Furthermore, a poor prognosis of the patients seems to be correlated with 
an increased microvessel density, which is a measure for angiogenesis101. Recently, evidence also 
demonstrated that BM angiogenesis increased progressively from MGUS to sMM to MM102. Research 
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proved that MM cells together with different cell types such as endothelial cells, fibroblasts but also 
to a minor extent mesenchymal cells (MSC), macrophages and adipocytes are promoting the pro-
angiogenic switch. In MM, angiogenesis is the result of an increased secretion of pro-angiogenic 
factors stimulating pro-angiogenic signaling. Proteases and pro-angiogenic factors are needed for 
endothelial cell stimulation and the degradation of extracellular matrix, causing the stimulation of 
this switch and inducing new vessel formation. Pro-angiogenic factors include hepatocyte growth 
factor (HGF), angiopoietin-1 and 2 (Ang-1; Ang-2), FGF and VEGF. For the proteases mainly matrix-
metalloproteinases 2 and 9 (MMP-2; MMP-9) expressed by MM cells are involved in the angiogenic 
process103–105. A major role in angiogenesis was attributed to VEGF, which is produced by MM cells 
and BMSC, which is essential for endothelial cell proliferation, differentiation and migration106,107. Key 
microenvironmental factors of MM, such as IL-6 and IGF-1 and the endothelial growth factor FGF 
stimulate VEGF production and thereby establish para-and autocrine loops reinforcing this vicious 
circle108–110.  
In addition, two recent studies demonstrated MM cell-derived exosomes as new inducers of 
angiogenesis111,112. Exosomes, cell-derived extracellular vesicles, secreted from a human MM cell line 
directly promoted proliferation and capillary structure formation and induced angiogenesis in vivo. 
These exosomes promoted the expression and secretion of VEGF, further enhancing angiogenesis112. 
Hypoxia-inducible factor (HIF)-1α is often overexpressed by MM cells due to the hypoxic BM 
environment, leading to increased secretion of pro-angiogenic cytokines113,114. Umezu et al. found 
that MM cells under hypoxic conditions secreted more exosomes with increased levels of miR-135b 
which induced increased expression of HIF-1α in endothelial cells, leading to enhanced 
angiogenesis111. Moreover, exosomes obtained from the serum of MM patients clearly promoted the 
proliferation of human vascular endothelial cells as compared to those from healthy donors or MGUS 
patients115. 
2.4.4 Osteoclasts and osteoblasts in multiple myeloma 
Osteolytic bone lesions are one of the most common symptoms and cause of morbidity during MM 
disease. This typical bone destruction is due to an unbalance of bone formation and bone resorption. 
It can be attributed to a dysfunction and decrease of osteoblast numbers, which play an important 
role in bone formation and to an increase in osteoclast number and activity, resulting in bone 
resorption. Moreover, osteoclasts were shown to stimulate MM survival by secretion of IGF-1, A 
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The mechanisms behind this bone destruction can be associated with different pathways. One of 
these pathways constitutes the wingless-type (Wnt) signaling pathway, which is crucial for the 
differentiation of osteoblasts and consequently bone resorption. Secretion of Dickkopf-related 
protein 1 (DKK-1), soluble frizzled related protein 2 (sFRP-2) and Wnt inhibitory factor-1 (WIF-1) are 
responsible for the inhibition of the Wnt signaling pathway, resulting in the myeloma-related 
inhibition of osteoblast differentiation and activity118,119. By means of a paracrine loop mediated by 
IL-6 and through direct cell-cell interactions between MM cells, osteoblasts and fibroblasts, DKK-1 
secretion is induced120. Additionally, MM cells are known to express sFRP-2 leading to suppression of 
bone formation119,121. Another mechanism involved in inhibition of osteoblast development is Runt-
related transcription factor 2 (Runx-2) activity122. Our group could also demonstrate that through 
deactivation of the Notch signaling pathway the osteoblastic differentiation was impaired in MM-
patient derived mesenchymal stem cells123. 
Osteoclast activating factors, including the receptor activator of NF-κB ligand (RANKL), MIP-1α, TNFα, 
IL-1, -3 and -6 are possible factors responsible in the osteoclast-mediated bone resorption process. 
RANKL and MIP-1α appear to be the most important ones116. Osteoclast formation is induced by 
RANKL expressing fibroblasts interacting with osteoblasts and RANK expressing osteoclasts, which is 
prevented by osteoprotegerin (OPG). Thus, osteoclast formation and bone resorption is determined 
by the balance of RANKL and OPG. This balance is disturbed within MM and consequently correlates 
with bone resorption. Overexpression of RANKL can be found on the surface of osteoblasts and 
fibroblasts. OPG, on the contrary, is downregulated when fibroblasts and osteoblasts interact with 
MM cells119,124. Vanderkerken et al. demonstrated that MM progression and survival could be 
reduced by the use of recombinant OPG125. MIP-1α was showed to be secreted by MM cells and was 
correlated with bone disease and poor prognosis126. Recent research has demonstrated MM cell-
derived exosomes as mediators of osteoclast formation and activation. MM-derived exosomes 
supported both survival and migration of osteoclast precursors, and induced their differentiation to 
osteoclasts, as well as their bone resorption activity. Moreover, exosomes obtained from the plasma 
of MM patients exhibited the same functions in osteoclast differentiation127.  
2.4.5 Adipocytes 
Till now, little attention has been given to the role of the adipocytes in the MM BM cavity. Absent in 
the BM of a new-born individual, their number increases with aging. This results in adipocytic 
deposits occupying up to 70% of the BM cavity in the elderly128,129. Adipocytes arise from MSCs and 
are a major type of BMSCs130–132. They are the primary component of adipose tissue or “fat”. 
Adipocytes in white adipose tissue (WAT) contain a single large membrane-enclosed lipid droplet, 
 
 
22         General introduction on multiple myeloma  
surrounded by a thin rim of cytoplasm, and express specific proteins such as adipocyte protein 2 
(aP2)133. They produce triglycerol and adipokines such as leptin and adiponectin, and serve as a major 
energy reserve134–136. The adipocytes in brown adipose tissue (BAT) contain a central nucleus, many 
small lipid droplets and mitochondria, and provide a vital source of heat to maintain body 
temperature (thermoregulation), especially in newborns and hibernating animals. Yellow adipose 
tissue (YAT) has a mixed characterization and gene expression pattern of WAT and BAT132. BM fat is 
categorized as YAT, with the abilities to initiate osteogenesis and provide energy in emergency 
situations137. A link between adipocytes and cancer was reported in several cancers. Adipocytes are 
believed to promote rapid cancer cell proliferation in ovarian cancer and induce tumor metastasis 
and inhibit apoptosis in breast cancer and leukemia138–140. Also in prostate carcinoma adipocyte 
secreted factors were demonstrated to enhance the aggressiveness of the cancer141. Clinical studies 
showed an association between BM adipocytes and an increased risk of MM, but specific biological 
mechanisms have yet to be elucidated142,143. Results demonstrated that adipocytes isolated from 
femoral BM biopsies supported MM cell proliferation and migration. However, few studies have 
determined the role of BM adipocytes in MM. Our group could demonstrate the contribution of 
adipocytes in the BM microenvironment by affecting proliferation, apoptosis and migration in MM. 
As MM cells invade the BM and have a diffuse growth pattern, BM adipocytes disappear during 
disease development, suggesting a role of BM adipocytes at the initial stage of the disease, before 
full remodeling of the BM microenvironment has occurred128.  
Leptin, a product of the obese gene, is a multifunctional cytokine predominantly produced by 
adipocytes. Different studies reported the effects of leptin on cancer cell growth, migration and 
invasion, suggesting that this hormone is capable of promoting aggressiveness of the cancer 
phenotype141,144. We showed that adipocytes were the only cells within the MM microenvironment 
secreting leptin128. In MM biology, a possible functional involvement of leptin was not published yet. 
We revealed that leptin promotes the interactions between BM adipocytes and MM cells. However, 
it didn’t appeared to be the predominant growth factor, suggesting that other growth factors are 
equally or even more important128. Leptin serum levels are reported to be increased in MM patients 
at diagnosis compared to healthy individuals. Patients with weak leptin receptor expression also tend 
to have a longer progression-free survival compared to patients with strong leptin expression145. Yu 
et al. recently demonstrated that upregulated leptin could stimulate proliferation of MM and reduce 
the anti-tumor effect of chemotherapy possibly via the activation of AKT and STAT3 pathways146.  
It becomes more and more clear that adipocytes should no longer be considered as a passive cell in 
the BM microenvironment and more research could be of great interest. 
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Figure 1: General overview of the interactions between MM cells and the bone marrow microenvironment. Within the 
bone marrow MM cells interact through autocrine and paracrine loops with several cell types resulting in angiogenesis, 
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2.4.6 The immune microenvironment in multiple myeloma 
 Myeloid derived suppressor cells  
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous mixture of myeloid cells in different 
maturation stages that expand in the blood and lymphoid organs of tumor-bearing animals and 
cancer patients. In mice, MDSC are characterized based on dual expression of CD11b and GR1 and 
further classified into Ly6Glow (monocyte morphology, MO-MDSC) and Ly6Ghigh cells 
(polymorphonuclear morphology, PMN-MDSC, or granulocyte MDSCs, G-MDSC)147. In humans, they 
are characterized as being CD33+ (a common myeloid marker) and CD11b+ cells without a marker for 
mature lymphoid or myeloid on their membrane including HLA-DR. They can be subdivided into two 
main groups based on CD14 positivity. Namely, the granulocyte MDSCs (G-MDSCs) being 
characterized by CD11b+ CD14− CD33+ CD15+ HLA-DR−/low and the monocytic-MDSC (M-MDSCs) that 
can be distinguished by a CD11b+ CD14+ CD33+ HLA-DR−/low profile147. The most important feature of 
MDSCs is regulating the immune system by their immunosuppressive capacity and the promotion of 
tumor development in MM. MDSCs inhibit innate and adaptive immunity by regulatory T cell 
activation and secretion of nitric oxid, reactive oxygen species and immunosuppressive cytokines 
(e.g. IL-10)147. STAT 3 has been identified as the main pathway through which MDSCs expansion is 
mediated in different cancers. Activation of the STAT3 pathway results in the targeting of genes such 
as cyclin D1, MYC, surviving, Bcl-Xl, and additionally upregulates myeloid-related proteins (e.g. 
Ariginase 1, S100A8, S100A9), leading to increased survival and proliferation147. 
Recently, our lab identified distinct subsets of MDSC in the BM of the 5TMM models (for information 
about the models see section 6.1). In the BM, a clear shift toward a CD11b+Ly6Glow population, 
typically considered to be the phenotype of MO-MDSC, was observed at the end-stage of the disease 
in the 5TMM models148. In addition, in this MO-MDSC population, different MDSC subsets could be 
discriminated based on their differential Ly6C expression: inflammatory monocytes (Ly6ChighSSClow), 
eosinophils (Ly6CintermediateSSChigh), and immature myeloid cells (Ly6CintermediateSSClow) MO-MDSCs were 
thus more potent in the inhibition of T cell proliferation compared to G-MDSC148. The different 
subsets in the MO-MDSC population contributed to immunosuppression, with the inflammatory 
monocytes being described as the most potent inhibitors. Moreover, myeloma-derived MDSC 
showed an upregulation of iNOS, arginase-1, and IL-10, compared to MDSC derived from naive mice. 
Specific inhibitors of arginase-1 and iNOS partially abrogated the immunosuppressive function of the 
MDSCs148. Regarding the MDSC population in MM patients some controversy exists. Brimnes and 
colleagues were the first to rapport an increase of strong suppressive CD14+HLA-DR−/low MO-MDSCs 
in the peripheral blood of newly diagnosed MM patients compared to healthy subjects149. In 
 
 
25         General introduction on multiple myeloma  
contrast, recent studies demonstrated no difference in the MO-MDSC population, but a significant 
increase in the immunosuppressive G-MDSC, defined as CD11b+CD14−CD33+CD15+ or 
CD11b+CD14−CD33+CD15+HLA-DRlow, in BM and peripheral blood of MM patients150,151. Different flow 
cytometry analyses, limited patient numbers and distinct treatment regimens of MM patients could 
explain the discrepancy seen in these results. 
Besides their role in immune suppression, MDSC also play a pivotal role in bone disease. MDSC are 
macrophage progenitors which are able to differentiate into osteoclasts. MDSC derived from MM-
bearing mice had a higher potential to differentiate into mature and functional osteoclasts in vitro 
and in vivo compared to MDSC from control mice. Co-inoculation of 5TGM1 MM cells and MDSC 
resulted in increased tumor burden and bone lesions. In addition, in vivo treatment with zoledronic 
acid, a potent nitrogen-containing bisphophonate, was able to induce a 30% reduction in MDSC 
numbers and was associated with a decrease in osteoclastogenesis to control levels152. Interestingly, 
it has been shown that mainly the BM MDSC population is able to differentiate into osteoclasts153.  
Little is known about the role and mechanisms of actions of MDSCs in protecting MM cells from drug 
assault. Our lab extensively performed research on the subject and data demonstrate MDSC-
mediated AMPK phosphorylation could increase survival of MM cells. Moreover, AMPK and MDSC 
targeting strategies showed promising preclinical results that could be applied for future MM 
treatment154. Various factors, including GM-CSF, COX2, TGF-β, IL-4, IL-6, VEGF produced by MM cells 
and the BM tumor microenvironment also appeared to be involved in the expansion and activation 
of MDSCs147. Furthermore, it is shown that the hypoxic MM microenvironment can modulate the 
function and differentiation of MDSCs155. Finally, MM-derived exosomes are also reported to be 
involved in the activation and expansion of MDSCs, enhancing their immunosuppressive functions, 
thus favoring MM progression156,157.  
 T regulatory cells  
T regulatory cells (Tregs) constitute an important subgroup of T cells that are involved in the 
maintenance of self-tolerance, control of auto-immunity and regulation of T cell homeostasis. They 
also regulate overall immune responses against infectious agents and tumor cells. Tregs develop 
during normal T cell maturation in the thymus and represent 5% to 10% of the CD4 T cell 
compartment in the peripheral blood. They express surface antigens such as CD4 and CD25 surface 
as well as CTLA-4, CD62L, CD69, CD134, CD71, CD54, and CD45RA. Their suppressive activity can be 
associated with an expression of the forkhead/winged helix family member forkhead box P3 (FoxP3), 
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which acts as a transcriptional repressor. Tregs can exert suppression on the basis of cell–cell contact 
and by secretion of immunosuppressive cytokines such as IL-10 and TGF-β158. 
At present, there is significant debate concerning Treg numbers and function in MM. In most cancers, 
they appear to be increased and functional, while in MM, the situation remains unclear. Prabhala et 
al. found significantly reduced numbers of FoxP3 cells in MGUS and MM patients while two other 
groups reported Treg cells to be increased and associated with a strong inhibitory function in MGUS 
as well as in MM. Finally, there are also studies showing no difference in Treg numbers in patients 
versus healthy controls149,159,160. The divergence in Treg function and numbers described by the 
different investigators might be due to differences in assay and purification techniques. Reports 
show increased functional Treg cells in stem cell harvests compared to other lymphocyte 
populations. The significance of this in relation to tumor response remains unknown, but this 
suggests that anti-tumor responses might be improved by the selective depletion of Treg cells before 
transplantation161. In a reconstitution of Treg cells after allogeneic stem cell transplantation in MM, it 
was found that donor-derived Treg cells expanded and accumulated in the BM of patients who 
underwent transplantation. Treg cells appeared to expand outside the thymus, had a strong 
inhibitory capacity and exhibited high levels of TGF-β162. The therapeutic implications of Treg cells in 
myeloma are diverse. In allogeneic transplantation, they might play a role in exacerbating graft 
versus host disease. However, their removal might not necessarily harm the graft-versus-myeloma 
effect163. Moreover, it is possible that depletion of Tregs might allow an anti-tumor effect to occur, 
especially if this effect can be enhanced with the adoptive transfer of effector T cells164. Conversely, if 
Tregs are deficient and dysfunctional, this might contribute to the impaired immune system in MM. 
Moreover, they might be responsible for the clinical observations of an increased incidence of 
autoimmune diseases and the high incidence of infections, which is associated with a higher 
morbidity and mortality.  
 Natural Killer cells 
Natural killer (NK) cells are a heterogeneous group of lymphocytes that initiate innate immune 
responses and have a strong cytotoxic anti-tumor capacity and several immuno-regulatory 
properties. In humans, NK cells are defined as CD3-CD56+ lymphocytes but express varying levels of 
other surface receptors that dictate their cytotoxic and immune-regulatory properties. In MM, NK 
cells are increased in PB and BM compared to healthy individuals165–167. However, this overexpression 
is not related to their activity status. The NK cell activating receptors, natural killer group 2D (NKG2D) 
and natural cytotoxicity receptors (NCRs), are reported to be decreased in MM patients and may 
contribute to immune escape of MM168,169. One of the proposed mechanisms consists of an increase 
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of soluble MHC class I polypeptide-related sequence A (MICA) levels in the circulation of MM 
patients, which is one of the ligands of NKG2D. This would trigger the downregulation of the latter 
and result in impaired lymphocyte cytotoxicity169. Another suggested mechanism is the expression of 
programmed cell death 1 (PD-1) on the NK cells of MM patients. Presentation of the ligand PD-L1, 
expressed on MM cells, downmodulates the NK cell effect versus the MM effect (for more 
explanation of the immune checkpoint factor PD-1 see section 4.4.4)170. NK cell cytotoxicity in 
humans is induced by the lack of human leukocyte antigen (HLA) expression on the target cell. In 
contrast to many tumor types, MM cells often do not show loss of HLA class I, suggesting an extra 
mechanism by which MM may evade targeting by NK cells. NK cell cytotoxicity can also be mediated 
through signaling via CD16, which mediates the antibody-dependent cellular cytotoxicity (ADCC) of 
NK cells. However, in MM patients this is often dysfunctional compared to healthy individuals171.  
 Myeloma-associated macrophages 
Macrophages constitute a very heterogeneous population originating from monocytes and possess a 
unique functional plasticity. They are capable of being immunostimulatory or immunosuppressive 
and either promote or restrain inflammation. Macrophages can be subdivided into distinct types 
according to their polarization status: M1 (or “classically activated”) and M2 (or “alternatively 
activated”). The hallmark of M1 macrophages is their immunostimulatory property by iNOS 
expression, high secretion of IL-12 and a low IL-10 production. On the other hand, M2 macrophages 
have increased amounts of IL-10 and low levels of IL-12 and TNFα and are consequently orchestrating 
immunosuppression172,173.  
Tumor-associated macrophages (TAMs), including MM-associated macrophages, resemble the M2-
like macrophage population. They are well known for their abundant infiltration in tumor tissues and 
their supporting role in tumor progression by impacting on angiogenesis, matrix remodeling and 
immunosuppression174. Generally, high levels of TAMs correlate with a poor prognosis in different 
cancers, also in hematological malignancies like MM175–177. In MM patients with active MM, high 
percentages of CD68+ macrophages were observed but not in non-active disease, MGUS or healthy 
controls175,178. However, the origin of myeloma-associated macrophages still remains unknown: “Are 
they coming from circulating monocytes or originating from BM residential precursors?” Myeloma-
associated macrophages stimulate the MM pathology in different ways. Firstly, they support MM 
growth and survival through cytokine secretion of IL-1β and TNFα, which in turn stimulates IL-6 
production from mesenchymal stem cells (MSCs)179. They also secrete IL-10, another factor with an 
immunosuppressive capacity and contribute to the inflammatory environment through toll-like 
receptor mediated recognition. Moreover, we demonstrated that the pro-survival effect induced by 
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TAMs was associated with activation of the STAT3 pathway, less cleavage of caspase-3, and thus less 
apoptosis180. Secondly, TAMs assist in the angiogenesis and vasculogenesis within MM pathology181. 
They secrete the pro-angiogenic factors VEGF, bFGF, IL-8, TNFα, TGF-β and IL-6 resulting in a positive 
feedback loop amplifying angiogenesis174,181. Finally, they support MM in a cell-cell-contact manner 
and protect MM cells from caspase-dependent apoptosis by IL-6 secretion and selectin-mediated 
interactions178. 
 Natural killer T cells  
For a detailed description of natural killer T cells see Chapter II. 
Figure 2: General overview of the interactions between MM cells and the immune microenvironment. Within the bone 
marrow MM cells interact with several immune cells. Interactions are mediated by cell-cell contact, cytokines and growth 
factors and are mainly stimulatory for Tregs, MDSCs and TAMs, which are contributing to the proliferation, migration and 
drug resistance of the MM cells. NK cells, NKT cells and CD8+/ CD4+ T cells fail to eradicate the MM cells. They are 






29         General introduction on multiple myeloma  
3. Diagnosis and Risk-Stratification of multiple myeloma 
The diagnosis of symptomatic myeloma requires the presence of three main criteria, as shown in 
Table 1. The first criterium consist of the presence of 10% or more clonal plasma cells infiltration in 
the BM and/or a biopsy proven plasmacytoma. Moreover, there has to be evidence of MM related 
end-organ damage, which includes the presence of one or more symptomatic CRAB criteria 
(hypercalcemia, renal insufficiency, anemia, or bone lesions). Finally, the presence of M-protein in 
the serum and/ or urine is essential to diagnose MM182,183. 
 
Table 1: Diagnostic classification of MGUS, sMM and MM 
CRITERIA MGUS sMM MM 
Serum M-protein < 3 g/dL ≥ 3 g/dL 
Present in serum and/ 
or urine at any level 
Clonal BM plasma cell < 10 % ≥ 10% 
≥ 10% or 
plasmacytoma 
End organ damage Absent Absent 
Present 
  CRAP criteria 
 
Calcium: ≥ 11,5 mg/dL 
 
Renal insufficiency:  
serum creatinine 
 > 2mg/ dL 
 
Anemia: hemoglobin  




fractures or sever 
osteopenia 
 
The prognosis of MM is depending on a range of factors like age, performance status and 
comorbidities but also on the stage and aggressiveness of the disease as well as the responsiveness 
to treatment. The International Staging System (ISS), replacing the former Durie-Salmon staging, 
helps providing prognostic information and is recommended as a standard assessment. The staging 
system consists of 3 stages (Stage I, II, III) based on beta 2 microglobulin (β2m) and the levels of 
serum albumin, outlined in detail in Table 2. They give an idea about the inflammatory status and 
disease activity184. Also cytogenic aberrations have an important contribution in determining the 
prognosis and are useful for both counseling and therapeutic decision-making. Therefore, it’s worthy 
to look with interphase fluorescent in-situ hybridization (iFISH) or metaphase cytogenics which type 
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of aberration is present in the patients. To evaluate the MM risk the International Myeloma Working 
Group (IMWG) advises to assess the ISS, and to look for t(11;14), t(4;14), t(14;16), t(6;14),t(14;20), 
trisomies, del17p and gain of 1q21 (Table 3)185. Based on the presence of cytogenic aberrations the 
Mayo Stratification of Myeloma and the Risk-Adapted Therapy (mSMART) Consensus Guidelines 
defined three risk groups, illustrated in Table 4. Patients with standard risk myeloma have a median 
overall survival (OS) of 8 to 10 years while those with high risk disease have a median OS of less than 
2 to 3 years despite tandem autologous stem cell transplantation (ASCT). For the intermediate risk 
group the OS is around 4 to 5 years186. Many other relevant markers are able to influence the risk for 
myeloma as well as predict the prognosis and determine the choice of treatment. These factors can 
be subdivided in 3 groups: tumor biology, tumor burden and patient-related factors. Tumor burden 
factors include extramedullary disease, while patient-related factors include age, renal function and 
the Eastern Cooperative Oncology Group performance status (Table 5). For the tumor biology factors 
it includes ploidy status, 17p-(p53 deletion), t(14;16), t(14,20), t(4,14), deletion 13 on conventional 
cytogenetic testing, alterations in chromosome 1, t(11;14), t(6;14), lactate dehydrogenase, plasma 
cell proliferative rate, presentation as plasma cell leukemia and a high-risk signature in gene 
expression profiling186. 
Table 2: International Staging System (ISS)184 
ISS Criteria Median survival (months) 
I 
β2m < 3,5mg/l 
serum albumin > 3g/dl 
62 
II 
β2m < 3,5mg/l  
or 
3,5 -5,5 mg/ml 
serum albumin < 3g/dl 
44 
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High ISS II and III, presence of t(4;14), 17p13 2 20 
Standard others 7 60 
Low 










Table 4: Risk stratification of active multiple myeloma186 





- cytogenetic del 13 
- hypodiploid 
- plasma cell labeling index 
>3% 
FISH: 
- Del 17p 
- t(14;16) 
- t(14;20) 
- high signature gene 
expression profiling 
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Table 5: ECOG performance status* 
Grade ECOG 
0 
Fully active, able to carry on all pre-disease 
performance without restriction 
1 
Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house 
work, office work 
2 
Ambulatory and capable of all selfcare but 
unable to carry out any work activities. Up and 
about more than 50% of waking hours 
3 
Capable of only limited selfcare, confined to 
bed or chair more than 50% of waking hours 
4 
Completely disabled. Cannot carry on any 
selfcare. Totally confined to bed or chair 
5 Dead 
* The Eastern Cooperative Oncology Group (ECOG) performance status is a scale used to assess how a patient’s disease is 
progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and 
prognosis. 
 
The above described criteria used for diagnosis and risk-stratification were partly responsible for the 
extraordinary evolution in the disease management and treatment of MM patients. Currently, more 
sensitive techniques are being explored to better capture the genetic diversity of MM as well as 
improve the clinical management. Applying a "liquid biopsy" blood test as a non-invasive strategy 
followed by the use of next generation sequencing techniques such as whole-exome and ultra-low 
pass-whole genome sequencing of cell-free DNA, circulating tumor cells and tumor DNA will enable 
serial temporal sampling and a better comprehension of the mutational landscape in MM. Moreover, 
this strategy will offer the possibility to longitudinally follow the dynamics of clonal evolution in MM 
over time and measure residual tumor burden for new complete remission definitions. However, 
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4. Treatment strategies in multiple myeloma 
Recent advances in the management of MM significantly improved the treatment outcomes of the 
patients in the last two decades. The median survival increased from about 2 years in the 1980s up to 
5 years in 50 % of the treated patients nowadays (even up to 10 years or longer for another 20%)189. 
The different phases of therapy constitute: initial therapy, ASCT (if eligible), consolidation/ 
maintenance therapy and treatment of relapse (Figure 3). Unfortunately, MM still remains an 
incurable disease where the quest for more efficient therapies with durable responses persists.  
4.1 Treatment scheme in multiple myeloma 
4.1.1 Newly diagnosed patients  
 Initial therapy: transplant eligible patients 
Depending on the age, the eligibility for ASCT and comorbidities different treatment schemes have 
been designed. Transplant eligible MM patients (below 65 years) receive an induction therapy of 
approximately 3-4 cycles of regimens including proteasome inhibitors (bortezomib, carfilzomib), 
Immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, pomalidomide), glucocorticoids 
(dexamethasone, prednisone), alkylating agents (melphalan) or anthracyclines (cyclophosphamide, 
doxorubicin)190–192. The most recommended induction therapy consists of bortezomib in combination 
with dexamethasone together with IMiDs or an alkylator. Bortezomib-based therapies were recently 
showed to be superior over other treatment regimens in terms of response, progression free survival 
and overall survival. However, a higher incidence of toxicity was observed193,194. After induction 
therapy, stem cells are harvested, followed by a high-dose therapy of the alkylator melphalan and an 
ASCT192. 
 Autologous stem cell transplantation (ASCT) 
The combination of novel agents together with ASCT showed a strong improvement of the long-term 
event free survival of patients compared to novel agents alone. At this moment there is no evidence 
of improved overall survival after early ASCT compared to ASCT at relapse1,192. The total therapy 
approach, including upfront therapy and early ASCT can prevent clonal evolution in MM and resulted 
in a cure for some patients195–197. For high risk patients this strategy is most of the time not enough 
and novel treatment regimens are necessary. Combination therapies, sequence, single or tandem 
ASCT, ASCT conditioning and treatment duration are currently under investigation198–200. 
Consolidation and maintenance therapy can be applied in order to enhance the quality of the 
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response after the transplantation. However, these approaches are not yet approved in Europe194,201. 
A second transplantation can be performed followed by additional cycles of bortezomib in 
combination with thalidomide and dexamethasone, since this was proven to prolong remission and 
the occurrence of event free survival. The maintenance approach aims to increase the time of 
remission after a successful induction therapy. Lenalidomide-based and bortezomib-based 
maintenance already proved to promote event free survival and overall survival194,201,202. However, 
still major considerations revolve around concerns for toxicity including second malignancies, optimal 
duration of therapy and selection of agent and cost of therapy. 
 Initial therapy: transplant non -eligible patients 
Patients over 65 years of age are in general not suitable for transplantation, mainly due to a poor 
physical condition or other comorbidity factors. For these patients, another strategy is used. 
Recommended front-line therapies constitute combinatory treatments of melphalan, thalidomide/ 
bortezomib and prednisone. Other bortezomib-based or IMiD-based combinatory therapies appear 
to be at least equally effective but have not been approved by the European Medicines Agency 
yet1,190. Maintenance therapies are currently not recommended. However bortezomib-based and 
lenalidomide-based therapies seem to have beneficial effects190. 
4.1.2 Relapsed refractory patients  
Even though many patients acquire a (stringent) complete response, in most of the cases a small 
population of residual plasma cells, also called minimal residual disease (MRD), remain and are 
ultimately leading to relapse203,204. This small remaining population of malignant plasma cells is 
undetectable when morphologically assessed in the BM. A lot of efforts have been made the last 
years in order to improve the detection of MRD such as PCR, multiparameter flow cytometry, 
positron emission tomography and sequencing203,204.  
Patients are monitored by biochemically identifying M-protein levels in the serum or urine and a 
follow-up of the CRAB criteria. When the level of M-proteins is significantly increased this can be an 
indication for relapse. However, treatment is generally started when high M-protein levels are 
detected even without clinical myeloma-related symptoms, especially in patients who had only a 
suboptimal response to former treatments and who have a negative cytogenetic profile. The therapy 
depends on different factors: response to initial therapy after diagnosis, age, presence of 
neuropathy/ nephropathy, degree of relapse and the cytogenetics190,205. In case of a long-term event 
free survival (>12months) young patients can undergo a second ASCT. If there was a long term 
remission of more than 1 year and no occurrence of toxicity, it is possible to treat the patient with 
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the same compounds used in the initial therapy. If this is not the case a switch to other drug classes, 
IMiD-based or bortezomib-based, are favored. The proposed rationale behind this is that at relapse, 
the selected clones that grow out are resistant to previous treatment regimens but can possibly still 
































Figure 3: Overview currently used treatments for newly diagnosed myeloma patients. All drugs present in the treatment 
scheme are reimbursed in Belgium, except for these indicated with *. VTD: velcade, thalidomide, dexamethasone; VCD: 
velcade, cyclophosphamide, dexamethasone; PAD: prednisone, adriamycin (doxorubicin), dexamethasone; ASCT: autologous 
stem cell transplantation; RVD: lenalidomide, velcade, dexamethasone; MVP: melphalan, velcade, prednisone; RD: 
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4.1.3 Supportive therapy  
In terms of survival, supportive therapy could be beneficial for all MM patients. As previously 
described, complications such as anemia, bone pain, hypercalcemia/-uricemia and infections, occur 
in MM208. Analgesic agents against pain and antibiotics to fight the multiple infections can be 
recommended. Both, bone fractures and pain can be reduced by radiotherapy of the osteolytic 
lesions. Biphosphonates are widely used to treat bone disease. Zoledronic acid and pomidronate for 
example had a survival benefit and anti-MM effects in symptomatic MM209,210. 
4.2 Proteasome inhibitors  
Proteasome inhibitors (PIs) have emerged 10 years ago as an important therapeutic strategy in MM. 
The ubiquitin-proteasome pathway is responsible for degradation of the majority of regulatory 
proteins in eukaryotic cells, including proteins that control cell-cycle progression, apoptosis, and DNA 
repair and therefore plays an essential role in maintaining normal cellular homeostasis. In cancer in 
general, higher levels of proteasome activity are seen compared to normal cells. Moreover, they are 
more sensitive to the pro-apoptotic effects of proteasome inhibition than normal cells. MM cells 
were particularly found to be susceptible to proteasome inhibition because they are proliferative, 
over-produce defective proteins which need to be degraded by the proteasome and additionally 
upregulate signaling pathways dependent on the 26S proteasome211. Since the first-in-class PI 
bortezomib, a substantial improvement in survival of MM patients has been observed over the past 
decade. Recently, second-generation PIs have been developed and are undergoing intense 
evaluation in clinical trials. Each PI can be distinguished regarding their specificities and affinities for 
the different catalytic sites within the ubiquitin-proteasome pathway212. PIs can be classified into 3 
groups, being the boronates, epoxyketones, and salinosporamides, based on their chemical structure 
and active moiety. 
 Boronates 
Bortezomib is a dipeptidyl boronic acid-based specific, reversible PI that inhibits the proteasome by 
mainly targeting the chymotrypsin-and caspase-like active sites212. Bortezomib suppresses tumor 
survival pathways, arrests MM growth, invasion, and angiogenesis213. Bortezomib directly induces 
apoptosis of MM cells, inhibits the activation of NF-κB in cells and in the tumor microenvironment, 
reduces adherence of myeloma cells to bone marrow stromal cells, blocks production and 
intracellular signaling of IL-6 in myeloma cells, stops the production and expression of proangiogenic 
mediators, and overcomes defects in apoptotic regulators, such as Bcl-2 overexpression and 
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alterations in tumor suppressor p53213,214. In addition, bortezomib has shown enhanced endoplasmic 
reticulum stress, associated with the disruption of an unfolded protein response. As a result of its 
mechanisms of action, bortezomib has also been associated with increased bone formation and 
osteoblastic activity, and decreased bone resorption and osteoclastic activity214–217.  
 Epoxyketones 
Carfilzomib is an irreversible PI belonging to the category of the epoxyketones. It enhances a potent 
and sustained inhibition of chymotrypsin-like activity with a greater selectivity for the chymotrypsin-
active sites compared to bortezomib. Carfilzomib has been shown to trigger cell cycle arrest, induce 
apoptosis, and activate stress response pathways in human tumor cell lines, including MM and other 
hematologic malignancies and solid tumors218,219. Importantly, carfilzomib has demonstrated activity 
against bortezomib-resistant cell lines and primary MM cells220. It has a good safety profile with less 
peripheral neuropathy compared to bortezomib221. Carfilzomib has good results in relapsed and 
refractory MM patients, including those who received bortezomib previously222. Moreover, 
promising combination activity with glucocorticosteroids and IMiDs was shown in NDMM223. 
 Salinosporamides 
Marizomib is a natural lactone compound derived from the marine bacterium Salinospora tropica 
which belongs to the salinosporamides. It is an irreversible PI that, unlike bortezomib and 
carfilzomib, inhibits both the chymotrypsin-like and trypsin-like protease activities. Marizomib only 
minimally affects the caspase-like active sites of the proteasome. Marizomib-induced apoptosis is 
predominantly the result of activation of caspase-8–mediated signaling pathways224. Marizomib has 
demonstrated anti-tumor activity in preclinical models of MM, other hematologic malignancies, as 
well as in solid tumors225. 
4.3 Epigenetic modulating agents in multiple myeloma 
DNA methylation and posttranslational histone modification constitute two epigenetic modifications 
that have a major impact on MM cell biology and greatly influence development and progression of 
MM (as previously discussed in section 2.3). Epigenetic modulating agents such as histone 
deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) are therefore under 
intensive investigation for their therapeutic use in MM. 
As demonstrated by us and others, HDACi used alone or in combination with conventional anti-MM 
agents have a potent preclinical anti-MM activity226–230. While single-agent HDACi appeared to 
mediate little to no clinical activity, combinatory treatment of the pan-HDACi vorinostat or 
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panobinostat in combination with respectively the proteasome inhibitor bortezomib or bortezomib 
plus dexamethasone did prolong progression free survival with respectively 0.8 months and 3.9 
months231–235. However, the clinical relevance in terms of overall survival is not yet clear and a high 
occurrence of side effects was observed234,235. In addition, a phase II trial of the combination of 
panobinostat with melphalan, thalidomide and prednisone was also associated with a high 
occurrence of side effects236.  
Aberrant DNA methylation can be targeted with the use of DNMTi leading to demethylation of 
DNA45. Commonly used DNMTi are the cytidine analogues 5-azacytidine (AZA) and 5-aza-2'-
deoxycytidine (decitabine). Their anti-tumor effects have been linked to two mechanisms: passive 
DNA demethylation and induction of DNA damage237. The commonly used DNMTi, AZA, has been 
shown to have anti-myeloma activity by promoting apoptosis and inhibiting IL-6 and NF-κB signaling 
pathways45,238. Additionally, AZA is directly cytotoxic and has been shown to cause double stranded 
DNA breaks, inducing p53-mediated cell cycle arrest and apoptosis239,240. Upon replication, cytidine 
analogue decitabine is incorporated into DNA thereby trapping DNMT enzymes. This consequently 
leads to the depletion of DNMT and a loss in ability to methylate DNA. The result is a genome-wide 
loss of methylation leading to re-activation of silenced genes, genomic instability and related anti-
tumor effects. Moreover, activation of a DNA damage response ultimately results in apoptosis239. At 
this moment, DNMTi are considerably less used in the clinic for treatment of MM compared to 
HDACi. Some clinical trials are ongoing to evaluate the safety of DNMTi and a phase II clinical trial in 
MM patients combining AZA and lenalidomide before and during ASCT was perfomed45. Cytotoxic T 
lymphocyte reactions targeting the MM cells were observed, demonstrating an adaptive immune 
response induced by AZA. However, it’s clear that further clinical trials are needed to evaluate DNMTi 
in clinic. 
There has also been considerable interest in combining DNMTi and HDACi to enhance the anti-tumor 
effects of both agents241. The mechanism of action involves a broad spectrum of effects that range 
from true epigenetic changes, chromatin-and DNA-related effects, disruption of the acetylome and 
micro-environmental effects45. Previous studies on these combinations demonstrated alterations in 
gene expression that may correlate with an enhanced apoptotic effect and direct modulation of 
downstream apoptotic effectors46,242–246.  
4.4 Immune therapy in multiple myeloma 
Fighting cancer by harnessing the body’s own immune system has been considered the holy grail in 
cancer therapy and at present also in MM more and more success is achieved in the field of immune 
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therapy. It is known that MM cells can evade the immune system through a variety of mechanisms: 
inhibition of tumor antigen presentation, secretion of immunosuppressive factors, recruitment of 
immunosuppressive cells and suppression of immune activation. Numerous strategies to modulate 
this immune evasion, such as passive and active immunotherapy, have been developed and are 
under evaluation. Passive immunotherapy includes tumor-directed monoclonal antibodies, while 
active immunotherapy acts directly on the patient’s own immune system to trigger an immune 
attack against cancer. Active strategies can be therapeutic vaccines, cytokines, mediators of T cell 
activation, etc247. An overview of the most relevant immune-targeting strategies in MM is given 
below. 
4.4.1 Immunomodulatory drugs (IMiDs) 
IMiDs directly affect the BM microenvironment and MM cells themself. They include thalidomide and 
its less toxic analogues lenalidomide and pomalidomide. IMiDs have pleiotropic mechanism of 
actions, resulting in anti-MM effects248. They have the capacity to modulate cytokines in the MM 
microenvironment by inhibiting the release of TNFα, IL-1 and IL-6 and triggering the release of IL-2, 
IL-12 and IFN-γ cytokines. They also induce inhibition of angiogenesis and increase immune effector 
cell numbers and functions of cytotoxic T-, NK- and NKT cells possibly via IL-2 and inhibition of 
immunosuppressive cell populations such as Tregs and MDSCs. By decreasing the expression levels of 
adhesion molecules on malignant MM cells and BMSCs, IMiDs abrogate interactions between MM 
cells and their microenvironment and sensitize the cells to other cytotoxic therapies. Moreover, they 
possess anti-proliferative properties through the upregulation of cyclin-dependent kinase inhibitors 
(p21, p27) and tumor suppressor genes in primary MM cells including early growth response proteins 
(Egr-1, -2 and -3). By modulating the NF-κB pathway and the expression of pro-and anti-apoptotic 
molecules they extra potentiate their anti-cancer properties249–252. 
Cereblon, an E3 ubiquitin ligase component, has recently been identified as a direct molecular target 
of IMiDs and has been shown to be crucial for the direct teratogenic, cytotoxic and immune related 
effects of IMiDs. Ikaros family zinc finger proteins 1 and 3 are two downstream transcription factors 
taking part in the IMiDs-mediated anti-cancer activity253,254. All these properties make IMiDs perfect 
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4.4.2 Vaccination strategies 
 Peptide-based vaccines 
Tumor-associated antigens, such as MAGE, NY-ESO1, WT-1, RHAMM-R3 and XBP-1, used as targets 
were able to induce cellular responses in a preclinical context when they were used individually 
and/or in combination. Initially, clinical results using single peptide-based vaccines demonstrated 
that these vaccines could be used with few adverse effects and induced immune responses, however 
with moderate effects on disease control. A preclinical study using T cells from MM patients  
researchers were able to generate peptide specific cytotoxic T lymphocytes by using, XBP-1, CD138 
and CS1 as immununogens255. Currently numerous peptide vaccination trials are ongoing and efforts 
were made to enhance the immunogenicity of these vaccines in combination with T cell therapy. 
Impressive immune responses were observed but clinical outcome was lacking256.  
 Idiotype-based vaccines 
The monoclonal immunoglobulin or idiotype protein (paraprotein) secreted by myeloma cells carries 
unique antigenic determinants. Immunotherapy with idiotype-pulsed DCs has been explored as a 
therapeutic strategy in MM for the past decade but the results have been disappointing. Less than 
50% of patients mounted idiotype-specific immune responses, and satisfactory clinical responses 
have rarely been observed257–259. To improve the efficacy of idiotype-pulsed DCs, Yi et al. pulsed them 
with CD40L. The idiotype-pulsed CD40L-DC vaccines were subsequently injected intranodaly in MM 
patients. Enhanced Th1 and specific CD8+ T cell responses were induced in 5 out of 9 patients260. 
 DC/MM fusion vaccines 
Another vaccination strategy involves DC/MM cell fusion vaccines. The advantage of this approach is 
the capacity of DCs to present several antigens from cell to host. These vaccines were already 
evaluated in phase I and II trials. In both trials DC/MM fusion vaccines were well-tolerated and 
triggered the tumor specific immunity through expansion of reactive CD4 and CD8 T cells and 
induction of tumor specific antibody responses261. In the second study, DC/MM fusion 100 days after 
ASCT was associated with the depletion of Treg cells. A quarter of the patients developed complete 
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 TriMix-DC vaccines 
In a TriMix-DC-based strategy DCs are electroporated with miRNA’s encoding for CD70, CD40L and 
constitutively active Toll-like receptor 4 in combination with miRNA encoding for TAA to induce co-
stimulation with T cells and induce TAA-specific CD8+ cells in patients. Showing successful results in 
stage III and stage IV melanoma patients, a similar approach was tested in MM by the group of Prof. 
Thielemans (VUB)263. TriMix-DCs proved to be efficient stimulators of T cells from MM patients in 
vitro. Preclinical studies showed promising results of a polarization of activated T cells towards a Th1 
response, leading to the start of a clinical trial in the hospital of the UZ Brussels264. 
4.4.3 Antibody therapies 
 Anti-CS-1(SLAMF7) antibody 
CS-1 or signaling lymphocytic activation molecule F7 (SLAMF7) is a glycoprotein expressed on normal 
plasma cells, MM cells as well as on NK and NKT cells. This has led to the appealing development of a 
humanized IgG1 monoclonal anti-CS1 (SLAMF7) antibody called elotuzumab, which has shown 
remarkable anti-myeloma activity in both preclinical and clinical studies. The monoclonal antibody 
has a dual mechanism-of-action. It directly activates NK cells via the SLAMF7 pathway and also 
targets SLAMF7 on MM cells, tagging them for NK cell-mediated destruction via antibody-dependent 
cellular toxicity265,266. Elotuzumab does not show significant clinical activity as a single agent. 
However, in combination with lenalidomide and dexamethasone high efficacy was demonstrated in 
relapsed/refractory MM267–270. Today, the combination elotuzumab, lenalidomide and 
dexamethasone is already approved by the U.S. (Food and Drug Administration) FDA for the 
treatment of patients who have received one to three prior therapies271.  
 Anti-CD38 antibody 
CD38 is a type II cell surface transmembrane glycoprotein being present on myeloid and lymphoid 
cell lineages in the BM, but also expressed on some non-hematopoietic cell types. It has different 
functions in cell adhesion, signaling and enzymatic activity. Since it is highly expressed on MM cells, 
CD38 is an interesting target for therapy. Daratumumab is a fully human IgG1κ mAb directed against 
CD38 that has shown anti-MM activity in different preclinical models, using mechanisms such as 
antibody-dependent cellular toxicity, complement dependent cytotoxicity and antibody-dependent 
cellular phagocytosis265,272. It also showed extraordinary effectiveness in heavily pretreated MM 
patients as a single agent with a manageable safety profile270,273,274. Based on these phase I/ II trials 
the U.S. FDA has granted accelerated approval for daratumumab to treat patients who have received 
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at least three prior treatments making it the first monoclonal antibody approved for the treatment of 
MM275. Currently, daratumumab is investigated in combination with proteasome inhibitors and IMiDs 
in newly diagnosed and relapsed/refractory MM patients. Since it has a favorable safety profile, 
clinical studies with daratumumab as maintenance therapy are conducted as well276. Several other 
anti-CD38 antibodies such as SAR650984 (Sanofi), MOR03087 (Morphosys) or Ab79 (Takeda) are 
currently also in the early phases of clinical development and testing, but daratumumab 
(Genmab/Janssen) seems to be the most promising270. 
4.4.4 Immune checkpoint inhibitors 
One of the most encouraging approaches to activate therapeutic anti-tumor immunity is the 
blockade of immune checkpoints. Immune checkpoint proteins, such as programmed death 1 (PD-1), 
cytotoxic T lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3) and T 
cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin-containing 
protein 3 (TIM-3), are inhibitory molecules that are essential for maintaining self-tolerance and for 
modulating the duration and amplitude of physiological immune responses in the peripheral tissues 
in order to prevent collateral tissue damage277,278. In a lot of cancers, the expression of immune-
checkpoint proteins is dysregulated and used by tumors as an important mechanism to evade the 
immune system. Because many of the immune checkpoints are initiated by ligand–receptor 
interactions, they can easily be blocked by antibodies or modulated by recombinant forms of ligands 
or receptors279. Remarkable results have already been observed in melanoma, kidney cancer, lung 
cancer, colorectal cancer and head and neck cancer280,281. Also in hematological malignancies 
immune checkpoint blockade looks like a promising strategy282. 
The PD-1 protein is a member of the B7 immunoglobulin superfamily and is expressed on T- and B 
cells, NK cells, DCs and monocytes. Multiple malignancies express the PD ligand 1 (PD-L1) molecule 
which has been correlated with poor prognosis281. MM cells were shown to express PD-L1 while 
normal plasma cells did not. High levels of PD-1 were observed on NK-and T cells from MM patients 
and not from healthy individuals170,283. These abnormal expression profiles in MM strongly 
encouraged the further investigation of immune modulation and immunotherapy in MM. Moreover, 
preclinical investigations showed anti-myeloma activity by inhibiting PD-1/PD-L1 signaling. MM 
growth was inhibited both in vitro and in vivo using an anti-PD-L1 antibody282. The anti-PD-1 mAb CT-
11 (pidilizumab) was tested to evaluate anti-MM effects and was able to enhance NK cell anti-tumor 
activity. Particularly, in presence of lenalidomide or with DC/MM fusion vaccine, downregulation of 
PD-L1 on MM cells was demonstrated170,283. A phase I study with pidilizumab already demonstrated 
tolerability in 30% of study patients with hematological malignancies. Currently, a phase II trial is 
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ongoing to assess efficacy of a DC/tumor vaccine in combination with pidilizumab following ASCT284. 
The phase I clinical trial with mAb nivolumab in MM patients showed no objective responses. 
Although, results were initially disappointing, disease remained stable for 18 of 27 patients282. 
Multiple other studies using different anti-PD-1 antibodies are ongoing in advanced MM patients and 
include pembrolizumab with pomalidomide, with lenalidomide/dexamethasone, or post ASCT285. 
Furthermore, a preclinical study noted that combining PD-L1 blockade with other immune 
checkpoint inhibitors (CTLA-4, LAG-3, or TIM-3) promotes survival of MM mice that underwent a low 
dose total irradiation286.  
An alternative for immune checkpoint blockade could be the use of agonist mAb, such as anti-CD137, 
directed against co-stimulatory molecules. Anti-CD137 demonstrated to induce potent T- and NK cell-
mediated responses in murine MM models287. Currently clinical trials with anti-CD137 mAbs are 
ongoing to evaluate the safety and beneficial effects in cancer patients288,289. 
Immune checkpoint inhibitors are a promising avenue that should eventually lead to more efficient 
combination strategies in MM.  
4.4.5 Chimeric Antigen Receptor (CAR) T cells 
Chimeric antigen receptor (CAR) T cell based therapy has shown great promise in lymphoma and 
certain kinds of leukemia and are currently also under investigation in MM. CAR T cells are 
engineered to replace the extracellular antigen binding domain by single chain variable fragments 
(scFv) of a mAb specific for a surface antigen with an intracellular signaling domain. They are then 
stimulated to proliferation so that a large number of the altered cells can be re-infused back into the 
patient and induce an anti-tumor response290. Antigen specificity of T cells is dependent on the T cell 
receptor (TCR) itself and the specificity of the TCR determined by major histocompatibility complex 
(MHC) molecules. The target killing function of the engineered CAR T cells is MHC-independent. A 
great advantage since T cell therapy is frequently confronted with tumor escape by MHC 
mutations291. Thus far, the few attempts to use CAR T cell therapy in multiple myeloma have shown 
limited success. One of the few successful examples is the CD19 targeted CAR T cell approach. Garfall 
et al. observed a low but more frequent expression of CD19 on malignant plasma cells and targeted 
this population using CTL019 cells, which are lentiviral transduced autologous T cells harboring the 
CD3zeta/ CD137 anti-CD19 chimeric receptor. Of the 9 patients involved more than half were in 
remission292. Another example is the B cell maturation antigen (BCMA)-directed CAR T cell. BCMA is 
uniformly expressed in more than 60% of the MM patients. Since BCMA is only expressed by plasma 
cells and a small fraction of B cells this looks an encouraging target. 11 patients with advanced MM 
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and a median of seven previously failed therapies have participated in the phase I clinical trial. Two 
patients treated at the highest dose had strong anti-cancer responses. One achieved a stringent 
complete remission, while the other had undetectable MM cells in the BM cells, but had not yet 
reached the complete remission status. Of the six patients treated on the lowest two doses, one 
patient experienced a short partial remission and the other five remained stable. Two patients on the 
second-highest dose maintained stable disease, and one patient obtained a very good partial 
response293. However, there are many challenges and unknowns that have to be taken into account 
such as cell dosage, toxicity, timing of CAR infusion and what immune cell to use, etc. In MM, many 
of the potential CAR target antigens have a broad normal tissue distribution. So being cautious is 
warranted.  
 
5. Drug resistance in multiple myeloma 
Drug resistance still constitutes a major obstacle for the successful treatment of MM. Despite the 
major advances obtained in the field, many patients relapse and become refractory to the available 
treatments. Resistance can be caused by either intrinsic (Figure 4) or extrinsic BM-mediated 
mechanisms. Intrinsic resistance is defined as an innate property of the MM cells to resist therapy at 
diagnosis. This can be caused by mutations, translocations, methylations or microRNA 
abnormalities294,295. However, in general most of the patients initially respond to treatments, but 
relapse later on and become insensitive to treatment. This is called acquired drug resistance. Below, 
different mechanisms contributing to MM drug resistance are discussed. 
5.1  Intrinsic mechanisms 
5.1.1 Drug efflux pumps 
The efflux ATP-dependent transporter P-glycoprotein, also referred to as MRD-1 or ABCB1, has been 
observed to be frequently overexpressed upon exposure to therapeutic agents such as doxorubicin, 
vincristine, dexamethasone and PIs (bortezomib and carfilzomib), resulting in a reduced 
accumulation of the drug in the cell and subsequently contributing to resistance295–299. In order to 
overcome this resistance, combinations with P-glycoprotein inhibitors (cyclosporine, verapamil and 
PS-833) and vincristine, adriamycin and dexamethasone were tested. Unfortunately, no clinical 
benefits were observed due to poor inhibition of the P-glycoprotein and toxicity300. ABCG2, another 
member of the efflux ATP-dependent transporter family, also appeared to be upregulated upon 
treatment, however it didn’t seem to contribute to multidrug resistance301. Recently, Zhou et al. 
could demonstrate the overexpression of NEK, which is responsible for the upregulation of the ABC 
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transporter family members (including P-glycoprotein), resulted in drug resistance to bortezomib and 
doxorubicin, consequently leading to rapid relapse and a poor outcome302. 
5.1.2 Alteration in drug targets and pathways 
The upregulation of the IGF-1/ IGF-1 receptor pathway has also been shown to contribute to 
bortezomib resistance in MM. Addition of IGF-1 reduced the sensitivity to bortezomib. Moreover, 
knocking down the IGF-1 receptor increased the sensitivity of MM cell lines and primary patients 
samples to bortezomib. Furthermore, combination of bortezomib and the IGF-1 receptor inhibitor 
OSI-906 acted synergistically in MM cell lines and murine xenograft MM models, whereas single 
agent therapy had no effect82. β-catenin, key protein in the canonical Wnt pathway, degrades via the 
ubiquitin-proteasome pathway. MM cell lines with higher β-catenin levels were bortezomib resistant 
and had higher levels of TCF-4 transcription factor (central player in Wnt signaling). Reduction of 
cytoplasmatic levels of β-catenin by arsenic trioxide increased the sensitivity of MM cells against 
bortezomib303. The group of Vacca et al. found that the C-MET pathway is constitutively expressed in 
relapsed resistant MM patients. C-MET phosphorylation in resistant MM cells could be observed304. 
Inhibition of the latter increased apoptosis, downmodulated the proliferation of resistant MM cells 
and reversed resistance towards bortezomib, melphalan, doxorubicin in vitro. In vivo tumor growth 
could be delayed in MM xenograft models304. Upregulation of heat shock proteins (HSP) can be the 
consequence of a down modulation of the ubiquitin-proteasome pathway and has been linked to 
drug resistance. They contribute to MM survival by maintaining protein homeostasis, blocking 
apoptosis and stabilizing oncoproteins. Different inhibitors such as HSP-70, HSP-90 and Hsf1, master 
regulator of heat shock expression, were developed and display promising results in combination 
with PIs regarding the reduction of MM activity305–308. 
The drug bortezomib induces a full inhibition of ubiquitinated protein hydrolysis through selective 
binding to the proteasome subunit β5 (PDMB5). In vitro studies, demonstrated that resistance to 
bortezomib has been linked with an overexpression or a point mutation of the PSMB5. Silencing of 
PSMB5 increased the sensitivity against bortezomib309. However, this could not be demonstrated on 
primary samples or relapsed patients after bortezomib treatment310. Activation of P53 has also been 
considered as an interesting novel treatment target to overcome drug resistance in MM. P53 
mutations are present in 2-3% of newly diagnosed patients, with an incidence increasing at later 
stages of the disease. Patients harboring a p53 mutation are in general resistant to all standard 
treatments311,312. P53 is a crucial tumor suppressor protein responsible for the control of cell cycle, 
apoptosis, DNA repair, cellular senescence and autophagy. Inactivation of P53 can be the result of 
mutated or overexpressed murine double minute 2 (MDM2)240. MDM2 inhibitors showed anti-
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myeloma activity in MM cell lines and primary cells from patients and inhibited MM cell growth in 
the BM microenvironment313. More recently, the oncoprotein mucin 1 C-terminal subunit (MUC-1-C) 
has been identified as an important drug target to overcome drug resistance. An upregulation of 
gluthation and TIGAR, the p53-inducible regulator of glycolysis and apoptosis was demonstrated by 
the authors in bortezomib MM resistant MM cells. Pharmacological inhibition of MUC-1 proved to be 
successful in the reduction of TIGAR and gluthation and increased oxidative injury and cell death in 
bortezomib resistant MM cells314. Approximately 20% of the MM patients harbor genetic lesions in 
genes of the NF-κB pathway leading to uncontrolled NF-κB activation and loss of functional TRAF3, 
being one of the most common deleted/ mutated genes37. Our lab recently reported the cellular 
inhibitor of apoptosis 2 (cIAP2) as being an important player in resistance of MM cells harboring 
TRAF3 deletions to proteasome inhibition37. Resistance was caused by a decrease of cleaved caspases 
upon treatment, activation of the canonical NF-κB pathway, and dysregulation of genes, including 
downregulated NF-κB target genes with known anti-tumor activity37. As mentioned before, cereblon 
is an essential drug target to mediate the anti-cancer effects induced by IMiDs. Transduced MM cells 
with shRNA for cereblon were less sensitive to lenalidomide compared to parental cells. Additionally, 
acquired resistance to IMiDs pomalidomide and lenalidomide was accompanied with a strong 
reduction in the cereblon protein. In 85% of lenalidomide refractory patients cereblon expression 
seemed to be decreased indicating its clinical relevance253. 
5.1.3 Alteration in drug metabolism 
Systemic and intracellular drug concentrations are determined by drug metabolizing enzymes. 
Oxidation, reduction, hydrolysis and conjugation are crucial processes for the protection of normal 
cells against toxins. Unfortunately, these reactions are also able to induce drug resistance due to 
activation of prodrugs or increased inactivation of drugs. We previously illustrated a correlation 
between bortezomib resistance and the active Notch pathway. Activation of the Notch pathway 
induced the expression of a cytochrome P450 enzyme, CYP1A1, involved in drug metabolism. 
Blocking CYP1A1 rescued bortezomib sensitivity315.  
The response rate of diagnosed MM patients to induction therapy melphalan is situated between 70-
80%, nonetheless all patients eventually relapse due to acquired resistance. Elevated gluthathion 
levels have been identified as one of the underlying mechanisms and this was linked with the 
upregulation of the y-glytamylcysteine synthetase enzyme. Blocking this last one with buthionine 
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5.1.4 Clonal evolution and heterogeneity  
Resistance and relapse of MM patients can also arise from an existing clone that has mutated or 
adapted to initial therapy (acquired resistance). For instance, the development of the different MM 
sub-clones with great genetic diversity during disease progression from MGUS to MM can lead to 
resistance318. They can differ in clonogenic potential, differentiation status and drug sensitivity. In 
high-risk patients it has been demonstrated that competing sub-clones can be present, evolve over 
time and develop therapeutic selection. Primary MM tumors can consist of different subpopulations 
such as B cells, activated B cells, pre-plasmablast cells, plasmablast cells and plasma cells as 
demonstrated by Leung-Hagesteijn et al319,320. Differences in bortezomib sensitivity could be 
observed for these different subpopulations and appeared to be linked to XBP-1 expression. Plasma 
cells and plasmablasts were XBP-1 positive and bortezomib sensitive (constituting the biggest 
population of the tumor) while pre-plasmablasts and earlier B cell progenitors (which are a minor but 
more immature population of the tumor) were negative and were insensitive to PIs. This population 
consequently expands and this results in relapse. MM patients resistant to bortezomib showed 
reduced expression levels of XBP-1 and IRE-1 compared to bortezomib sensitive patients. This clearly 
indicates that absence for XBP-1 promotes resistance to PIs and that tumor progenitors mediate 
treatment failure in MM319,320. 
Our lab investigated the clonogenic potential of CD138+ and CD138-MM cells. CD138+ cells showed to 
have a higher tumor–initiating and clonogenic capacity compared to CD138-MM cells. However 
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Figure 4: Summary of the different intrinsic mechanisms of drug resistance in multiple myeloma. Mechanisms including 
increased drug efflux, clonal evolution, altered drug targets, drug metabolism and pathways are all implicated in the 
development of MM resistant cells to therapy. Mucin A C-terminal subunit (MUC-1); Heat shock protein (HSP); Glutathion 
(GSH); Cereblon (CRBN); Cytochrome P450 family 1, subfamily 1, polypeptide 1 (CYP1A1); insulin-like growth factor 1 




5.2 Extrinsic mechanisms 
As already briefly mentioned before, BM microenvironment interactions are a crucial factor in MM 
pathology (section 2.4). Cell adhesion-mediated drug-resistance (CAM-DR) represents an extrinsic 
drug resistant mechanism caused by cell-cell contact or adhesion of cells to the extracellular matrix 
(ECM) proteins, including fibronectin. Adhesion of MM cells to fibronectin via β1 integrins results in a 
G1 arrest due to increased protein levels of p27kip1, inhibition of cyclin A and cyclin E kinase activity, 
upregulation of p21Cip1/Waf1 or downregulation of Bim (a member of the apoptotic Bcl-2 
family)89,92. Antisense oligonucleotides for p27kip1 were not able to abrogate the adhesion of MM 
cells to fibronectin; however, MM cells became more sensitive to cytotoxic agents89. Furthermore, it 
has been demonstrated that β1 integrin adhesion increases IL-6 (gp130) mediated STAT3 
phosphorylation in MM cells, leading to increased tumor proliferation and survival322. The sensitivity 
of MM cells to bortezomib and dexamethasone could be increased by the use of a monoclonal 
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antibody directed against IL-6, named CTNO 328323. These observations highlight the crucial role of 
IL-6 in anti-apoptosis and drug resistance in MM. Shain and colleagues demonstrated that adhesion 
of MM cells to fibronectin induced drug resistance by CD95-mediated programmed cell death by 
regulating the cellular localization and availability of c-FLIPL (c-Fas-associated death domain-like IL-1-
converting enzyme-like inhibitory protein-long)324. Hepatocyte growth factor (HGF) promoted the 
adherence of MM cells to fibronectin via VLA-4 integrins and activation of the PI-3K/AKT pathway 
and NFκB pathway325. It has been observed that VLA-4 induces phosphorylation of several signal 
transduction molecules including CD19-receptor-associated protein tyrosine kinases and focal 
adhesion kinase (pp125FAK or FAK), which is an upstream activator of MAPK/ERK signaling 
pathway326,327. FAK plays a major role in inhibiting apoptosis both in adherent cells and suspension 
cells. Heat shock proteins (HSP) were also associated with CAM-DR as adhesion of MM cells to BMSCs 
and fibronectin upregulates HSP-70 in MM cells. Blocking HSP-70 resulted in enhanced melphalan-
induced apoptosis328. Increased survivin expression could be observed after co-culturing human MM 
cell lines with BMSCs. Furthermore, inhibition of survivin reduced MM cell proliferation and 
increased sensitivity to doxorubicin, melphalan and dexamethasone329. Adherence of MM cells to 
BMSCs also increased B7-H1 molecules, Bcl-2 en FasL expression on MM cells and was associated 
with drug resistance to melphalan and dexamethasone330. TNFα secreted by plasma cells upregulates 
the expression of adhesion molecules on both MM plasma cells upregulates the expression of 
adhesion molecules on both MM cells and BMSCs, increasing the adhesion of both cell types to each 
other, with associated CAM-DR and induction of IL-6 and VEGF secretion331. 
Adhesion of MM cells to BMSCs induces activation of the Notch pathway. Pharmacological inhibition 
of the Notch pathway with a γ-secretase inhibitor (GSI) results in apoptosis of MM cells and 
prevented BMSCs-mediated drug resistance332. Treatment with GSI significantly increased the 
cytotoxicity of chemotherapeutic agents including doxorubicin and melphalan332. It has been found 
that lenalidomide-resistent cell lines overexpress the hyaluronan-binding protein CD44, a 
downstream target of the Wnt/β-catenin pathway333. Lenalidomide resistant models demonstrated a 
higher adhesion capacity and inhibition of CD44 by short hairpin RNA or monoclonal antibodies was 
able to reduce adhesion and increase sensitivity towards lenalidomide. Suppression of the Wnt/ β-
catenin pathway by FH535 also increased lenalidomide cytotoxicity333. 
Chromosomal translocations and gene mutations could also be involved in CAM-DR induced drug 
resistance. For example, knockdown of MMSET protein in MM cells harboring t(4.14) reduced MM 
cell proliferation, induced apoptosis and changes two genes (DSG2 and ADAM9) that were associated 
with CAM-DR59. Mutations in oncogenes including RAS and c-MAF were also described to be involved 
in adhesion of MM cells to BMSCs334,335. 
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6. Preclinical models in multiple myeloma 
Preclinical in vivo models are essential and crucial tools for understanding the pathophysiology of 
MM. Over the years, different mouse models have been developed in order to study MM but also to 
improve current therapeutic approaches and to screen the efficacy of new treatments. Although, 
each model has his advantages, pitfalls and restrictions which will be briefly discussed in the next 
part. 
6.1 5TMM models 
The 5TMM models are syngeneic and immunocompetent murine models that were originally derived 
from aged C57Bl/KaLwRij mice that spontaneously developed MM. By isolation of plasma cells from 
the BM of diseased mice and subsequently intravenous injection in young healthy mice these models 
can be maintained336,337 (Figure 5). Different models such as the 5T33MM, 5T2MM and 5TGM1 exist, 
these models are mimicking the human disease closely and are characterized by elevated M-protein 
levels in the serum, which are correlating with disease progression. Additionally, a major colonization 
of MM cells can be observed within the BM, spleen (5T2MM and 5T33MM) and the liver (5T33MM). 
The 5T33MM model is known to be aggressive and developing within 3 to 4 weeks, while the 5T2MM 
is a less aggressive model. This model takes 12 weeks to develop the disease. In contrast to the 5T33, 
the 5T2MM model also display occurrence of bone lesions17,338,339. The 5TGM1 model constitutes a 
sub-clone of the 5T33MM cells and can grow in vitro as well as in vivo. The characteristics of this 
model are similar to these of the 5T33MM model together with the occurrence of osteolysis338,340. 
The main asset of the 5TMM models is the close interaction with the syngeneic and 
immunocompetent BM environment in which they develop. This makes them attractive models to 
study the interactions between MM cells and the BM microenvironment, but also the 
intercommunication between different immune cells, such as NKT cells and MDSCs 341,342. However, 
since these models are entirely murine, differences on biological aspects between mice and men can 
be a limiting factor for some experiment setups. Also in terms of genetics they only represent a single 
subtype of MM. 
6.2 Transgenic models 
Other models used to study MM are transgenic models. They are developed by dysregulating key 
genes involved in the MM development. The Eµ-XBP-1s and Eµ-MAF models for example, are using 
this approach where respectively x factor box binding protein-1 spliced isoform (XBP-1s) and MAF 
genes are dysregulated, leading to the formation of mixed B-lymphomas and MM-like tumors343,344. 
The Vk* MYC model, another preclinical murine model, is genetically engineered to activate the c-
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myc oncogene under control of kappa light chain (Vk) regulatory elements. The activation of the MYC 
transgene in the germinal center of B-lymphocytes, results in the spontaneous development of 
MGUS, ultimately leading to MM345. These models are ideal to investigate the role of the 
dysregulated genes enhancing progression to MM, together with compounds targeting these genes. 
The pitfalls of these murine models hampering their general use are the labor intensiveness to 





Figure 5: Schematic overview for the propagation and maintenance of the 5TMM murine models. PCs: plasma cells. 
 
6.3 Xenograft models 
In the xenograft models human MM cell lines or primary MM cells are engrafted into 
immunodeficient mice. These severe combined immunodeficient mice (SCID) lack functional B and T 
cells, preventing graft rejection. The engraftment of human MM cells can be administered locally or 
systemically resulting in palpable tumors or in a diffuse spread MM346–348. Nonetheless, the BM 
microenvironment is not taken into account and the success of engraftment rather remains poor. 
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Two other used engraftment strategies are based on the implantation of human fetal bones 
containing human myeloma cell lines or primary MM cells. Here, MM cell growth is sustained by the 
presence of the human fetal microenvironment347,349,350. However, some pitfalls are linked to this 
model such as ethical issues, the large number of primary MM cells needed as well as the allogeneic 
background of the BM microenvironment. By implantation of MM cells into three-dimensional bone-
like poly-ε caprolactone polymeric scaffolds coated with murine or human BM stromal cells these 
limitations can be overcome351. Also ectopic MM models exists, where MM patient-derived BM 
biopsy are implanted into SCID mice. Upon growth, implants are removed and fragmented for serial 
passages by intramuscular/subcutaneous implantations or intravenous injections352. The intratibial 
injection of human MM cells is a relatively new model. MM cells seem to grow exclusively in the BM 
and major features of the human MM disease such as M-protein spike and bone lesions are exhibited 
in this model. The asset here is that primary MM cells obtained from newly-diagnosed patients with 
different classifications or from relapse refractory patients showing a resistant phenotype can be 
used353. In this way many models mimicking the patient heterogeneity can be developed when 
sufficient patient material can be obtained and if the engraftment was successful. The overall major 
limitations of xenograft models are the absent immune system and the fully compatible 
microenvironment. However, these models can be used to test novel potential anti-MM agents 
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Abstract 
Natural killer T (NKT) cells constitute a unique subset of innate-like T lymphocytes which differ from 
conventional T cells by recognizing lipid antigens presented by the non-polymorphic major 
histocompatibility complex (MHC) I-like molecule CD1d. Despite being a relatively infrequent 
population of lymphocytes, NKT cells can respond rapidly upon activation with glycosphingolipids by 
production of cytokines which aim to polarize different axes of the immune system. Due to their dual 
effector capacities, NKT cells can play a vital role in cancer immunity, infection, inflammation and 
autoimmune diseases. It is believed that modulation of their activity towards immune activation can 
be a useful tool in anti-tumor immunotherapeutic strategies. Here we summarize the characteristics 
of NKT cells and discuss their involvement in immunosurveillance. Furthermore, an update is given 
about their role and the progress that has been made in the field of multiple myeloma (MM). Finally, 
some challenges are discussed that are currently hampering further progress. 
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1. Natural killer T cells: subsets and function  
Natural killer T (NKT) cells constitute a highly conserved heterogeneous subset of innate-like T 
lymphocytes. This small population owns unique phenotypic and functional properties that set them 
apart from conventional T cells by exhibiting characteristics of both the innate and the adaptive 
immune system1,2. They diverge from conventional T cells by recognizing foreign and self 
(glyco)sphingolipid antigens presented by the non-polymorphic major histocompatibility complex 
(MHC) I-like molecule CD1d, expressed on professional antigen-presenting cells (APCs)2,3. Originally 
NKT cells were defined as expressing both the CD3 and αβ T cell receptors (TCR) and lineage markers 
from natural killer (NK) cells, such as CD56 or CD161 (human) and NK1.1 (murine). It is now generally 
accepted that this description is no longer accurate since these cells only seem to be a part of the 
broader NKT cell family4. Moreover, NKT cells have a remarkable capacity to produce extensive 
amounts of cytokines upon stimulation to activate NK cells, dendritic cells (DC), regulatory and 
conventional T cells and B cells5,6. Thereby enhancing a cascade of complementary cytokines and 
chemokines and stimulating additional populations to mediate immune surveillance6. Due to their 
broad cytokine profile, NKT cells can both exert an immune enhancing and immunosuppressive role 
and play therefore a vital role in various pathologies, such as cancer, infection, inflammation and 
autoimmune diseases6–10. Modulating their activity towards immune activation could be a useful tool 
for improving vaccines in cancer, infectious diseases and other therapeutic settings. 
 
1.1 Type I Natural Killer T cells 
The type I NKT cells also referred to as “invariant” NKT cells (iNKT) are the main studied 
subpopulation of NKT cells and are usually linked to promotion of tumor immunity. They express a 
semi-invariant TCRα chain (Vα14-Jα18 in mice, Vα24-Jα18 in humans) paired with a heterogeneous 
Vβ chain repertoire (Vβ2, 7 or 8.2 in mice and Vβ11 in humans)2. Type I NKT cells often express other 
NK surface markers such as NK1.1 (in some mouse strains) or CD161 (in human), NKG2D, CD44, 
CD56, CD69, CD94, CD122 and members of the Ly49 family7,8. iNKT cells can be further subdivided 
according to their CD4/CD8 co-receptor expression: CD4+ and CD4-CD8-subsets, and a small subset of 
CD8+ cells (only human) have been described11–13. Type I NKT cells are present in different tissues, 
such as the spleen (0,2 - 0,5% of the T lymphocytes), bone marrow, thymus, lymph nodes and blood 
(0,01 - 0,5% of the T lymphocytes) in mice11,14. The highest frequency is found in the liver with around 
10 to 30% of all T lymphocytes15. These hepatic iNKT cells possess a strong anti-tumor capacity and 
show different functional characteristics than the NKT cells from other tissues14. In humans, type I 
NKT cells appear to be approximately 10 times less abundant in the liver than in mice while for the 
spleen, bone marrow, blood and lymph nodes the ranges remain similar. The highest prevalence is 
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found in the omentum, representing 10% of the white adipose tissue T cell population, whereas their 
frequency and number in the peripheral circulation vary widely between individuals1,7,11,16. 
Identifying lipid antigens recognized by NKT cells is still an ongoing challenge. Type I NKT respond to 
α-and β-linked glycosphingolipids among which α-Galactosylceramide (αGalCer, KRN700), an 
exogenous synthetic glycolipid originally extracted from the marine sponge Agelas mauritianus or 
microorganisms symbiotic with the sponge4,17. α-GalCer is the most-well characterized agonist for 
type I NKT cells in humans and mice and shows a very potent capacity to induce cytokine release by 
iNKT cells2 . Today, several new analogues of αGalCer, showing weaker or stronger agonistic 
potential, have been synthetized including, α-C-GalCer, naphthylurea 6"-derived α-GalCer (NU-α-
GalCer), C20:2, DB06-1 and OCH18. Also microbial and self-glycolipid iNKT cell antigens such as 
ceramide structures (Sphingomonas species), diacylglycerols (Borrelia burgdorferi and Streptococcus 
pneumoniae), cholesteryl-sugars (Helicobacter pylori) but also phospholipids (Mycobacterium 
tuberculosis), the lysosomal glycosphingolipid isoglobotrihexosylceramide (iGb3) and the 
peroxisomal derived lipid plasmalogen lysophosphatidylcholine (lyso-PC) have been identified19–25. 
More recently, in their quest to find new endogenous ligands Kain et al revealed the presence of 
mammalian α-linked glucosylceramides26. This defies the previous hypothesis where it was thought 
that humans were not able to make α-linked sugar moieties due to the presence of natural anti-α-
linked sugar antibodies27. Direct CD1d-agonist stimulation of the TCR complex is accompanied by the 
rapid and robust release of T-helper 1 (Th1), Th2 and Th17 cytokines, including interferon-gamma 
(IFN-γ), interleukins (IL)-2, -4, -10, -13, -17, -21 and 22, granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and tumor necrosis factor-alpha (TNFα)3,7,10 (Figure 1). In addition, it was reported 
that cytolysis in a perforin-dependent manner, through the Fas-FasL axis or through expression of 
intracellular granzyme B is also promoted upon iNKT stimulation28–30. Similar to conventional T cells, 
through the engagement of costimulatory pathways such as CD40-CD40L and B7-CD28, DC are 
induced to maturate and secrete IL-12. In turn, IL-12 stimulates NK, NKT, and other T cells to produce 
IFN-γ which subsequently activates bystander cell activity and stimulates more downstream effector 
populations such as NK cells, CD8+ T cells and γδ cells7. Type I NKT cells are indirectly activated in 
response to pattern-recognition receptor (PRR) of toll-like receptor (TLR) signalling by APCs together 
with presentation of self-antigens through CD1d, inducing cytokine secretion by APCs such as IL-12, 
IL-18 and type I α/β IFNs7,21,31,32 (Figure 1). Also during inflammation, type I NKT cells can be 
stimulated in a TCR independent manner by different stimulatory and co-stimulatory signals, such as 
engagement of peroxisome proliferator activated receptor (PPAR)γ through bacterial products such 
as lipopolysaccharide (LPS)31,33. Activation of Fcγ receptors by antigen-IgG complexes, interaction of 
NK1.1 receptors with their ligands on APCs and activation of TLRs of previously activated type I NKT 
cells also take part in additional activation mechanisms of type I NKT cells31. 
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Figure 1: Major iNKT cell activation pathways. (A) Direct activation of iNKT cells occurs when the TCRVα14/24 interacts 
with a ligand presented by a CD1d molecule present on DCs or other APCs. DCs present exogenous glycosphingolipids such 
as the synthetic α-GalCer or microbial lipid-derived antigens and subsequently activate the iNKT cell. This CD1d dependent 
activation is followed by the secretion of cytokines such as IFN-γ and IL-4. (B) Indirect activation of iNKT cells can be induced 
by cytokine secretion of DCs such as IL-12. Engagement of a microbial Ag to the pattern-recognition receptor (PRR) of the 
toll-like receptor (TLR) present on APCs (e.g DCs) triggers IL-12 co-stimulation. IL-12 secreted by DCs binds to its receptor, IL-
12R, on iNKT cells which activates iNKT cells by inducing IFN-γ secretion. The activation occurs in the presence or absence of 
self or low affinity endogenous lipid antigens. Besides IL-12, also other cytokines such as IL-18 and type I-IFN (α & β) can be 
secreted and activate iNKT cells in a CD1d independent manner. iNKT, Invariant natural killer T; DCs, Dendritic cells; TCR, T 
cell receptor; α-GalCer, Alpha-Galactosylceramide; IL-12, Interleukin 12, IL-12R; Interleukin 12 receptor; TLR, Toll-like 
receptor; PRR, Pattern-recognition receptor; IFN, Interferon.  
 
1.2 Type II Natural Killer T cells 
Type II NKT cells are a CD1d-restricted subset that expresses more diverse αβ-TCRs (for example 
Vα3.2Jα9 or Vα8 with Vβ8 TCRβ-chain). They have an activated or memory phenotype and many also 
express NK surface markers3,34. Moreover, they have the ability to suppress autoimmunity and inhibit 
tumor rejection. In contrast to type I NKT cells, their distribution and physiological role is less 
understood. They compromise a minor subset in mice but constitute a major subgroup of the T cells 
in the bone marrow, liver and gut of humans15,35. Type II NKT cells are non-reactive to α-GalCer. 
 
 
78 iNKT cells in multiple myeloma 
Currently, the most widely studied type II NKT antigen is sulfatide, a glycolipid abundantly present in 
neuronal tissue, liver, kidney and pancreas36,37. Recent research also identified a range of 
hydrophobic antigens, such as lysosulfatide, lyso-PC, small aromatic (non-lipid) molecules and other 
lipids such as β-Glucosylceramide (β-GlcCer)(C24:0) and β-Galactosylceramide (β-GalCer) as being 
potential activators of type II NKT cells38–41.  
 
1.3 Other invariant-like T cells 
Next to the different subsets of NKT cells, it is worth to briefly mention another population of semi-
invariant T cells, called mucosal-associated invariant T cells or MAIT cells. They are restricted to a 
monomorphic MHC I-like molecule MR1. Similar to NKT cells, they express an invariant TCRα-chain 
(Vα33Jα19 in mice and Vα7.2α19 in humans) combined with a limited but not invariant range of 
TCRβ-chains42. Rare in laboratory mice, they appear to be a very significant subset of T cells in 
humans, accounting for 1-10% of T cells in peripheral blood and being predominantly present in liver 
and mucosal tissues. Surprisingly, a completely new and unexpected class of antigens was shown to 
be presented by MRI molecules to MAIT cells, namely vitamin B2 (riboflavin) metabolites43–45. 
Although these cells are not CD1d restricted, their similarities with NKT cells are intriguing46. 
Research on MAIT cells has till now been hampered due to the lack of identification tools and the 
unknown nature of the antigens. However, very recently Reantragoon et al. were able to develop 
MR1 tetramers which allowed them to better phenotypically characterize human and mouse MAIT 
cells47. This development will lead to an increased understanding of the nature of MAIT cells. Also γδ 
T cells belong to this non-conventional invariant T cell group. Being innate-like lymphocytes, they 
differ from conventional αβ T cells since they do not express the CD4 and CD8 co-receptors but 
express Toll-like receptors and share a number of markers with NK cells48. Subsequently, antigen 
recognition by γδ TCR is not restricted to MHC molecules. γδ TCR recognize a diverse array of self and 
nonself-antigens, such as small peptides, soluble or membrane proteins, phospholipids, prenyl 
pyrophosphates, and sulfatides, while αβTCR bind peptides  presented by MHC class I or class II 
molecules. In humans, γδ T cells represent 0.5 – 16% (on average: 4%) of all CD3+ cells in adult 
peripheral blood, and organized lymphoid tissues (thymus, tonsil, lymph nodes, and spleen), <5% in 
tongue and reproductive tract and 10 – 30% in intestine. In adult mice, 1 – 4% of all T cells in thymus, 
secondary lymphoid organs and lung are γδ T cells. γδ T cells are more abundant in other mucosal 
sites where they constitute 10 – 20% of all T cells in female reproductive organs, 20 – 40% of the 
intestinal intra-epithelial T cells and 50 – 70% of skin dermal T cells49. Moreover, the γδ TCR 
repertoire is restricted and depends on the tissue type and their localization. The conditions that lead 
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to responses of γδ T cells are not fully understood, and current concepts of them are 'first line of 
defense', 'regulatory cells', or 'bridge between innate and adaptive responses'. 
 
2. Natural killer T cells: Implications in tumor immunity  
2.1 Enhancement of tumor immunity 
Type I NKT cells are able to kill cancer cells directly or indirectly via the downstream activation of 
other innate and adaptive immune cells. Direct NKT lysis can be induced by perforin , via the Fas-FasL 
axis or through expression of intracellular granzyme B28,50. In vitro observations demonstrated that 
tumor cells expressing CD1d were more prone to  lysis induced by NKT cells51,52. This strengthens the 
hypothesis that high CD1d expression levels on tumor cells correlate with lower metastasis rates52. 
However, most of the tumor immunosurveillance by type I NKT cells is initiated by Th1 cytokines and 
is mainly dependent on the recruitment and activation of other cytolytic cell populations. In fact, 
large amounts of IFN-γ and cross-activation of NK cells are necessary for tumor protection upon α-
GalCer stimulation. Cytokines such as IL-12 and IL-18 are also necessary to reach optimal IFN-γ levels, 
consequently leading to tumor immunity53–55. Proof that tumor immunosurveillance by type I NKT 
cells occurs through CD1d became clear when adoptive transfer of liver DN type I NKT cells from WT 
into CD1d KO mice (lacking all NKT cells) did not confer protection. In Jα18 KO mice (missing type I 
but retain type II NKT cells) the NKT cell population was able to be recovered and tumor immunity 
could be rescued upon NKT cell transfer30,56. Nevertheless, in contrast with CD4+ liver type I NKT cells, 
protection could only be generated using the DN liver type I NKT subset. From these studies it can be 
concluded that different subsets of NKT cells can have different functions in tumor 
immunosurveillance14. Surface marker expression, anatomical origin as well as different antigens can 
alter the immunological capacity and function of NKT cells. Type I NKT cells not only increase 
protective cell responses but can also enhance tumor immunity by modifying the effects of 
immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs), suppressive IL-10 
producing neutrophils and T regulatory cells57–60.  
 
2.2 Suppression of tumor immunity 
Type II NKT cells possess an immunosuppressive activity in tumor immunology. By counteracting type 
I NKT cells and negatively influencing other immune cells they are capable to down-regulate tumor 
immunosurveillance61,62. CD4+ type II NKT cells are producing more IL-13 and IL-4 than type I cells63. 
By the release of Th2 cytokines, type II NKT cells have been shown to suppress autoimmune T cell 
responses. The original observation was made in a 15-12RM fibrosarcoma model where CD8+ 
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cytotoxic T cells were suppressed by CD4+ type II NKT cells through production of IL-13 which in turn 
induced TGF-β, leading to suppression of the anti-tumor activity63,64. Later on, a similar observation 
was also reported in several other solid tumor models such as in a CT26 colon carcinoma lung 
metastasis model, a subcutaneous CT26-L5 colon carcinoma model, an orthothopic K7M2 
osteosarcoma model and a renal cell adenocarcinoma liver metastasis model65. CD1d KO mice and 
Jα18 KO mice were compared side-by-side in different tumor models. CD1d KO mice were resistant 
to tumor growth while Jα18 KO mice behaved similar to wild type mice. This confirms the hypothesis 
that type II NKT cells present in Jα18 KO were sufficient for suppression of tumor 
immunosurveillance. Anti-CD4 treatment was able to abrogate the retained suppression, consistent 
with the original observation that the suppressing cell type has a CD4+ phenotype65. Furthermore, 
direct selective stimulation by sulfatide significantly induced growth of CT26 lung metastasis. The 
effect was retained in Jα18 KO mice but was lacking in CD1d KO mice. This indicated that the effect of 
sulfatide was only type II NKT cell specific. As a result, it was assumed that type II NKT cells also 
suppress anti-tumor immune responses in humans in a similar way61. 
 
Although the immunosuppressive role is often attributed to type II NKT cells, there are a number of 
exceptions reported in literature where type I NKT cells appear to support immunosuppression66–68. 
Th2 cytokines (IL-13, TGF-β) produced by type I NKT cells conferred immunosuppression, 
subsequently leading to the inhibition of cytotoxic T cells and NK cell activity. The outcome of type I 
NKT cell-activation is dependent on different factors such as the antigens, co-stimulatory signals and 
the cytokine milieu which determine the plasticity of these cells. Immunosuppressive Tregs have 
been shown to be supported by activated type I NKT cells through IL-2 production, but subsequently 
suppressed the NKT cells in a cell-cell contact manner69. Two studies have reported type I NKT cells 
capable of directly suppressing tumor immunity in animal models of hematological malignancies. In a 
RMA/ T cell lymphoma model, NKT deficient mice had augmented cytotoxic T cell activity and greater 
survival rates than WT mice67. In a model of Burkitt’s-like B cell lymphoma, Jα18 KO mice had 
significantly fewer splenic tumors than WT or CD1d KO mice. Stimulation of type I NKT cells with α-
GalCer did not increase tumor burden, it decreased tumor specific CD8+ T cells66.  
 
2.3 Cross regulation 
It has been demonstrated that type I and type II NKT subsets not only exert positive or negative 
effects on different cell populations but also cross-regulate each other. CD1d KO mice, deficient in 
both NKT types, showed strong resistance towards tumor growth in the CT26 colon carcinoma 
model, whereas Jα18 KO mice, lacking only type I NKT cells, showed higher sensitivity to tumor 
growth than WT mice. Consequently, this suggests that type I NKT cells may reduce the suppressive 
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effect of type II NKT cells61. The in vivo activation of type II NKT cells by sulfatide enhanced new 
tumor formation, and abrogated or reduced the positive clinical effects of α-GalCer when 
administered together. For example, decreased pro-inflammatory cytokine secretion was observed, 
thereby indicating that type II NKT cells may also have the ability to suppress type I NKT cell 
activation. Addition of the type II antigen sulfatide in vitro inhibited α-GalCer-induced IFN-γ, IL-2, and 
IL-4 production61,63,70,71. Moreover, Halder RC et al demonstrated by use of the model of concanavalin 
A-induced hepatitis, that the activation of sulfatide-reactive type II NKT cells and plasmacytoid DCs in 
the liver contributed to the anergy, or hyporesponsiveness of type I NKT cells72. However, it is unclear 
if this mechanism is similar in a tumor setting. Nevertheless, the finding that immune-protective type 
I and immune-suppressive type II NKT cells cross-regulate each other establishes an NKT regulatory 
axis and creates the opportunity to exploit this knowledge in a clinical setting. The success of 
immunotherapies may depend on which way the balance of the axis is shifted. Enhancing the activity 
of type I NKT cells while simultaneously blocking type II NKT cells could be a promising strategy for 
future anti-tumor therapies73. 
 
3. Natural killer T cells: Implications in multiple myeloma 
Different research groups provided evidence of type I NKT cells being quantitatively and qualitatively 
defective in MM, subsequently hampering their anti-tumor effects74 (Figure 2). The group of 
Dhodapkar et al. demonstrated that type I NKT cells are still detectable in the blood and tumor bed 
of MM patients at both early and progressive stages of the disease but they could observe that 
advanced stages of MM were associated with the progressive loss of the ability of iNKT cells to 
secrete IFN-γ. The type I NKT dysfunction could be overcome in vitro by using dendritic cells (DCs) 
pulsed with α-GalCer. When MM patients were injected with α-GalCer loaded DCs (at monthly 
interval 2 injections), their type I NKT cell pool expanded 100 fold, with improved function and these 
effects lasted for several months. Altogether, these results suggest that clinical progression is linked 
to an acquired but potentially reversible defect in type I NKT cells and supports the hypothesis that 
iNKT cells help in controlling the malignant growth of the MM cells74,75. Together with other groups 
they further demonstrated that MM cells are expressing CD1d and are sensitive to lysis induced by 
type I NKT cells, making them interesting targets for NKT directed therapies74. Spanoudakis et al has 
shown that CD1d was highly expressed on premalignant and early myeloma. With disease 
progression CD1d expression levels were down-regulated and eventually lost altogether in advanced 
MM patients and in most of the studied myeloma cell lines, leading to a reduction in survival76. 
Engagement of CD1d by anti-CD1d monoclonal antibodies was able to induce myeloma cell death in 
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vitro which was not induced by caspase-activation but was rather associated with overexpression of 
the pro-apoptotic protein Bax and mitochondrial membrane potential loss76.  
 
Figure 2: NKT dysregulation in multiple myeloma. Type I NKT cells are quantitatively and qualitatively defective in MM 
which hampers their anti-tumor potential. A dramatic drop of type I NKT cell number can be observed in tumor mouse 
models and MM patients. CD1d expression levels are down-regulated in advanced MM patients and expression is lost in 
most of the studied myeloma cell lines. Moreover, advanced stages of MM are associated with a progressive loss of function 
and their capacity to secrete IFN-γ. LEN has the ability to induce type I NKT expansion in presence of α-GalCer and to 
stimulate IFN-γ secretion by NKT cells in MM patients. Combination therapy provides downstream activation of NK cells, 
monocytes and eosinophils and ultimately promotes tumor suppression. A reduction of paraprotein is detected in the serum 
or urine. NKT, Natural killer T; DC, dendritic cells; NK, natural killer; Th, T helper; α-GalCer, Alpha-Galactosylceramide; IFN, 
Interferon. 
 
We recently investigated the number, activity and characteristics of type I NKT cells in the syngeneic 
preclinical 5T33MM murine model, an immunocompetent model which mimics the human disease 
closely77. Consistent with previous observations, our results demonstrated a dramatic drop of type I 
NKT cell numbers in the liver and spleen at the end stage of the disease. This decline was also 
detectable in the 5T2MM model, a slower progressing model. The ability of murine type I NKT cells to 
secrete IFN-γ in response to α-GalCer loaded mature DCs was abrogated at the end stage of the 
disease due to a decline in NKT number. Treatment with α-GalCer loaded DCs significantly increased 
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the survival of MM diseased mice for 1 week when they were injected on the same day of 5T33MM 
inoculation77. The group of Mattarollo et al. could also demonstrate that a single vaccination of 
irradiated tumor cells pulsed with α-GalCer was able to inhibit MM development and prolong 
survival of Vk*MYC mice78. Nonetheless, the expression of CD1d in the 5T33MM model was still high 
at the end stage of MM and lacked the potency to activate type I NKT cells and cause tumor cell lysis 
after stimulation with α-GalCer. We also found that the 5T33MM cells lacked the necessary co-
stimulatory molecules such as CD40, CD80 and CD86 potentially explaining our observations77. Hong 
et al. however demonstrated that a vaccine consisting of α-GalCer-loaded MOPC315BM myeloma 
cells efficiently promoted anti-tumor immunity, slowed down tumor growth, induced established 
tumor regression and protected (surviving) mice from tumor rechallenge. Strong humoral immune 
responses, including myeloma-specific antibodies and cellular immune responses, such as myeloma-
specific CD8+ cytotoxic and memory T cells were induced and Treg cells were significantly 
decreased79. It is known that MM correlates with a high vascular index. Targeting angiogenesis is 
therefore an important therapeutic tool to reduce MM progression. We were able to demonstrate 
that the conditioned medium of α-GalCer stimulated NKT cells induced a reduction in endothelial cell 
proliferation, migration and network formation and increased their apoptosis in vitro, whereby the 
JAK-STAT signalling pathway was highly activated. Furthermore, injecting α-GalCer in vivo led to a 
significant reduction in microvessel density80. 
 
Song et al. succeeded in activating and expanding CD1d-restricted type I NKT cell lines isolated from 
newly diagnosed and advanced MM patients81. The results showed that type I NKT cells could secrete 
Th1-polarized cytokines in response to α-GalCer loaded DCs or primary MM cells and that they could 
induce direct cytotoxicity against the primary MM cells. LEN, a derivate of thalidomide and one of 
the novel drugs used to treat MM, is effective in inducing complete or good partial responses and is 
able to improve the survival of MM patients74. It has among others immunomodulatory properties, 
although the specific cellular targets and molecular mechanisms responsible for the 
immunomodulatory actions of LEN have not been fully elucidated yet. Song et al. provided preclinical 
evidence that a combination of type I NKT immunotherapy with LEN led to an increased Th1 cytokine 
production and reduced Th2 cytokine levels (Figure 2)81. The group of Chang et al. observed an even 
greater effect when LEN was combined with dexamethasone75. They further obtained striking results 
when α-GalCer loaded DCs were injected in 3 MM patients at stage III. Intravenous injection of α-
GalCer loaded mature DCs in these patients, who had received chemotherapy and stem cell 
transplantation, gave a remarkable boost in the expansion of circulating type I NKT cells which 
sequentially resulted in a reduction of the serum and urine levels of M-protein. A sustained 
expansion of type I NKT cells, lasting 3 months after vaccination, was observed in one of the patients. 
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An increase of different factors such as IL-12 p40, IP-10 and MIP-1β in the patient serum levels were 
detected75. Confirming previous in vitro results, Dhodapkar et al found that LEN had the ability to 
enhance type I NKT expansion in presence of α-GalCer and to stimulate IFN-γ secretion by NKT cells 
in both healthy donors and MM patients (Figure 2). The combination therapy provided downstream 
activation of NK cells, monocytes and eosinophils by upregulating surface receptors such as NKG2D, 
CD56 and CD16, ultimately promoting tumor suppression82.  
 
Data on type II NKT cells and MM are scarcely present in literature. However, their increase in the 
peripheral blood of MM patients was reported by Chang DH et al. Those type II NKT cells appeared to 
be specific for lyso-PC and had a Th2-skewed profile with high expression levels of IL-1339. Taken 
together, these data suggest that NKT cells are a particularly attractive subset to target and 
encourage the rationale for type I NKT cell-mediated immunotherapy in MM.  
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                 Tabel 1. Brief overview of α-GalCer–based clinical trials in different cancers. 
 
α-GalCer: alpha-galactosylceramide; APCs: antigen-presenting cells; GM-CSF: granulocyte macrophage colony-stimulating factor; i.a.: 
intraarterial; i.d.:intradermal; i.v.: intravenous; MoDCs: monocyte-derived dendritic cells; NKT: natural killer T cells; PBMCs: peripheral blood 






Therapeutic setting Cancer type Clinical outcome Immunological 
responses 
Ref. 
α-GalCer (i.v.) Solid tumors 7 out of 24 patients had stable 
disease 
Increase in IL-12, 





MoDCs (i.v. & i.d.) 
metastatic 
malignancies 
2 patients out of 12 with 
decreased tumor markers in 
serum, 1 with tumor necrosis 
Expansion NKT cells, 
activation of T and 






Non-small cell lung 
cancer  
5 out of 9 had no change in 
disease status, 4 patients had 
disease progression, but 1 case 
had increase in NKT cells, 2 cases 
had significant responses 
Expansion NKT cells, 







Renal cell cancer 
Multiple myeloma 
The patient had stable disease 
The patient had stable disease 
The 3 patients had decreased 
levels of paraprotein in serum or 
urine 
Expansion NKT cells 
and antigen-specific 
memory T cells 
75
 
Ex vivo expanded NKT cells 
with autologous α-GalCer-
pulsed PBMCs (i.v.) 
Non-small cell lung 
cancer  
4 out of 6 patients had a stable 
disease, 2 patients had disease 
progression 
Expansion NKT cells, 





APCs (via nasal submucosa) 
Head and neck 
squamous cell 
carcinoma 
1 out of 9 patient had a partial 
response, 5 patients had a stable 
disease, 3 patients had disease 
progression 
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor 
tissue and PBMCs 
86
 
α-GalCer-pulsed APCs (i.v.) Non-small cell lung 
cancer 
5 out of 17 patients had a stable 
disease, the remaining 12 had 
disease progression 
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor 
tissue and PBMCs 
87
 
In vitro expanded NKT cells 
(i.a.) and  α-GalCer-pulsed 
APCs (via nasal submucosa) 
Head and neck 
squamous cell 
carcinoma 
1 out of 8 patients had disease 
progression, 3 patients reacted 
partially, 4 patients had a stable 
disease 
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor 
tissue and PBMCs 
88
 
In vitro expanded NKT cells 
(i.a.) and  α-GalCer-pulsed 
APCs (via nasal submucosa) 
Head and neck 
squamous cell 
carcinoma  
5 out of 10 patients reacted 
partially, 5 patients had a stable 
disease 
Expansion NKT cells, 
elevated IFN-γ cell 
number in tumor 




MoDCs (i.v) and LEN (oral, 
10mg/day, 3 28 day cycles) 
Multiple myeloma 3 out of 6 patients with 
decreased levels of paraprotein 
in serum or urine 
NKT, NK, monocyte 
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4. Natural killer T cells: Challenges 
The use of α-GalCer and other glycolipids to activate type I NKT cells has engendered a lot of 
preclinical success in mice, leading to multiple clinical trials in humans (Table 1). However, the 
benefits for patients remains limited since the translation of these preclinical benefits into clinical 
trials is associated with some challenges90. As noted above, the frequency of type I NKT cells is much 
lower in humans than in mice and numbers are more variable between individuals which possibly can 
contribute to the heterogeneity in clinical responses15,91,92. In advanced stages of cancers, like MM, 
the number and function of type I NKT cells is often reduced. Therefore, the effects of NKT activation 
may be less amplified in humans than in mice90. Moreover, we can also presume that patients that 
participated in these trials had a much more advanced disease than mice in which α-GalCer had a 
significant greater therapeutic effect. It is worth to mention that it has been demonstrated in mice 
that following injection of α-GalCer, type I NKT cells cannot be restimulated for at least two month93–
95. This means they are sensitive to anergy which is a property that can also explain the lack of 
success in humans. Being confronted in our research with this problem as well we have the opinion 
that this is one of the major obstacles which need to be overcome to give a future to an NKTbased 
immunotherapeutic approach. Specifically, marked increase in programmed death-1 (PD-1) 
expression after α-GalCer stimulation has been shown to hamper the beneficial and/ or long lasting 
effects of NKT cell-mediated treatment96. We also believe that a suboptimal activation due to 
uncontrolled distribution of α-GalCer remains a big problem. Therefore, it would be of great value to 
develop new α-GalCer carrier systems (e.g. nanovectors, liposomes and exosomes) to optimize NKT 
cell responses and cancer immunotherapy97,98. Also the different (sub)populations, their adaptable 
reactivity against ligand agonists and the different APCs involved in the antigen presentation add 
more complexity and can explain the paradox regarding the NKT cell subpopulations. Furthermore, it 
is possible that the presence of different endogenous self-antigens, leading to auto-reactivity, can 
activate different pathways in the NKTs that are modulating the NKT cell – cell talk99. Finally, our 
knowledge of the presence of endogenous ligands is still very limited hampering our true 
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In multiple myeloma (MM), survival and progression largely rely on the crosstalk with the bone 
marrow (BM) microenvironment, inducing immune escape, angiogenesis, bone destruction and drug 
resistance. Despite great therapeutic advances, still most of the MM patients relapse and remain 
incurable. Over the past years, immunotherapy has emerged as a new field in cancer therapy. Here, 
the immune cells of the patient itself are activated to target the tumor. In MM, several effector cells 
of the immune system are present in the BM microenvironment; unfortunately, they are mostly all 
functionally impaired. In this study we focused on the immune system in MM, particularly on CD1d-
restricted T cells recognizing glycosphingolipid-based antigens, the invariant natural killer T (iNKT) 
cells. These cells have the capacity upon activation to rapidly release copious amounts of cytokines, 
such as interferon (IFN)-γ, affecting a wide range of innate and adaptive immune responses. In recent 
years, manipulation of iNKT cells emerged as an attractive target for immunotherapy due to their 
crucial role in the initial steps of protective and/or anti-tumor immunity. The discovery of synthetic 
compounds such as α-Galactosylceramide (α-GalCer), potently activating iNKT cells, led already to a 
better manipulation of their immune responses. We and others demonstrated iNKT cell defects in 
MM, including impaired IFN-γ production, decreased cell prevalence and a strong reduction in CD1d 
expression levels on antigen presenting cells. While the total picture of iNKT cells as players in the 
immune system is rapidly evolving, the cause of their deficiency in hematological malignancies, such 
as MM, still remains to be determined. Therefore this study aimed to unravel and overcome 
mechanisms being responsible for iNKT cell deficiency in MM by use of patient samples and the 
preclinical immunocompetent 5T33MM murine model. 
 
Specific aims of the study: 
 
1. To investigate the crosstalk between leptin receptor activation and iNKT cell-mediated anti-
tumor immunity in MM development.  
Fatty deposits can occupy up to 70% of the BM cavity with aging, yet surprisingly little attention has 
been given to the role of BM adipocytes and their secreted adipokines in MM development. BM 
adipocytes may support MM oncogenesis by stimulating migration and proliferation of malignant 
plasma cells through secretion of myeloma-supportive adipokines such as leptin and are known to be 
negative regulators of the hematopoietic environment. Leptin plays a crucial role in energy 
homeostasis but also displays immune modulatory properties. Nevertheless, its role in anti-tumor 
immunity is unclear. iNKT cells have been shown to closely interact with adipocytes in a CD1d 
dependent manner. Because increasing fat deposition with aging coincides with elevated risk for MM 
development, we investigated if this could be the result of an impaired iNKT cell anti-tumor immunity 
mediated by adipokines, such as leptin (Chapter IV). 
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2. To investigate the role of the immune checkpoint molecule, PD-1, in iNKT and Mucosal-
associated invariant T (MAIT) cell deficiency in MM. 
MM cells create an immunologic milieu characterized by the disruption of effective antigen 
presentation, loss of effector cell function and complexity, and upregulation of pathways that 
promote tolerance and T cell anergy. A critical element of tumor-mediated immunosuppression is 
the presence of the negative checkpoint molecules, such as PD-1, that inhibit immune activation and 
the expansion of antigen specific T cells. In health, these pathways represent an essential stopgap 
against hyperactivation and the generation of autoimmunity. In the setting of malignancy, 
upregulation results in an exhausted T cell phenotype that promotes disease growth and resistance 
to immunotherapy. Therefore, we aimed to evaluate the implications of PD-1 in invariant T cell 
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Abstract 
A hallmark of bone marrow changes with aging is the increase in adipocyte composition, but how this 
impacts development of multiple myeloma (MM) is unknown. Here, we report the role of the 
adipokine leptin as master regulator of anti-myeloma tumor immunity by modulating the invariant 
natural killer T (iNKT) cell function. A marked increase in serum leptin levels and leptin receptor (LR) 
expression on iNKT cells in MM patients and the 5T33 murine MM model was observed. MM cells 
and leptin synergistically counteracted anti-tumor functionality of both murine and human iNKT cells. 
In vivo blockade of LR signalling combined with iNKT stimulation resulted in superior anti-tumor 
protection. This was linked to persistent IFN-γ secretion upon repeated iNKT cell stimulation and a 
restoration of the dynamic antigen-induced motility arrest as observed by intravital microscopy, 
thereby showing alleviation of iNKT cell anergy. Overall our data reveal the LR axis as novel 
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Introduction 
Multiple myeloma (MM) is a monoclonal plasma cell cancer predominantly developing in the bone 
marrow (BM). Despite great improvements with novel therapeutic agents achieved in the past 
decade, MM still remains incurable for the majority of patients. Therefore, there is a unmet need for 
novel therapeutic targets1. 
In MM, a complex crosstalk of different cell types within BM confers survival and growth to MM cells 
and induces angiogenesis, bone destruction, immune escape and drug resistance2. Fatty deposits 
occupy up to 70% of BM cavity with aging, yet surprisingly little attention has been given to the role 
of BM adipocytes and associated adipokines in MM development. BM adipocytes may contribute to 
MM oncogenesis by promoting migration and proliferation of malignant cells through secretion of 
myeloma-supportive adipokines such as leptin. Moreover, they are known to be negative regulators 
of the hematopoietic environment3,4. Recently, it became clear that adipose tissue itself contains a 
broad range of immune cells, both of the innate as well as the adaptive origin. Reciprocal interactions 
of immune mediators with adipocytes have been described, giving rise to the emerging field of 
immunometabolism5. Invariant natural killer T (iNKT) cells, are unconventional, lipid antigen reactive 
T cells with important roles in anti-tumor immunity and have been shown to closely interact with 
adipocytes in a CD1d dependent manner 6–8. In MM, defective IFN-γ production by iNKT cells and 
reduced iNKT cell frequencies were described 8–12. Moreover, CD1d expression levels on antigen 
presenting cells are progressively downregulated upon MM progression8,13. Because increasing fat 
deposition with aging coincides with elevated risk for MM development, we hypothesized this could 
be the result of impaired anti-tumor immunity mediated by leptin. We therefore tested the crosstalk 
between BM adipose tissue and iNKT cell function through release of the leptin in the onset of MM.  
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Material and methods 
Mice, cell lines, flow cytometry and antibodies 
Details of the 5T33MM murine model, C57BL/KaLwRijHsd CD1d-/-mice, cell lines, flow cytometry and 
antibodies used in this study are presented in supplementary materials and methods. 
 
Myeloma patients  
BM, peripheral blood and serum samples were collected from untreated newly diagnosed MM 
patients (NDMM, n=19) and from age and gender matched healthy controls (n=11) and MGUS 
patients (n=18). Patient characteristics are summarized in supplementary Table 1. All patients gave 
informed consent, and the study was conducted in accordance with the Declaration of Helsinki. 
Approval was obtained by the Ethic Board of UZ Brussel (B.U.N. 143201316382) and Tumourbank of 
Lille (CSTMT102).  
 
iNKT – MM cell co-culture assay 
For murine experiments, isolation and expansion of 5T33MMvv, 5T2MM cells and iNKT cells were 
performed as previously reported14–16 17. The isolation of DCs and loading with α-GalCer is explained 
in the supplementary materials and methods as well as the iNKT cell expansion. 5x104 5T33MMvv / 
5T33MMvt / 5T2MM cells, 5x104 iNKT cells, 105 α-GalCer loaded or vehicle loaded DCs were co-
cultured in triplicate. Murine recombinant leptin (0,25 µg/ml, Sigma-Aldrich) and/or bispecific 
nanobody 2.17-mAlb (50 µg/ml) were added. Construction, production, and purification of nanobody 
2.17-mAlb is described elsewhere18. Supernatants of co-cultures were collected after 48 h for IFN-γ 
measurements by ELISA (eBioscience).  
 
For human co-culture experiments, iNKT cells were expanded by isolating PBMCs from healthy adult 
individuals using Ficoll centrifugation and incubating them for 7 days with α-GalCer (100ng/ml) and 
IL-2 (5U/ml, Roche). Subsequently, PBMCs were incubated with mAbs directed against TCRVβ11, 
TCRVα24 (Beckman Coulter) and 7-AAD (Becton Dickinson). TCRVα24+Vβ11+7-AAD-(iNKT fraction) 
were cell sorted into 96-well plates (FACSAria, Becton Dickinson). TCRVα24-Vβ11-7-AAD-CD3+ cells 
were used as iNKT depleted T cells and stimulated with anti-CD3 and anti-CD28 Abs (eBioscience). 
Antigen presenting cells (APCs, 1x105) were collected from PBMCs after CD2 Dynabeads depletion 
(Invitrogen), loaded with α-GalCer (100ng/ml) or vehicle and subsequently co-cultured with 5x104 
RPMI 8226/ JJN-3/ U-266 MM cells and 5x104 iNKT cells. Human recombinant leptin (0,25 µg/ml, R&D 
Systems) and/or bispecific nanobody 2.17-mAlb (50µg/ml) were added. Also for stimulated 
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iNKTdepleted T cells, effects of recombinant leptin and/ or RPMI 8226/ JJN-3/ U-266 MM cells were 
tested similarly as described above. Supernatants of co-cultures were collected after 24 h for IFN-γ 
measurements by ELISA (eBioscience). 
 
In vivo treatment with α-GalCer and 2.17m-Alb leptin receptor antagonist in MM 
C57BL/KaLwRijHsd and C57BL/KaLwRijHsd CD1d-/-mice were randomized and inoculated with or 
without 5T33MM as previously described and weekly i.p. injected with 2µg α-GalCer14,19. Serum IFN-γ 
levels were determined by ELISA after the primary and second stimulation with α-GalCer. Mice were 
treated for 10 days with 2.17-mAlb or control BcII10-mAlb nanobody (i.p., 200 μg mouse−1 day−1) and 
weighted daily18,20. After α-GalCer restimulation flow cytometry was performed on 3 mice per group 
to determine activation, BrdU incorporation and intracellular cytokine release of iNKT and NK cells in 
indicated organs. At early established disease monitored and identified by two independent 
researchers, serum M-spike levels, TNFα and IL-6 levels were measured by ELISA (eBioscience)21.  
 
Intravital imaging 
Cxcr6GFP/+ CD11cYFP/+ mice were i.p. injected weekly with 2 µg α-GalCer or vehicle, treated during 10 
days with 2.17-mAlb or control BcII10-mAlb nanobody (i.p., 200 μg mouse−1 day−1) and weighted daily 
as described above. On day 14, mice were anesthetized (ketamine/xylazin) and tail vein cannulation 
was performed to provide a route for i.v. compound administration. Mice were held in a custom-built 
stabilization device and further anesthetized with isoflurane. The liver was surgically exposed in the 
imaging chamber at 36°C and continuously superfused with 36 °C PBS. Imaging was performed on a 
LSM710 confocal microscope (Carl Zeiss) equipped with MaiTai Deep-See multiphoton laser (Spectra-
Physics) and excitation wavelength at 890 nm. Baseline control iNKT cell speed was recorded 1 hour 
prior to i.v. injection with 2 µg α-GalCer. Imaging was continued 3 hours post-injection, after which 
i.v. injection with tetramethylrhodamine-labeled 70 kDa dextran (Life Technologies) was given as 
quality control. Images were analyzed with ImarisTrack (Bitplane) to quantify iNKT cell speeds 
(µm/min) over time. iNKT cell velocities after α-GalCer injection relative to average pre-injection 




Results are expressed as mean ± SEM. Sample sizes were estimated through power analyses using 
G*Power3.1 (http://www.gpower.hhu.de). Student t-tests, one-way ANOVA with Bonferroni 
correction and non-parametric Mann-Whitney U-tests were used to address statistical significance. 
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For intravital imaging Linear Mixed Models for Repeated Measures were used. P values <0.05 were 
considered statistically significant. 
 
Results 
Increased leptin levels and leptin receptor expression on iNKT cells in MM 
To investigate a potential role for leptin signaling in MM, serum leptin levels were assessed in newly 
diagnosed MM (NDMM) patients next to age-matched patients diagnosed with monoclonal 
gammopathy of undetermined significance (MGUS) and healthy controls (HC). Significant increases of 
serum leptin levels were seen in NDMM patients relative to HC and MGUS patients (Figure 1a). 
Although a positive correlation was seen between body mass index (BMI) and serum leptin levels in 
HC and MGUS patients this correlation was totally absent in NDMM patients, suggesting that leptin 
levels in these patients were influenced by disease status rather than being related to physical 
features (Figure S1). Interestingly, significantly higher percentages of T cells from NDMM patients 
expressed the leptin receptor (LR) (Figure 1b). As previously reported, iNKT cells were reduced in 
NDMM patients (data not shown)8–12. Detectable blood and BM residing iNKT cells in NDMM patients 
expressed markedly higher levels of LR (Figure 1b). Of note, LR expression levels were even higher for 
BM derived cells as compared to cells in circulation underscoring the relevance for MM disease 
(Figure 1b). Moreover, the LR increase was clearly higher within the iNKT compartment compared to 
mainstream T cells (Figure 1b).Similar results regarding serum leptin levels and LR expression were 
obtained in the murine 5T33MM model, a well-validated pre-clinical immunocompetent model 
mimicking human MM disease closely(Figure 1c and 1d)14,22. 
MM cells and leptin synergistically counteract iNKT anti-tumor effects  
In order to assess whether leptin has a direct or indirect impact on iNKT cell function in MM, co-
culture experiments with NKT and MM cells (murine and human) were performed in absence or 
presence of exogenous leptin and/or LR blocking (Figure 2 and S2). Both in murine and human 
assays, high IFN-γ levels were observed when iNKT cells were stimulated with α-GalCer loaded 
dendritic cells (DC α-GalCer). However, IFN-γ levels dropped when DC α-GalCer stimulated mouse or 
human iNKT cells were co-cultured with respectively murine 5T33MMvv cells or human JJN-3 MM 
cells (Figure 2). When leptin was added to α-GalCer stimulated iNKT cells, decreases in IFN-γ levels 
were observed both for murine and human iNKT cells (Figure 2). Remarkably, iNKT cells co-cultured 
with MM cells (5T33MMvv or JJN-3 cells) and leptin completely lost their capacity to secrete IFN-γ 
(Figure 2). These results were confirmed in co-culture assays using other murine (5T33MMvt, 
5T2MM) and human (RPMI 8226, U-266) MM cell lines (Figure S2). To examine whether this also 
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impacts conventional T cells, human co-culture experiments were set up with iNKT cell depleted T 
cells in presence of aCD3/CD28 Abs. Of interest, addition of MM cells combined with leptin caused 
much less profound reductions in T cell derived IFN-γ levels (data not shown), suggesting iNKT cells 
seem to be particularly prone to the dual effect of MM and leptin mediated inhibition of cytokine 
production. As expected LR blockade neutralized effects of exogenous added leptin on iNKT cell IFN-γ 
production (Figure 2). Altogether these data suggest that a combination of MM cells and leptin 
synergistically counteracts the iNKT cell anti-tumor function. 
 
  
Figure 1: Leptin and its receptor on iNKT cells in MM. A) Serum leptin levels of NDMM patients (n=19) are compared with 
MGUS patients (n= 18) and healthy controls (n= 11). B) Mean Fluorescence Intensity (MFI) of leptin receptor expression on 
T and iNKT cells in blood and BM of NDMM compared to healthy individuals. For iNKT cell data analysis, a minimum cutoff 
of 500 events was set to allow proper statistical analyses. C) Leptin serum levels measured in 5T33MM WT mice at week 1, 
2 and 3 after inoculation (n=4) compared to naive C57BL/KaLwRij mice (n=4). D) MFI of leptin receptor expression on iNKT 
cells in liver, bone marrow, spleen and blood at week 1, 2 and 3 after inoculation with 5T33MM cells compared to leptin 
receptor levels in naive C57BL/KaLwRij mice (n=3). Natural killer T cells (NKT); Leptin (L); Leptin receptor (LR); Monoclonal 





















Figure 2: iNKT co-cultures with leptin and 2.17-mAlb Leptin receptor antagonist. A) Mean IFN-γ levels of murine iNKT co-
culture experiments. The experiment was performed with 5T33vv MM cells. Respective conditions are iNKT cells + α-
GalCer-loaded DC’s; iNKT cells + α-GC-loaded DC’s + MM cells; iNKT cells + α-GC-loaded DC’s + MM cells + 2.17-mAlb; iNKT 
cells + α-GC-loaded DC’s + 2.17-mAlb; iNKT cells + α-GC-loaded DC’s + leptin; iNKT cells + α-GC-loaded DC’s + leptin + MM; 
iNKT cells + α-GC-loaded DC’s + leptin + 2.17-mAlb. B) IFN-γ levels of human iNKT co-culture experiment with JJN-3 human 
MM cell line. Human co-culture experiments were performed using the same set-up as murine co-culture experiments. 
Natural killer T cells (NKT); Vivo (vv); Vitro (vt); Dendritic cells (DC); Alpha-Galactosylceramide (α-GC); Leptin Receptor 
antagonist (2.17-mAlb); Leptin (L). * p<0.05, ** p<0.01, *** p<0.001 
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Leptin receptor blockade boosts iNKT mediated MM tumor protection 
To investigate functional impacts of leptin signalling in iNKT cells towards MM tumor progression in 
the 5T33MM model (Figure 3a), we tested treatment with α-GalCer combined or not with a specific 
LR blocking nanobody (2.17-mAlb)18. To account for direct effects of iNKT cells, similar experiments 
were performed in mice backcrossed to a CD1d-/-background, thereby lacking CD1d restricted NKT 
cells. As expected from leptin metabolic features, weight gain was observed in mice receiving LR 
antagonists, while this remained stable in control treated mice (Figure 3b). Consistently, fat pad 
weights significantly increased upon treatment with 2.17-mAlb (Figure 3c) while spleen and liver 
weights remained unchanged (data not shown). As expected, serum IFN-γ levels significantly 
increased in 5T33MM WT mice, in both control and treated groups receiving primary α-GalCer 
injections (day 1, Figure 4a), while in CD1d-/-mice no cytokine release upon α-GalCer stimulation was 
observed (Figure S3a). Restimulation with iNKT cell agonists such as α-GalCer results in blunted 
cytokine responses caused by iNKT cell anergy, a well-described hyporesponsive state23–25. Consistent 
herewith, α-GalCer restimulation in 5T33MM WT mice did not lead to significant IFN-γ cytokine 
release upon secondary stimulation (Figure 4a). Surprisingly however, 5T33MM WT mice receiving 
the combination with LR antagonist displayed substantial serum IFN-γ levels after second α-GalCer 
restimulation (Figure 4a) while this was absent in 5T33MM CD1d-/-mice (Figure S3a). We also 
evaluated the impact of LR blockade on α-GalCer restimulation in non-diseased (naive) 
C57BL/KaLwRijHsd mice. Here, partial rescue of iNKT cell functionality (IFN-γ secretion) could also be 
observed (Figure 5a), and comparable findings were measured in conventional C57BL/6 mice (data 
not shown).  
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Figure 3: In vivo treatment with 2.17-mAlb Leptin receptor antagonist and α-GalCer. A) Schematic overview of the 
experiment. 5T33MM WT and 5T33MM CD1d
-/-
mice were inoculated together with 2µg α-GalCer at day 0. α-GalCer was re-
injected weekly at day 6 and day 13. Injections with leptin antagonist 2.17-mAlb (200µg/mice) were started at day 4 and 
repeated during 10 days. Treatment groups were naive (n=5), MM (n=8), MM + 2.17-mAlb (n=10), MM + α-GalCer (n=10), 
MM + α-GalCer + 2.17-mAlb (n=10). B) Mice were weighted daily. Weight curves from one 5T33MM WT mouse 
representative for each group are shown. Similar weight curves were seen for 5T33MM CD1d
-/-
mice (data not shown). C) 
Fat pad weight at the end of the experiment for both 5T33MM WT and 5T33MM CD1d
-/-
mice. Alpha-Galactosylceramide (α-
GC); Leptin Receptor antagonist (2.17-mAlb); WT (wild type).* p<0.05, ** p<0.01, *** p<0.001 
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Figure 4: Combination effects of leptin receptor blockade and iNKT cell activation in MM in vivo. A) Serum IFN-γ levels 
16h after first stimulation and second stimulation with α-GalCer are for 5T33MM WT mice. B) Serum M-spike in 5T33MM 
WT and CD1d
-/-
mice. C) Serum TNFα and IL-6 levels at the end of the experiment for each treatment group in 5T33MM WT 
mice. Alpha-Galactosylceramide (α-GC); Leptin Receptor antagonist (2.17-mAlb); Tumor necrosis factor alpha (TNFα); 
Interferon gamma (IFN-γ); Interleukine 6 (IL-6); Wild type (WT). * p<0.05, ** p<0.01, *** p<0.001 
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A striking feature of iNKT cells is their motility pattern in organs where they reside such as liver. 
Because ligand induced iNKT cell activation is associated with motility arrest, we hypothesized that 
observed effects on altered cytokine release by iNKT cells in presence of LR neutralization may be 
reflected in altered iNKT cell dynamics. Therefore we utilized intravital dual photon microscopy in 
Cxcr6GFP/+ CD11cYFP/+ reporter mice26,27 in steady state condition and upon a-GalCer stimulation. Under 
steady state conditions, iNKT cells rapidly migrate through liver sinusoids to scan their environment 
for potential triggers (Supplementary Video 1 and 2)

. After primary injection with α-GalCer, iNKT 
cells rapidly go into antigen-induced motility arrest as part of their activation (Supplementary Video 1 
and 2)

 leading to steep reductions in measured iNKT cell speed (Figure 5b, red line). Similar arrests 
upon primary stimulation were also seen with LR antagonism (Figure 5b, purple line). In striking 
contrast, restimulation with α-GalCer failed to induce a ligand-induced iNKT cell arrest, which mirrors 
decreased cytokine production responses in anergic iNKT cells (Figure 5b, blue line and 
supplementary video 3). Interestingly, α-GalCer restimulation in presence of LR blockade showed 
partial rescue of antigen-driven iNKT cell deceleration (Figure 5b green line and Supplementary Video 
4). Taken together, our data indicate that leptin signaling significantly impacts iNKT cell 
responsiveness upon repeated stimulation with α-GalCer by both influencing iNKT cell surveillance 
and cytokine production. This effect seems even more pronounced in a MM setting where leptin 
levels are progressively increased. 
 
                                                          

 Link to videos: https://drive.google.com/drive/folders/0B3BC3mG2v5kybmEzcDFWX2JrV0U?usp=sharing 
 
 




















Figure 5: Effects of leptin receptor blockade and α-GalCer stimulation in MM-free mice. A) Serum IFN-γ levels of naive 
C57BL/KalwRij mice after first stimulation and second stimulation with α-GalCer, with and without leptin receptor 
antagonist co-treatment. B) Results show a ratio of the iNKT cell speed (µm/min) after injection with α-GalCer, relative to 
the preinjection speed (µm/min) within the same mouse. Alpha-Galactosylceramide (α-GC); Leptin Receptor antagonist 
(2.17-mAlb); Interferon gamma (IFN-γ). ** p<0.01, *** p<0.001 
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Based on these results we hypothesized that LR signaling blockade combined with iNKT cell 
stimulation could lead to even more efficient and synergistic anti-MM effects in vivo. In agreement 
with previous studies, α-GalCer stimulated iNKT cells significantly decreased BM tumor load and 
serum M-spike levels in 5T33MM WT mice (Figure 4b)10,28. However, therapeutic responses were 
suboptimal as a substantial fraction of mice did not respond sufficiently. Marked synergy was 
observed when repeated α-GalCer injections were combined with 2.17-mAlb treatment. Only very 
low measurable serum M-spike levels opposed to single (α-GalCer or 2.17-mAlb) treatments in 
5T33MM WT mice were observed (Figure 4b). Anti-tumor effects were reflected by marked changes 
in serum TNFα and IL-6 concentrations (Figure 4c). Remarkably, mice treated with LR antagonist 
alone also showed significantly reduced M-spike levels (Figure 4b), even though no increased IFN-γ 
levels were observed during treatment (Figure 4a). However, within 5T33MM CD1d-/-mice no 
differences in disease and cytokine profile were detected between treated mice indicating that LR 
blocking effects using glycolipid antigens were strictly iNKT cell dependent (Figure 4b and S3b).  
iNKT cell stimulation combined with LR antagonism induces enhanced activation, proliferation and 
cytokine release of iNKT cells in MM 
To further investigate how iNKT function is modulated by leptin in MM we restimulated iNKT cells 
with α-GalCer with or without 2 days of LR antagonist treatment and assessed their activation, 
proliferation and cytokine profile. α-GalCer stimulation led to iNKT cell upregulation of CD69 and 
CD25 levels in liver, spleen, BM and blood and also resulted in bystander activation of NK cells (Figure 
6a and S4a). Combination of α-GalCer and 2.17m-Alb, however markedly augmented iNKT and NK 
activation. These observations were absent in control MM mice, mice only treated with 2.17mAlb 
nanobody and in 5T33MM CD1d-/-mice (Figure 6a and S4a). Additionally, the α-GalCer and LR 
blockade combination also displayed higher fractions of BrdU positive iNKT and NK cells versus other 
treatment groups (Figure 6b and S4b). As expected, this effect remained absent in 5T33MM CD1d-/-
mice (data not shown). We also determined the impact of combined α-GalCer -2.17mAlb treatment 
on iNKT IFN-γ and TNFα cytokine secretion in response to restimulation with α-GalCer. In line with 
altered dynamics and more persistent cytokine release, intracellular iNKT IFN-γ and TNFα levels were 
preserved in presence of LR antagonism, in contrast to controls (Figure 6c). Effects were also visible 
on NK cells, although the levels were much less pronounced (data not shown). 
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Figure 6: Activation, proliferation and cytokine secretion of NKT and NK cells. A) Percentage expression levels of activation 
marker CD69 for iNKT and NK cells in liver, spleen, bone marrow and blood. B) Fluorescence histograms representing BrdU 
incorporation of iNKT and NK in the liver of 5T33MM WT mice. C) Percentage of TNFα and IFN-γ positive iNKT and NK in 
liver, spleen and bone marrow of 5T33MM WT mice. Alpha-Galactosylceramide (α-GC); Leptin Receptor antagonist (2.17-
mAlb); Tumor necrosis factor alpha (TNFα); Interferon gamma (IFN-γ); Wild type (WT). * p<0.05, ** p<0.01 
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Discussion 
Our data provide several new and unexpected results which underscore the instrumental role of the 
adipokine leptin in MM progression by modulating iNKT cell mediated anti-tumor immunity (For an 
overview of the findings see Figure 7). 
We observed increased serum leptin levels and LR expression levels on predominantly iNKT cells in 
NDMM patients and in the immunocompetent 5T33MM mice, a well-validated preclinical model for 
MM. Importantly, leptin levels were independently from BMI values linked to NDMM, which point to 
a role for an aberrant LR signaling in MM pathology. It should be noted that serum leptin and LR 
expression levels showed a bimodal distribution in NDMM patients, suggesting that the potential 
leptin-LR dysregulation may not affect all NDMM patients. Alternatively, this could reflect differences 
in degree of BM fatty deposition, which remains to be determined. Interestingly, iNKT cells make up 
a large proportion of lymphocytes in white adipose tissue (WAT)29,30. Moreover, they seem to have a 
striking role in regulating WAT inflammation, metabolism and weight control and are poised towards 
anti-inflammatory cytokine production as they closely interact with adipocytes in a CD1d dependent 
manner6–8,31. Obesity in humans and murine models is associated with a greatly reduced iNKT cell 
population and decreased CD1d expression levels. In this regard, increase in adipocyte composition 
or leptin/LR expression in MM BM could directly influence iNKT cell features. Indeed, both murine 
and human iNKT-MM cell co-culture assays revealed both MM and leptin to independently 
downmodulate the iNKT pro-inflammatory (i.e. anti-tumor) function. These profound 
immunosuppressive effects of leptin linked with cancer and particularly on human iNKT cells is a 
compelling novel observation. Leptin directly suppresses iNKT cells by modulating cytokine 
production, expansion and activation. While MM cells in BM of MM patients express the LR, they do 
not secrete leptin themselves (data not shown), suggesting that leptin is only secreted by adipocytes 
in the BM microenvironment3. However, MM cells do secrete different immunomodulating factors, 
such as IL-6 and IL-16 which could potentially inhibit iNKT cell function in vivo32,33. Leptin also directly 
promotes MM proliferation which, by increasing tumor load, may undermine iNKT cell mediated 
anti-tumor immunity3.  
Blocking LR signalling on α-GalCer activated iNKT cells leads to superior tumor protection in vivo. 
Indeed, dual treatment in 5T33MM WT mice resulted in remarkable reduced serum M-spike levels 
versus only a partial effect when α-GalCer alone was given. In addition, strong reduction in TNFα and 
IL-6 levels in MM mice confirmed the major impact blocking leptin signaling has on MM. TNFα and IL-
6 are important cytokines involved in MM pathogenesis and are known to be secreted by BM stromal 
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cells and MM cells which in turn directly and/or indirectly influence MM cells in autocrine and 
paracrine manners34.  
It cannot be excluded that leptin induces primary or bystander effects on other immune cells. 
However, our data are consistent with a primary role for iNKT cells as targets affected by leptin in 
context of MM. First, LR levels were most abundantly expressed on iNKT cells versus other T cells and 
other lymphocytes such as NK cells. Secondly, effects of LR blockade on MM development were 
lacking in 5T33MM CD1d-/-mice. Both leptin and α-GalCer mediated tumor suppressive effects were 
absent, which underscore a major role for leptin in modulating iNKT cell driven protective responses 
in MM. LR blockade resulted in enhanced iNKT cell activation and consistently increased iNKT cell 
production of IFN-γ and TNFα, which in turn leads to downstream activation of NK cells. This was also 
found to be absent in CD1d-/-mice treated with LR blockade. It should be noted that under steady 
state conditions, iNKT cell deficiency, did not lead to enhanced tumor growth in the 5T33MM model. 
However, given profound production of leptin during MM development, anti-tumor protective 
effects of iNKT cells become gradually overruled. In line with this, LR blockade had a striking impact 
on MM-development as measured by M-spike levels, an observation that was clearly undetectable in 
the absence of iNKT cells. This suggests that effects of leptin antagonism are iNKT cell dependent.  
Unexpectedly, we found one of the major mechanisms underlying enhanced protective effects of in 
vivo iNKT cell activation in presence of LR antagonism be caused by its ability to reverse or prevent 
anergy. Thus, combining α-GalCer with LR blockade strongly amplified and prolonged iNKT cell 
activation and modulated iNKT threshold activation upon repeated α-GalCer administration. Anergy 
induction represents a major drawback in efficacy of iNKT based therapies 23,35. By means of intravital 
microscopy, we are the first to provide a detailed time course of iNKT cell dynamics in response to α-
GalCer. We observed that ligand-induced TCR-mediated iNKT cell arrest, one of the earliest events in 
iNKT cell stimulation, was blunted under conditions of restimulation. Thus, rather than inducing a 
TCR mediated arrest, iNKT cells retained motility in liver upon restimulation. Importantly, we 
demonstrated that LR antagonism partially rescued this iNKT cell motility arrest, suggesting that the 
exhausted antigen-mediated iNKT cell function can be partially restored by leptin blockade and 
further extends the notion that this may interfere with TCR-mediated signaling under certain 
conditions. Interestingly, the therapeutic impact, e.g. increase in IFN-γ release by restimulated iNKT 
cells upon LR blockade, was profoundly amplified in the MM setting where leptin levels are 
particularly elevated compared to healthy mice, presumably secondary to increased BM fatty 
infiltration and upregulation of LR on iNKT cells. While previous studies highlighted an intriguing 
relationship between adipose tissue, antigen presentation of glycolipid antigens and iNKT cells, our 
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data provide an alternative explanation of the relation between adipocytes and iNKT cells through 
release of adipokines.  
Underlying mechanisms of leptin signaling blockade on iNKT cell anergy are not entirely clear. It can 
be anticipated that aberrant leptin levels and LR expression significantly impact TCR-mediated 
signaling directly by influencing iNKT cell activation threshold and function but also indirectly by an 
effect on the programmed cell death protein 1 (PD-1) pathway, clearly linked to iNKT cell anergy23,35. 
These mechanisms are not mutually exclusive and could have a synergistic effect. However, other 
mechanisms may also be involved in this context, LR stimulation results in JAK2 transphosphorylation 
and activation of several signaling cascades including STAT3, MAPK, PI3K and mTOR pathways 36–39. 
Intriguingly, tuberous sclerosis 1 (TSC1), negative regulator of mTOR signaling, has been linked to 
iNKT cell anergy as TSC1 deficiency in iNKT cells results in resistance to α-GalCer-induced 
hyporesponsiveness and correlated with impaired upregulation of PD-140. The mTOR pathway seems 
also involved in direct cell growth, proliferation and migration of MM cells and mTOR kinase 
inhibitors and dual inhibitors of PI3K/mTORC1 have showed promising in vitro and in vivo effects in 
preclinical MM studies41. JAK2 and STAT3 inhibitors have also led to downregulation of PD-L1 in non-
small lung cancer cells which could be compatible with a role of leptin-induced JAK/STAT signaling in 
inducing anergy and immunosuppression in MM as described here42. In any case, our data support 
the concept that hyperleptinemia is promoting MM tumor progression and iNKT cell dysfunction and 
underscores the leptin-LR axis acts as an immune checkpoint in MM.  
In summary, our study unveils a previously unknown link between leptin and iNKT cells in MM 
immunosuppression. The data enforce a novel paradigm in which adipokines released by 
accumulating adipocytes within MM play an instrumental and crucial role in suppressing anti-tumor 
immunity which can be reversed by LR antagonism. Overall, pharmacological targeting of leptin 
signaling acting as a new checkpoint inhibitor represents a novel strategy for immunotherapy in MM.  
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Overview findings 
 
Figure 7: Overview general findings. We were the first to reveal the leptin – leptin receptor (LepR) axis as an important 
iNKT cell-mediating pathway in MM and anti-tumor immunity. Progressive increases of leptin secreted by adipocytes and 
LepR expression levels were observed on iNKT cells during MM progression (red upward arrows). Leptin proved to 
profoundly directly inhibit (black blocking arrow) the iNKT cell functionality and to stimulate MM cells (normal black arrow), 
reinforcing the inhibition on iNKT cells even more (synergistic effect leptin and MM cells on iNKT cells, black blocking 
arrow). iNKT cell stimulation combined (normal green arrow) with LepR antagonism (green blocking arrow) induced 
enhanced activation (alleviated anergy), proliferation, motility and cytokine release of iNKT cells in MM (green box with 
upward arrows). Moreover, cross-activation of NK cells could be observed (green box with upward arrows). An almost 
complete tumor protection was observed when the combination of α-GalCer-mediated iNKT stimulation and a LepR 
antagonist was used (green bow with upward arrows). However, several questions still remain unanswered (light blue) and 
will be the objective of future research. What are the mechanisms inducing a leptin increase in MM and what is the impact 
of leptin on other immune cells in MM? Are there also other adipokines involved? And by which leptin-stimulated 
mechanisms do MM cells contribute in iNKT cell impairment. Alpha-Galactosylceramide (α-GalCer); Leptin Receptor (LepR); 
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Supplementary material and methods 
Mice 
Male C57BL/KaLwRijHsd mice were purchased from Envigo (Horst, The Netherlands) and used when 
they were 6 to 8 weeks old. Mice were housed and maintained following the conditions approved by 
the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussels (license no. 
LA1230281). The animal ethics meet the standards required by the United Kingdom Coordinating 
Committee on Cancer Research Guidelines (UKCCCR, 1998). Ethical committee obtained by the VUB 
animal ethics committee with approval number 14_281_12. The 5T33MM and 5T2MM model 
originated spontaneously in C57BL/KaLwRij mice as previously described and have since been 
propagated in vivo by intravenous transfer of the diseased BM into young syngeneic mice, which in 
turn develop myeloma in 3-4 week and 10-12 weeks respectively1,2. 
C57BL/6 CD1d-/-mice (The Jackson Laboratory) were backcrossed onto the C57BL/KaLwRijHsd 
background. The backcrossing was accelerated by the use of a marker-assisted accelerated 
backcrossing system (MAX BAX system, Charles River Laboratories). After 5 generations, 
C57BL/KaLwRijHsd CD1d+/-mice were crossed to generate the final C57BL/KaLwRijHsd CD1d-/-mice. 
For the intravital imaging, C57BL/6 Cxcr6GFP/GFP and CD11cYFP/YFP mice (The Jackson Laboratory) were 
crossed to obtain the Cxcr6GFP/+ CD11cYFP/+ mice. 
 
Cell lines 
The 5T33MMvt cell line resulted spontaneously from cultured 5T33MMvv grown in vitro, 
independently from the BM stroma. RPMI 8226, JJN-3 (American Type Culture Collection) and U266 
(ATCC) are three well characterized human cell lines that were selected for our experiments. They 
were cultured as previously described and regularly tested for mycoplasma contamination1,3–5.  
 
Generation of Dendritic cells and loading with α-GalCer 
Murine BM progenitor cells were isolated by flushing the content out of the femur and tibia of naive 
mice with sterile PBS. DCs were cultured from these BM progenitor cells and plated in 100×20 mm 
cell culture dishes (Greiner Bio-One, GmbH, Germany) at 2×106/mL in RPMI 1640 GlutaMAXTM 
medium (GIBCO, Life Technologies, Ghent, Belgium) supplemented with 10% FetalClone I (FCI, 
Hyclone, Logan, USA) and 1% Penicilin/Streptomycin (Lonza, Basel, Switzerland). 20 ng/mL of 
recombinant mouse granulocyte macrophage colony stimulating factor (recombinant murine GM-
CSF, PeproTech, London, UK) and 50µM β-mercaptoethanol (β-ME, Sigma-Aldrich) were added to the 
culture at day 0. On day 3, 50% of the media was completely refreshed with fresh medium containing 
GM-CSF and β-ME. On day 6 media was refreshed again. On day 8, the immature DCs were harvested 
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and 10 ng/mL GM-CSF was used to mature DCs overnight together with 10 µg/mL α-GalCer or vehicle 
(0.5% Tween-20 in PBS, as a control). α-GalCer, dissolved in DMSO at 1 mg/mL was kindly provided 
by Prof. Dr. S Van Calenbergh (Laboratory of Medicinal Chemistry, University of Ghent, Belgium) and 
kept at −20°C. On day 9, after extensive washing, α-GalCer loaded/unloaded DCs are ready to be 
used for co-culture experiments. 
 
Isolation and expansion iNKT cells 
Six livers from C57BL/KaLwRij mice were removed, dissected, strained and pooled. The resulting 
cellular suspension was layered over a Percoll density gradient (GE Healthcare, Diegem, Belgium). 
Following centrifugation, liver mononuclear cells (MNCs) were collected and subsequently stained 
with APC-labelled CD1d/a-GalCer tetramer in combination with CD3 (17A2, eFluor©450, eBioscience, 
Vienna, Austria). Afterwards, they were purified by fluorescence activated cell sorting (FACS Aria II, 
BD Biosciences). FACS sorted iNKT cells were then resuspended in complete RPMI 1640 medium and 
cultured in vitro using a combination of recombinant murine IL-2 (10 ng/mL, eBioscience) and Il-12 (1 
ng/ ml, eBioscience) together with plate-bound T cell receptor (TCR) (anti-CD3 and anti-CD28, 
eBioscience) before being expanded in the presence of murine recombinant IL-7 (eBioscience). Using 
this expansion technique, approximately 108 iNKT cells can be generated within 18-20 days of 
culture, after which they can be used for co-culture assays. 
 
Isolation 5T33MMvv cells 
For 5T33MM vivo (vv, primary MM cells) cells mice were sacrificed when terminally ill. The BM was 
flushed out of femurs and tibiae. The 5T33MM cells were subjected to red blood cell lysis. Viability 
was more than 95% and the purity was reaching more than 85%, as measured by flow cytometric 
analysis. 
 
Flow Cytometry and antibodies  
Liver, spleen were isolated as previously described1,6 . BM cells were isolated as described earlier in 
the article. Murine lymphocytes were resuspended in staining buffer containing saturating amounts 
of anti-Fcγ Receptor type II/type III monoclonal antibodies (Miltenyi Biotec, Sunnyvale, CA). PE-
labelled CD1d/a-GalCer tetramer was added at room temperature, 15 min before the addition of the 
mouse leptin R biotinylated antibody (R&D Systems, Minneapolis, MN), TCRβ (H57-597, APC-
Cyanine7, eBioscience), CD3 (145-2C11, PE-Cyanine7, eBioscience), CD4 (RMA4-5, V500, BD 
HorizonTM) and NK1.1 (PK136, eFluor©450, eBioscience) during 30 min on ice. 7-AAD (BD 
PharmigenTM) was also included for the exclusion of death cells. After washing the cells, an anti-APC 
HRP labeled secondary antibody (eBioscience) was added against the mouse leptin R biotinylated 
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antibody. Living single cells were acquired on a FACSCantoII (BD Biosciences) flow cytometer and 
analyzed using FlowJo (TriStar) software. iNKT cells were identified as: 7AAD-CD3+CD1d/a-GalCer 
tetramer+ cells and subsequently further characterized for TCRβ, CD4, NK1.1 or leptin receptor 
expression. Immunostaining for BrdU was performed using the BrdU flow kit as per the supplier’s 
instructions (Becton Dickinson). Mice were injected with BrdU in 0.1 ml of sterile PBS (100 mg/kg 
body weight) i.p. 4 h before sacrifice. For cytokine analysis intracellular stainings FITC-conjugated 
anti-IFN-γ (XMG1.2) and APC-conjugated anti-TNFα (MP6-XT22) antibodies (eBioscience) were used. 
 
Human mononuclear cells were stained with 7-AAD (BD PharmigenTM) for the exclusion of death 
cells together with PE-conjugated anti-human Vα24Jα18 TCR (6B11) and Amcyan-conjugated anti-
CD3ε (UCHT1) to identify the iNKT cells within the T cell population, subsequently Pacific Blue-
conjugated anti-CD4 (OKT4), Alexa Fluor 700-conjugated anti-CD8 (OKT8) (all eBioscience) were used 
to distinguish the subpopulations, the APC-conjugated anti-human leptin receptor (R&D Systems) 
was used to determine leptin receptor expression on human iNKT cells. The staining were acquired 
on a FACSLSRII (Becton Dickinson). Analyses were performed using FlowJo software (Tree Star Inc.).  
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Figure S2: iNKT co-culture experiments with leptin and the 2.17-mAlb Leptin receptor antagonist. A) Mean IFN-γ levels of 
murine iNKT co-culture experiments are illustrated. Experiments were performed with different murine MM cell lines: 
5T33MMvt and 5T2MM. Respective conditions are iNKT cells + α-GalCer-loaded DC’s; iNKT cells + α-GC-loaded DC’s + MM 
cells; iNKT cells + α-GC-loaded DC’s + MM cells + 2.17-mAlb; iNKT cells + α-GC-loaded DC’s + 2.17-mAlb; iNKT cells + α-GC-
loaded DC’s + leptin; iNKT cells + α-GC-loaded DC’s + leptin + MM; iNKT cells + α-GC-loaded DC’s + leptin + 2.17-mAlb. B) IFN-
γ levels of human iNKT co-culture experiment are illustrated. Human co-culture experiments were performed using the same 
set-up as the murine co-culture experiments. Different human MM cell lines were tested including RPMI 8226 and U-266. 
Natural killer T cells (NKT); Vivo (vv); Vitro (vt); Dendritic cells (DC); Alpha-Galactosylceramide (α-GC); Multiple myeloma 












































Figure S3: The combination effects of leptin receptor blockade and iNKT cell activation in 5T33MM C57BL/KaLwRij CD1d
-/-
A) IFN-γ levels in the serum 16h after the first stimulation and second stimulation (one week later) with α-GalCer are 
represented. B) Serum TNFα and IL-6 levels were determined by ELISA at the end of the experiment for each group in 
5T33MM C57BL/KaLwRij CD1d
-/-
mice. Alpha-Galactosylceramide (α-GC); Leptin Receptor antagonist (2.17-mAlb); Multiple 














































































































































































































































Figure S4: Evaluation of CD25 expression and proliferation of NKT and NK cells after leptin receptor blockade and iNKT 
cell activation. A) Flow cytometry analysis was performed after second re-stimulation with 2µg α-GalCer and 2 days of 
initiated treatment with the leptin antagonist 2.17-mAlb (200µg/mice). 3 mice were evaluated in each treatment group in 
5T33MM C57BL/KaLwRij and C57BL/KaLwRij CD1d
-/-
mice. Percentage expression levels of activation marker CD25 are 
illustrated for iNKT and NK cells in liver, spleen, bone marrow and blood of the different treatment groups. B) Table with an 
overview of the % BrdU incorporation ± SD of iNKT and NK cells in the liver for each treatment group in 5T33MM 
C57BL/KaLwRij WT and C57BL/KaLwRij CD1d
-/-
mice.  Natural killer T cells (NKT); Natural killer cells (NK); Alpha-
Galactosylceramide (α-GC); Multiple myeloma (MM) Leptin Receptor antagonist (2.17-mAlb) 





















































































































128 Article 1: leptin receptor blockade in multiple myeloma 
 
 
Supplementary table 1: Characteristics healthy controls, MGUS and NDMM patients 
 Number Mean Range 
Control individuals (n= 11) 
Age (years)  60 54-65 
Gender (M/F) 5/6   
BMI1  24,8 19-37 
Monoclonal gammopathy of undetermined significance (n=18 ) 
Age (years)  77 59-91 
Gender (M/F) 12/6   
BMI1  25,4 16-35 
Newly Diagnosed multiple myeloma (n= 19) 
Age (years)  69 55-83 
Gender (M/F) 8/11   
BMI1  25,4 19-31 
M-component type 
IgG 14   
IgA 3   
IgM 1   
IgD 1   
Light chain type 
Kappa 11   
Lambda 8   
ISS Stage1 
Stage I 7   
Stage II 7   
Stage III 5   
Adverse cytogenetics  
13q 5   
t(4,14) 2   
17p 3   
1
BMI: Body Mass Index; ISS: International Staging System 
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Supplementary videos 
Link to videos: 
https://drive.google.com/drive/folders/0B3BC3mG2v5kybmEzcDFWX2JrV0U?usp=sharing 
 
Supplementary Videos:  
These videos show intravital time-lapse sequences of iNKT cells (green) in the liver prior to (left 
panel) and after injection with α-GalCer (right panel) in the same mouse. Blue signal corresponds to 
collagen fibers visualized by second harmonics. Red cells are CD11c-YFP positive (dendritic cells or 
majority of Kupffer cells). 
 
Supplementary Video 1: α-GalCer-mediated iNKT cell arrest in the liver. A decrease in iNKT cell 
speed due to ligand-induced TCR-mediated arrest can be seen after injection with α-GalCer (right 
panel).   
 
Supplementary Video 2: α-GalCer-mediated iNKT cell arrest after treatment with leptin receptor 
antagonist. Mice that were pretreated with vehicle and leptin receptor antagonist showed a 
decrease in iNKT cell speed due to ligand-induced TCR-mediated arrest after injection with α-GalCer 
(right panel).   
 
Supplementary Video 3: Strongly blunted arrest response after α-GalCer injection in mice with 
anergic iNKT cells. In mice that were pretreated α-GalCer, the iNKT cells showed a dramatically 
reduced ligand-induced TCR-mediated arrest after renewed injection with α-GalCer (right panel).  
 
Supplementary Video 4: Partial rescue of ligand-mediated arrest response after pretreatment with 
leptin receptor antagonist. Mice that were pretreated with α-GalCer and 2.17-mAlb showed a partial 
rescue of the ligand-induced TCR-mediated iNKT cell arrest after renewed injection with α-GalCer 
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“Both mucosal-associated invariant and natural killer T cell deficiency 
in multiple myeloma can be countered by PD-1 inhibition” 
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Mucosal-associated invariant T (MAIT) cells primarily contribute to immune defense against 
infectious pathogens and regulate pathogenesis of various inflammatory diseases 1. They are 
innate-like T lymphocytes expressing an invariant TCR Vα7.2-Jα33 chain in humans and displaying 
high expression levels of CD161 and IL-18R. They are primarily localized in mucosal tissue and 
respond to vitamin B2 metabolites in an MHC class 1b (MR1)-dependent manner1. Despite a different 
ontogeny, MAIT cells share a close lineage relationship with iNKT cells, another invariant T cell subset 
recognizing glycolipids and important for anti-tumor immunity1,2. Moreover, it has been suggested 
that they share a common niche and could therefore be functionally redundant3. Recently, MAIT 
cells have been implicated in cancer and were shown to support anti-tumor immunity4; however 
their exact role remains a less explored area. Until now, most reports on involvement of MAIT cells 
in cancer has been limited to mucosa-associated cancers5. Recently however, Wallace et al reported 
MAIT cell deficiency in chronic lymphocyte leukemia (CLL), suggesting a possible involvement of 
MAIT cells in hematological malignancies as well4. Further investigation of MAIT cell functionality in 
cancer patients beyond mucosa-associated malignancy is therefore warranted. In multiple myeloma 
(MM), invariant T cells such as iNKT cells have been reported by us and others to be deficient6. Until 
now, this hasn’t been investigated for MAIT cells and whether they prove to be important in MM is 
far from established. Their similarities with iNKT cells and regulatory functions, together with recent 
reports suggesting their possible involvement in non-mucosa associated malignancy, make them a 
logical candidate for further studies. Therefore, we examined the phenotype and functionality of 
MAIT cells in MM.  
A total of 14 newly diagnosed MM (NDMM) patients and 14 age-matched healthy controls were 
enrolled in this study (clinical characteristics in supplementary Table 1). The frequency of MAIT cells 
(CD3+Vα7.2+CD161+) in total CD3+ lymphocytes was determined by flow cytometry in peripheral 
blood (PB) and bone marrow (BM) of NDMM patients and healthy counterparts (Figure 1A). MAIT cell 
percentages were significantly lower in NDMM patients compared to healthy individuals (Figure 1B). 
Reduced circulating MAIT cell numbers have also been reported in autoimmune disorders (such as 
systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis) and infectious diseases 
(tuberculosis, HIV) next to malignancies (CLL and mucosa-associated cancers) 4,5,7–11; however we are 
the first to show MAIT cell disturbances in MM. MAIT cells can be subdivided into CD4+, CD8+ and 
double negative subsets (Figure 1C). In PB and BM, most of the MAIT cells carry either a CD8+ or 
double negative phenotype. Analysis of MAIT cells in NDMM patients by flow cytometry revealed 
significantly lower percentages of the CD8+ MAIT cell subset and the double negative fraction (Figure 
1D), while the CD4+ fraction remained unchanged (data not shown). Therefore, reduced CD8+ and DN 
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subset levels seem to contribute to total MAIT cell number reduction in MM. Similar observations 
were published for SLE, HIV and multiple sclerosis but were not yet reported in other cancers8,10,11. 
 
 
Figure 1: MAIT cell numbers are decreased in NDMM patients compared to healthy controls and correlate with 
decreased iNKT cell numbers. A) Flow cytometry data plots illustrating the MAIT cell gating strategy in the peripheral 
blood and BM of healthy controls (n=14) and NDMM patients (n=14). B) MAIT cell percentages within peripheral blood and 
BM T cells in healthy controls and NDMM patients. C) Representative MAIT cell subsets as determined by flow cytometry 




MAIT cell percentages within peripheral blood and BM T cells in healthy controls and NDMM 
patients. E) Spearman’s correlation analysis between MAIT cell levels and NKT cell levels in blood and BM of NDMM 
patients. * p<0.05, ** p<0.01, *** p<0.001 
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Additionally, similar decreases of iNKT cell numbers in MM could be observed (Figure S1A, S1B), in 
line with earlier reports6. Since MAIT and iNKT cells share a close lineage relationship we 
subsequently evaluated a potential relationship between both in NDMM patients, by analyzing the 
association between the MAIT cell levels and iNKT cell levels (Figure 1E). Spearman’s correlation 
analyses revealed a significant correlation between MAIT cell percentages and the total iNKT cell 
levels in NDMM patients, suggesting that MAIT cell deficiency is linked to iNKT cell impairment. 
Next, we evaluated the cytokine profile of MAIT cells in order to determine their functionality in 
NDMM. PBMCs from 7 NDMM patients and 7 healthy controls were stimulated for 4 hours in 
presence of PMA and ionomycin. Subsequently, expression levels of IFN-γ, IL-17, IL-22 and TNFα 
were examined by flow cytometry (Figure 2A). Expression of IFN-γ, IL-17, IL-22 and TNFα was absent 
on unstimulated MAIT cells of both patients and healthy individuals (data not shown). However, 
when stimulated, percentages of IFN-γ and TNFα positive MAIT cells were found to be significantly 
reduced in PBMCs derived from NDMM patients compared to healthy controls (Figure 2B). IL-17 and 
IL-22 MAIT cell expression levels were unchanged between NDMM patients and healthy donors 
(Figure 2B). As described in other studies, the majority of MAIT cells (80-90%) produce TNFα and IFN-
γ compared to a minority (3% on average) of IL-17 and IL-22–producing MAIT cells2. Together, these 
data suggest that MAIT cells of NDMM patients have a disturbed Th1 function. This could be either 
due to reduced production of Th1 cytokines or polarization of their cytokine profile. 
In order to assess whether iNKT cells have the capacity to activate MAIT cells, PBMCs from 7 NDMM 
patients and 7 healthy controls were incubated for 72 hours in presence or absence of α-GalCer, a 
strong glycolipid agonist for iNKT cells. Subsequently, CD69 and CD25 expression was determined in 
the MAIT cell population by flow cytometry (Figure. 2C). In healthy subjects, marked increases of 
CD69+ and CD25+ MAIT cells could clearly be observed after stimulation with α-GalCer in comparison 
with vehicle conditions (Figure 2D). In contrast, percentages of CD69+ and CD25+ MAIT cells were 
markedly reduced upon iNKT stimulation in NDMM patients. These findings suggest that a 
dysfunction of iNKT cells, MAIT cells or a combination of both could be responsible for a reduced 
activation of MAIT cells in NDMM patients as has also been observed in SLE10. Altogether this further 
supports the intriguing concept that dysfunctional iNKT – MAIT cell interactions can be involved in 
pathological conditions. Although underlying mechanisms of cross regulation between iNKT and 
MAIT cells are currently unknown, it can be anticipated that iNKT – MAIT cell communication is partly 
cytokine mediated. However, it should also be noted that iNKT cell activation leads to bystander 
stimulation of a broad range of downstream effector cells, including NK cells which could potentially 
also contribute to MAIT cell activation1. This will be the subject of future research. 
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Figure 2: Impaired functionality of MAIT cells in NDMM patients compared to healthy controls. A) Representative IFN-γ, 
IL-17, and TNFα expression levels in the MAIT cell population of healthy individuals (n=7) and NDMM patients (n=7) as 
determined by intracellular flow cytometry after stimulation with PMA and ionomycin. B) Percentages of IFN-γ, IL-17, IL-22 
and TNFα levels produced by MAIT cells in response to PMA and ionomycin are illustrated. C) Flow cytometry data plots of 
CD69 and CD25 expression levels within the MAIT cell population of healthy donors (n=7) and NDMM patients (n=7) after 3 
days of stimulation with or without α-GalCer (DMSO Vehicle) D) Percentage CD69 and CD25 positive NKT and MAIT cells 
after 3 days of stimulation with or without α-GalCer (Veh). DMSO (DMSO vehicle); Alpha-galactosyl ceramide (α-GalCer); * 
p<0.05, ** p<0.01, *** p<0.001 
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PD-1 is a well-known target for immune checkpoint inhibition in cancer, as tumor cells are able to 
evade the immune system by PD-1 – PDL1/2 signaling. In conventional T cells, PD-1 is absent on naïve 
T cells but upregulated after T cell activation. Recent reports highlighted PD-1 and its ligand PD-L1/2 
as being implicated in induction and maintenance of iNKT cell anergy12–14. We therefore investigated 
whether the observed iNKT and MAIT cell dysfunction was related to aberrant PD-1 expression that 
was determined by flow cytometry (Figure 3A). Interestingly, PD-1 levels were increased both on 
iNKT and MAIT cells in BM and PB of NDMM patients (n=14) as compared to healthy controls (n=14) 
(Figure 3B). Comparable results were observed in the 5T33MM murine model (Figure S2A). We next 
assessed the impact of PD-1 blockade on MAIT cell function in NDMM patients by performing co-
culture experiments in vitro. PBMCs from 7 NDMM patients and 7 healthy controls were incubated 
for 72 hours in the presence or absence of α-GalCer with or without PD-1 blockade. Remarkably, 
activation of MAIT cells by α-GalCer stimulated iNKT was recovered in NDMM patients in presence of 
PD-1 blockade compared to the condition with α-GalCer and PD-1 block alone (Figure 3C). Similar 
immune activation by α-GalCer together with PD-1 blockade was found in the 5T33MM model 
(Figure S2B). Successful re-activation of MAIT cells by PD-1 blockade suggests that the PD-1 pathway 
is one of the contributors mediating MAIT cell dysfunction in MM and disturbing MAIT–iNKT immune 
interactions. Moreover, PD-1 blockade combined with α-GalCer stimulation led to a strong reduction 
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Figure 3: Increased PD-1 levels on MAIT and iNKT cells in NDMM patients and restoration of MAIT cell activation by iNKT 
stimulation and PD-1 blockade in vitro. A) Flow cytometry data plots illustrating PD-1 expression levels on MAIT and iNKT 
cells in the peripheral blood and BM of healthy controls (n=14) and NDMM patients (n=14). B) Percentages PD-1 positive 
NKT and MAIT cells among peripheral blood and BM in healthy controls (n=14) and NDMM patients (n=14). C) Percentage 
CD69 and CD25 positive cells within the MAIT cell population of healthy donors (n=7) and NDMM patients (n=7) after 3 days 
of stimulation with or without α-GalCer (DMSO) and anti-PD-1. DMSO (DMSO vehicle); Alpha-galactosyl ceramide (α-
GalCer); Programmed death 1 checkpoint molecule (PD-1) * p<0.05, ** p<0.01, *** p<0.001 
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To the best of our knowledge, we are the first to demonstrate that MAIT cells are numerically and 
functionally impaired in NDMM patients (For an overview of the findings see Figure 4). Additionally, 
this was found to be linked with iNKT cell deficiency and elevated PD-1 levels. PD-1 blockade 
together with α-GalCer-stimulated iNKT cells rescued this deficiency and conferred tumor protection 
in the 5T33MM murine model. These results open doors for further studies and stimulates research 
to elucidate the exact role of MAIT cells in MM. Apart from evaluating MAIT cells in other MM 
patient subsets (MGUS, smoldering MM and relapse), long-term studies in large cohorts of patients 
will allow us to evaluate if these alterations can be linked to clinical outcome. Furthermore, it is of 
interest to evaluate MAIT and iNKT cell levels in anti-PD-1 treated MM patients. However, we believe 
that the impact of MAIT cells in the MM microenvironment as well as improvement of their effector 
functions via immune checkpoint blockade represents a relevant and attractive field for 
immunosurveillance and immunotherapy in MM. In line with Richter et al. demonstrating clinical 
regression after combining lenalidomide and iNKT cell stimulation in MM patients, we provide 
supplementary evidence for harnessing invariant T cells to prevent MM15. Therefore, targeting 
invariant T cells which simultaneously stimulate both innate and adaptive immunity, together with 
PD-1 blockade, might provide a more broad immune activation and could therefore give more 
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Overview findings 
 
Figure 4: Overview general findings. The implication of checkpoint molecule PD-1, in mediating iNKT cell deficiency and 
deficiencies in mucosal-associated invariant T (MAIT) cells, another invariant T cell subset, was evaluated. Not only iNKT 
cells but also MAIT cells proved to be numerically and functionally impaired in MM (red boxes with downward arrows), a 
novel observation that hasn’t been reported before. Moreover, we discovered MAIT cell deficiency to be correlated with 
reduced iNKT cell numbers in MM (red dotted arrow line). MAIT cells showed poor activation by α-GalCer-stimulated iNKT 
cells, illustrating a dysfunctional interaction between MAIT and iNKT cells (red cross). Remarkably, elevated PD-1 levels 
were found on both iNKT and MAIT cells (red upward arrow), contributing in the immune escape, proliferation and survival 
of MM (red upward arrows). Treatment with a combination of PD-1 blockade (green blocking arrow) and α-GalCer-
mediated iNKT stimulation (green normal arrow) was able to significantly rescue the functionality of iNKT and MAIT cells 
and conferred superior tumor protection in MM (green boxes with upward arrows). However, several questions still remain 
unanswered (light blue) and will be the objective of future research. What is the role of MAIT cells in MM? What about MR1 
expression in MM? What is the mechanism between the MAIT – iNKT interaction? Are there other checkpoint molecules 
involved in the immunodysfunction of MAIT and iNKT cells? Alpha-Galactosylceramide (α-GalCer); Programmed death 
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Supplementary material and methods 
5T33MM mice 
C57BL/KaLwRijHsd mice were purchased from Envigo (Horst, The Netherlands). Housing, 
maintenance and experiments were performed following regulations approved by the Ethical 
Committee for Animal Experiments, Vrije Universiteit Brussel (CEP n° 14_281_12). The 5TMM murine 
models have been previously described 1–3. 
 
Myeloma Patients 
After informed consent, BM and peripheral blood were collected from 14 untreated NDMM patients 
and age matched healthy controls. Patient characteristics are summarized in supplementary Table 1. 
The study was conducted in accordance with principles of the Declaration of Helsinki. Research was 
approved by the Ethic Board of UZ Brussel (B.U.N. 143201316382) and Tumourbank of Lille 
(CSTMT102).  
 
Flow Cytometry and antibodies  
Immunophenotyping was determined by flow cytometry using fluorochrome-conjugated monoclonal 
antibodies (mAbs). Analyses were performed using FlowJo software (Tree Star Inc., Ashland, OR).  
Peripheral blood and BM samples from 14 healthy donors and 14 NDMM patients were collected in 
heparin-containing tubes. Human iNKT and MAIT cells were identified phenotypically as previously 
reported4–7. Mononuclear cells were obtained after Ficoll density gradient centrifugation 
(Histopaque, Sigma-Aldrich) and stained with PE-conjugated anti-human Vα24Jα18 TCR (6B11), 
PERCP Cy5.5-conjugated anti-CD161 (HP-3G10), Amcyan-conjugated anti-CD3ε (UCHT1), Pacific Blue-
conjugated anti-CD4 (OKT4), Alexa Fluor 700-conjugated anti-CD8 (OKT8), PE-eFluor 610-conjungated 
anti-PD-1 (J43) (all eBioscience, San Diego, CA), Brilliant Violet 605-conjungated anti-TCRVα7.2 (3C10, 
Biolegend, San Diego, CA) and acquired on a FACSLSRII (Becton Dickinson). Intracellular cytokine flow 
cytometry was performed to determine the expression levels of IFN-γ, IL-17, TNFα and IL-22 in MAIT 
cells of NDMM patients and healthy controls. MAIT cells were stained with PERCP Cy5.5-conjugated 
anti-IFN-γ, PERCP Cy5.5-conjugated anti-IL-17, PE-conjugated anti-TNFα, and PE-conjugated anti-IL-
22 (all eBioscience) and analyzed by flow cytometry (FACSCanto II; Becton Dickinson). For the 
analysis of activation markers, APC-conjugated CD69 (FN50) and PE-Cy7-conjugated CD25 mAbs 
(BC96, both eBioscience) were used. 
Murine liver, blood, spleen were isolated as previously described1,8. BM cells were isolated as 
described earlier in the article. Lymphocytes were isolated and resuspended in staining buffer 
containing anti-Fcγ Receptor type II/type III monoclonal antibodies (Miltenyi Biotec). Cells were 
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stained with PE-labelled CD1d/α-GalCer tetramer, FITC-conjugated anti-279 (PD-1, J43), APC-Cy7-
conjugated anti-TCRβ (H57-597), PE-Cy7-conjugated anti-CD3 (145-2C11), Pacific Blue-conjugated 
anti-NK1.1 (PK136, all eBioscience), Amcyan-conjugated anti-CD4 (RMA4-5) and 7-AAD (Both Beckton 
Dickinson) and living cells were acquired on a FACSCantoII (BD Biosciences) flow cytometer. 
 
Functional MAIT cell assays 
PBMCs (1,5 x106/ well) were incubated in complete RPMI 1640 with 2mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 10% FBS (Life technologies BRL), stimulated with Phorbol-
Myristate-Acetate (PMA, 100 ng/ml; Sigma-Aldrich), ionomycin (1 µM; Sigma-Aldrich) and brefeldin A 
(GolgiPlug; 10 µg /ml; BD Biosciences) for 4 hours and subsequently stained for MAIT markers. After 
fixation in 4% paraformaldehyde and permeabilization with Perm/Wash solution (BD Biosciences), 
MAIT cells were intracellularly stained for IFN-γ, IL-17, TNFα and IL-22 and analyzed by flow 
cytometry. 
PBMCs (1,5 x 106/ well) were stimulated with α-GalCer (100 ng/ml; Department Chemistry; Ghent 
University) or 0,1% DMSO (vehicle) and incubated with or without anti-human anti-PD-1 Ab (5 µg/ml, 
eBioscience) for 3 days in the presence of IL-2 (100 U/ml, Roche). After 72 hours, PBMCs were 
stained and analyzed by flow cytometry for MAIT cells and iNKT cells markers next to the activation 
markers CD69 and CD25.  
 
NKTMM co-culture assay 
Isolation of 5T33MMvv, 5T2MM, iNKT and BM cells were performed as previously described1,8,9,10. 
5x104 5T33MMvv / 5T33MMvt / 5T2MM cells, 5x104 iNKT cells, 105 α-GalCer loaded or vehicle loaded 
DCs were co-cultured in triplicate in presence or absence of murine anti-PD-1 Ab (5 µg/ml, Bioceros, 
The Netherlands). After 24 hours supernatants of co-cultures were collected for IFN-γ measurements 
by ELISA (eBioscience), following manufacturer’s instructions.  
 
In vivo treatment with α-GalCer and anti-PD-1 in MM 
Naive C57BL/KaLwRijHsd mice were i.v. injected with 5 x 105 5T33MM cells and i.p. injected with 200 
µg murine anti-PD-1 Ab and 2 µg α-GalCer. α-GalCer injections were repeated weekly (day 6, day 13) 
and anti-PD-1 Ab was given twice a week. Serum IFN-γ levels were determined by ELISA, 16 hours 
after i.p. α-GalCer administration (day 0 and day 6). Mice were sacrificed when first signs of 
morbidity appeared (in general at day 21). Serum M–spike levels were determined by protein 
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Statistics 
Results are expressed as mean ± SEM. Spearman’s Correlation, one-way ANOVA with Bonferroni 
correction and Mann-Whitney U-tests were used to address statistical significance. 
 
Supplementary figures 
Figure S1: Decreased iNKT cell numbers in NDMM patients compared to healthy controls. A) Flow cytometry data plots 
illustrating the iNKT cell gating strategy in the peripheral blood and BM of healthy controls (n=14) and NDMM patients 
(n=14). B) iNKT cell percentages within peripheral blood and BM T cells in healthy controls and NDMM patients. * p<0.05, 
** p<0.01, *** p<0.001 
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Figure S2: Increased PD-1 expression on iNKT cells in the 5T33MM murine model and restoration of iNKT functionality by 
PD-1 blockade in vitro. A) Percentages PD-1 positive NKT cells in liver, spleen, BM, blood of the 5T33MM murine model. B) 
Mean IFN-γ levels of murine iNKT co-culture experiments are illustrated. The experiment was performed with 5T33vv, 5T33vt 
and 5T2 MM cells. Respective conditions are iNKT cells + α-GalCer-loaded DC’s; iNKT cells + α-GC-loaded DC’s + anti-PD-1; 
iNKT cells + α-GC-loaded DC’s + MM cells; iNKT cells + α-GC-loaded DC’s + MM cells + anti-PD-1. Vivo (vv); Vitro (vt); Alpha-
Galactosylceramide (α-GalCer); Multiple myeloma cells (MM). * p<0.05, ** p<0.01, *** p<0.001 
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Figure S3: In vivo treatment of PD-1 blockade and α-GalCer restored tumor immunity in the 5T33MM murine model. A) 
Schematic overview of the experiment. C57BL/KaLwRij mice were inoculated together with 2µg α-GalCer and 200µg anti-PD-
1 at day 0. α-GalCer was re-injected weekly at day 6 and day 13. Injections with anti-PD-1 were given twice a week. 
Treatment groups were MM + veh (n=14), MM + anti-PD-1 (n=16), MM + α-GalCer (n=15), MM + α-GalCer + anti-PD-1 
(n=13). B) Serum M-spike levels and percentage malignant plasma cell in the BM. C) IFN-γ levels in the serum 16h after the 
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Supplementary table 1: Characteristics healthy controls and NDMM patients 
 Number Mean Range 
Control individuals (n= 14) 
Age (years)  62 54-76 
Gender (M/F) 8/6   
Newly Diagnosed multiple myeloma (n= 14) 
Age (years)  70 57-81 
Gender (M/F) 8/6   
M-component type 
IgG 10   
IgA 3   
IgM 1   
IgD -   
Light chain type 
kappa 7   
lambda 7   
ISS Stage1 
Stage I 4   
Stage II 6   
Stage III 4   
Adverse cytogenetics  
13q 5   
t(11,14) 9   
17p 2   
1
ISS: International Staging System 
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Treatment of multiple myeloma (MM) changed considerably over the last two decades with the 
introduction of novel therapeutic agents such as autologous stem cell transplantation, proteasome 
inhibitors and immunomodulatory drugs, as well as combination therapies, significantly improving 
the survival outcomes for patients1,2. Although few remain in long-term remission, the majority of 
MM patients still relapses and eventually dies from the disease, usually due to a resistant clone. It is 
well established today that MM is associated with a progressive immune dysregulation, resulting in a 
loss of immunosurveillance and subsequently promoting tolerance and tumor progression2. Although 
MM is primarily a disease of the B cell lineage, the T cell compartment is also strongly affected3. A 
significant loss in T cells of the CD4, CD8, iNKT and MAIT cell subsets is reported, while on the other 
hand a recruitment and a concomitant rise in suppressor cells, including Treg cells, TAMs and MDSCs 
is observed4–10. MM immune dysregulation also disturbs other aspects of the immune system as well, 
directly affecting antigen presentation and the upregulation of inhibitory antigens and checkpoint 
molecules that promotes immune escape and growth advantage for malignant clones11,12. Therefore, 
there is a crucial need to continue preclinical research and to find new therapeutic strategies to 
target the immune system in the treatment for MM. Currently, immunotherapy is revolutionizing the 
landscape of cancer treatment and has the potential to improve patient outcomes significantly in the 
future. Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has 
experienced a renaissance. This success is based on progress in both preclinical and clinical science, 
including the development of new immunotherapeutic strategies. Immunotherapy mobilizes and 
boosts the patient’s own immune system through various approaches that utilize adaptive or innate 
immunity, as previously highlighted in the general introduction (see section 4.4, Chapter I). 
In this thesis we primarily focused on iNKT cell immunology in MM. iNKT cells represent a distinct 
population of T lymphocytes, with features of both conventional T cells as well as NK cells. As a result 
of their unique ability to recognize endogenous lipid antigens in a CD1d-dependent manner, iNKT 
cells have a constitutive memory phenotype and moreover, as being one of the first responders of 
the immune system, are capable of rapidly responding to stimulation by producing a broad range of 
cytokines13. In addition, through direct interactions, in particular via CD1d and CD40L-CD40 signaling, 
as well as indirect interactions with other immune cells, iNKT cells are capable of maturing DCs and 
activating B cells, and thus are crucial in enhancing antigen-specific B-and T-cell responses14. Their 
ability to bridge the innate and adaptive immunity and their capacity to modify the immune 
microenvironment influences the capability of the host to control tumor growth, making them an 
important population to be harnessed in the clinic for the development of anti-cancer therapeutics. 
Indeed, one of the advantages of iNKT cell-targeted anti-tumor immunotherapy is that, compared 
with current anti-cancer immunotherapies (that only target one arm of the immune system), a 
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variety of anti-tumor immune effector cells, such as NK cells, B cells, neutrophils, DCs, CD8+ and CD4+ 
T cells, can be targeted simultaneously. Moreover, another benefit of iNKT cell-targeted anti-tumor 
immunotherapy over a more traditional T cell-based immunotherapy is the competency of iNKT cells 
to target both MHC-negative and MHC-positive cancer cells15. The importance of iNKT cells in tumor 
immunosurveillance is further emphasized by the observation of reduced iNKT cell numbers and an 
impaired function in a large number of cancers, including a broad range of solid malignancies but also 
in hematological malignancies, as reported by us in MM5,16–18. The use of iNKT cell deficient mice and 
the identification of strong iNKT cell glycolipid agonists, such as α-galactosylceramide (α-GalCer) and 
its analogues, have led to the development of synthetic lipids that have shown potential in 
vaccination and treatment of cancers19. 
Two main iNKT cell-directed therapeutic options have been exploited thus far, including 
administration of iNKT cell-activating ligands (all human studies described to date have used α-
GalCer), administration of antigen presenting cells (APCs) pulsed with α-GalCer, transfer of ex vivo-
expanded and/or activated iNKT cells14. The use of α-GalCer and other glycolipids has engendered 
preclinical success in mice, leading to multiple clinical trials in patients with anal cancer, renal cell 
cancer, MM, non-small cell lung cancer and head and neck squamous cell carcinoma (see Table 1, 
Chapter II). Despite the benefits for patients looking promising, results remain disappointing and far 
from effective since iNKT cell-based immunotherapy is associated with some challenges limiting its 
efficacy20. Of note, the frequency of iNKT cells is much lower in humans compared to mice and 
additionally humans also have a heterogeneous range of iNKT cell numbers, possibly contributing to 
the heterogeneity in clinical responses21–23. Although we know that low numbers of iNKT cells are 
associated with poor prognosis in autoimmune or malignant disease, it remains unknown if high or 
low numbers of iNKT cells are an important biomarker for the outcome of an iNKT cell-based 
therapy20,24,25. Studies aimed at enhancing iNKT cell-mediated anti-tumor immunity have shown that 
the use of α-GalCer leads to the potent stimulation of iNKT cells but unfortunately results in iNKT cell 
over-activation and an exhausted state26–28. This means they are sensitive to anergy which is a 
property that, next of being exploited by cancer cells as an immune evasion mechanism, could be an 
explanation for the lack of therapeutic success. Moreover, suboptimal activation due to an 
uncontrolled distribution of α-GalCer also potentially can be a problem hindering the beneficial 
effects of an iNKT cell-based immunotherapy29,30. Furthermore, the existence of different NKT 
(sub)populations, their adaptable reactivity against ligand agonists and the different APCs involved in 
the antigen presentation makes iNKT immunotherapy a more complex story13,31,32. Finally, our 
knowledge of the presence of endogenous ligands is still very limited hampering our true 
understanding of iNKT cell biology33. In order to overcome the different challenges described above 
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and to enable a correct manipulation of iNKT cells in anti-tumor therapy, it is of great interest to 
further enlarge our understanding about iNKT cell biology and the factors activating and regulating 
these cells or making them deficient in pathologic conditions and cancers such as MM.  
In this PhD project we aimed to unmask the mechanisms responsible for iNKT cell immune 
dysfunction in MM. By subsequently rescuing iNKT immune impairment anti-MM effects could be 
generated (Chapter IV and V): 
In chapter IV, we investigated the curious interplay between leptin receptor signaling and iNKT cell-
mediated anti-tumor immunity in MM. Adipocytes were recently identified as an immunosuppressive 
population in the BM niche and since an age-related increased adipose tissue mass in the BM is 
correlated with an elevated risk for MM development, we hypothesized this could be the result of a 
defective anti-tumor immunity mediated by adipokines such as leptin34. Our results revealed that 
leptin controls the iNKT cell function and modulates iNKT cell threshold activation, subsequently 
preventing long term anti-tumor effects in MM. Blockade of leptin receptor signaling with an in-
house made antagonist in combination with iNKT stimulation was able to counteract the 
immunosuppression of iNKT cells and resulted in superior tumor protection as a result of an 
alleviation of iNKT cell anergy. Interestingly, these findings may let us think that the leptin-leptin 
receptor axis acts like an immune checkpoint barrier, enhancing immune suppression and evasion in 
pathologic conditions with elevated leptin/ leptin receptor levels, such as detected in MM. Being 
confronted in our research with iNKT cell anergy induced by MM cells themselves and by repeated 
injections of α-GalCer we further elaborated on the subject. In chapter V we found that, in MM, iNKT 
cells showed a marked increase in programmed death-1 (PD-1) expression, hampering the beneficial 
and/ or long lasting effects of an iNKT cell-mediated treatment. The use of an anti-PD-1 checkpoint 
inhibitor restored their anti-tumor properties and subsequently combining PD-1 blockade with α-
GalCer stimulation led to a superior anti-MM effect. Being interested in the innate-like T cells in 
general, we also made another observation in this study. Never being investigated before in MM, we 
discovered MAIT cells to be numerically and functionally impaired in MM as well. Moreover, we 
demonstrated that their deficiency was found to be correlated with iNKT cell deficiency. A 
dysregulation of MAIT cells in cancer and especially in non-mucosa-associated cancer is gaining 
interest in the field and is becoming reported by several researchers35–42. Also on MAIT cells we 
found PD-1 levels to be high in MM. Blocking PD-1 together with iNKT cell stimulation partially 
restored the MAIT cell functionality. These observations, next to demonstrating the importance of 
blocking anergy to obtain beneficial therapeutic outcomes, also further highlights one of the 
advantages of iNKT cell immunotherapy described above, being the ability to activate different other 
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effector cells of the immune system. However, the role and function of MAIT cells in MM remains 
unknown and certainly needs investigation in the future. 
We can state that anergy affects the efficacy of an iNKT cell-based immunotherapy in cancers, such 
as MM, in two ways: On the one hand, anergy is used as a switch-off mechanism for the immune 
system by the cancer itself to enhance immune escape43. On the other hand, studies aimed at 
enhancing iNKT cell-mediated anti-tumor immunity have shown that multiple use of α-GalCer leads 
to the potent over-activation of iNKT cells but results in a functionally blunted state because of 
anergy induction26,28,44. In the next paragraph, we will discuss and suggest some future approaches to 
overcome anergy hampering the success of an iNKT cell-based immunotherapy in cancer, and thus 
also in MM. 
1. As a first approach to improve iNKT cell-based immunotherapy we suggest the targeting of 
immune checkpoint proteins. The scientific turning point for cancer immunotherapy came with the 
understanding that T cell immune responses are controlled through on and off switches, so called 
‘immune checkpoints’ that protect the body from possibly damaging immune responses. Immune 
checkpoint pathways, such as PD-1 and CTLA-4 help to maintain immune equilibrium in health but 
are upregulated in the presence of malignancy, fostering a state of immune tolerance. The 
upregulation of these negative costimulatory signals induces an anergic state of T cells, blunting T cell 
activation and expansion, and blocking T cell–mediated killing of cancer cells45. PD-1 ligands, PD-L1 or 
PD-L2, are frequently expressed on tumor cells and can further minimize the immune response. 
Remarkable results with different PD-1 (nivolumab, pidilizumab and pembrolizumab) and PD-L1 
(atezolizumab and avelumab) inhibitors indicated promising clinical efficacy and a well-tolerated 
toxicity profile in various cancer patients with melanoma, non-small cell lung cancer, kidney cancer 
and head and neck cancers46,47,48–50. Also in hematological malignancies immune checkpoint blockade 
looks a promising strategy to revert anergy of the immune system51. PD-L1 is expressed in a variety of 
hematological malignancies such as leukemia and peripheral T-cell lymphoma and has been 
correlated to poor prognosis52–55. In MM, studies have demonstrated the expression of PD-L1 on MM 
cells and immune cells and expression of PD-1 on different T cell subsets and natural killer cells 
within the MM microenvironment56–58. In chapter V we revealed that the majority of iNKT and MAIT 
cells of MM patients expressed PD-1 and that PD-1 blockade ameliorated the iNKT cell-based 
immunotherapy. This is in line with others who have shown that PD-1 possesses a significant impact 
in α-GalCer-induced iNKT cell anergy59. Namely, iNKT cells from α-GalCer-treated PD-1-deficient mice 
do not show an anergic response to α-GalCer-stimulation and α-GalCer-induced anergy can even be 
prevented in WT mice by blocking the PD-1/PD-L interaction by using anti-PD-1 or a combination of 
anti-PD-L1 and anti-PDL-2 mAbs59. In a mouse B16 melanoma model, the anti-metastatic activities of 
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α-GalCer-activated iNKT cells could be restored by abrogating the PD-1/PD-L1 interaction during 
initial α-GalCer treatment59. In the future, we would like to investigate the blocking of PD-L1 and PD-
L2. Based on the known interactions of the PD-1 ligands, it is theoretically possible that the PD-1 
antibody has a distinct biological activity from PD-ligand antibodies. A PD-1 antibody blocks PD-1 
interaction with both PD-L1 and PD-L2 but not the interaction between PD-L1 and CD80 while most 
PD-L1 antibodies block the interaction between PDL1 and CD80 and between PD-L1 and PD-1 but not 
with PD-L260. Thus, it is possible that using a combination of both would ameliorate the therapeutic 
effects even more. 
However, blockade of the CTLA-4 and PD-1/PD-L1 pathways only represents the tip of the iceberg in 
the realm of potential immune checkpoint targets. Ongoing studies on regulation of immune 
responses have led to the identification of multiple other immunologic checkpoint pathways namely 
lymphocyte activation gene 3 protein (LAG-3), T cell immunoglobulin mucin receptor 3 (TIM-3), T-cell 
immunoreceptor with Ig and ITIM domains (TIGIT) and V-domain immunoglobulin (Ig)-containing 
suppressor of T cell activation (VISTA)61,62. Preclinical studies also indicated the possibility of 
simultaneous co-expression of different checkpoint molecules, such as LAG-3 or TIM-3 being co-
expressed with PD-1 on tumor-infiltrating lymphocytes63,64. This could lead, without simultaneous 
targeting, to a suboptimal response to immunotherapy. Regarding the improvement of the iNKT cell-
based immunotherapeutic approach it should therefore be of great value to further investigate these 
different newly identified checkpoint proteins and their relation with iNKT cell anergy. Moreover, we 
are convinced that the list of immune checkpoint molecules is still far from being complete. In our 
search for mechanisms contributing to iNKT cell dysfunction in MM, we discovered a new immune 
checkpoint therapeutic approach that alleviated iNKT cell anergy and prolonged the activation of α-
GalCer-stimulated iNKT cells: the targeting of the leptin-leptin receptor axis mediated by the 
immunosuppressive adipocytes in the MM microenvironment (Chapter V). However, the mechanisms 
behind leptin-induced anergy in MM are still unknown and should clearly be the subject of further 
investigation. The use of a conditional leptin and/or leptin receptor knock out in MM in future 
research could help elucidate this part of the story. Moreover, understanding the contribution of 
leptin an its receptor in mediating anergy could also be beneficial for the treatment of a large variety 
of other cancers such as breast, pancreas, lung, thyroid, endometrial and gastrointestinal cancer, 
where the leptin-leptin receptor axis also clearly plays a role in the pathology65,66. Given the results 
achieved within this PhD project, it would be of interest to study whether simultaneous blockade of 
the leptin receptor and PD-1 together with the stimulation of iNKT cells with α-GalCer or another 
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2. In addition to inhibitory checkpoint molecules, it has become clear that co-stimulatory 
molecules are also involved in T cell exhaustion. Co-stimulatory molecules can be subdivided in the 
ICOS/ICOSL family, the B7/CD28 family, the CD40/CD40L family and tumor necrosis factor 
(TNF)/tumor necrosis factor receptor family, including molecules such as OX40 (CD134) and 4-1BB 
(CD137)67. All of the above mentioned molecules were demonstrated to be involved in iNKT cell co-
stimulation as reviewed in 68. Desensitization of co-stimulatory pathway signaling through the loss of 
adaptor molecules can result in anergy and allow tumors to evade the immune system69. Therefore it 
could be relevant to exploit the potential beneficial role of co-stimulation, eventually together with 
immune checkpoint blockade to reverse exhaustion by using agonistic antibodies to positive co-
stimulatory pathways, and by this way improve iNKT cell based-immunotherapy.  
3. Target altered gene expression. Recent reports have demonstrated that induction of E3 
ubiquitin ligases, including Casitas B cell lymphoma-b (CBl-b), Itch, Deltex-1, and gene related to 
anergy in lymphocytes (GRAIL), is required to induce and maintain T cell anergy, thus implicating the 
protein ubiquitination pathway in development of immune tolerance70–73. The E3 ubiquitin ligase 
GRAIL functions via the ubiquitination and degradation of actin cytoskeleton-associated proteins, in 
particular Arp2/3-5 and coronin 1A, thereby maintaining the unresponsive state of anergic T cells74. 
Wu et al. demonstrated the implication of an impaired upregulation of GRAIL expression in α-GalCer-
induced anergy of iNKT cells75. Deltex-1 is a transcription target of the nuclear factor of activated T 
cells (NFAT). As a result of an upregulation of Calcium and NFAT signaling, Deltex-1 expression 
increases during T cell anergy. Subsequently, the expression of two anergy-associated molecules: 
growth arrest and DNA-damage-inducible 45 β (Gadd45β) and CBl-b is upregulated73. The E3 ligase 
Itch was currently only reported to mediate tolerogenic/ anergic processes in Th2 cells via mitogen 
and extracellular kinase kinase 1 (MEKK1) - JNK signaling. Both the role of GRAIL, Deltex-1 and Itch in 
α-GalCer-induced iNKT cell anergy is till now unclear, but interesting to further look into. Especially 
since CBl-b was recently demonstrated to be directly involved in α-GalCer-induced iNKT cell anergy76. 
Kojo et al. namely observed that α-GalCer experienced iNKT cells had an enhanced CBl-b expression, 
stimulating the monoubiquitination of Caspase recruitment domain-containing protein 11 (CARMA1) 
and consequently affecting IFN-γ production through the NF-κB activation pathway. Interestingly, 
CBl-b-deficiency largely rescued reduced IFN-γ production, while CARMA1 deficiency drastically 
reduced the iNKT cell IFN-γ production in response to α-GalCer treatment76. These observations may 
indicate that α-GalCer experienced iNKT cells may have distinct regulatory mechanisms of 
hyporesponsiveness and impaired cytokine production. Furthermore, Safford et al. identified the zinc 
finger transcription factor early growth response gene 2 (Egr2) and Egr3, as being associated with an 
increase in CBl-b77. Consequently, targeting CBl-b, Egr2 and/ or Egr 3 by small molecule or peptide 
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antagonists and CARMA1 by agonists could clearly be of benefit in a combinatory administration with 
α-GalCer to prevent iNKT cell anergy. 
Additionally, tuberous sclerosis 1 (TSC1), a negative regulator of the mTOR signaling was identified by 
Wu and colleagues to also play a crucial role in iNKT cell anergy as well75. Deficiency of TSC1 in iNKT 
cells resulted in resistance to α-GalCer-induced anergy. In response to secondary antigen stimulation, 
an increased expansion and cytokine production by iNKT cells was observed. Moreover, TSC1 
appeared to be correlated with an impaired upregulation of PD-1, Egr2, and GRAIL. Interestingly, 
TSC1-deficient iNKT cells displayed enhanced anti-tumor immunity in a melanoma lung metastasis 
model75. Targeting TSC1 looks very promising as a strategy for improving α-GalCer-induced anergy. 
To conclude, Stephen et al. also identified a new mechanism potentially mediating T cell 
exhaustion78. Briefly, they found that TCR activation induced increases in chromatin organizer special 
AT-rich sequence-binding protein-1 (Satb1) expression. Focusing on the immunosuppressive cytokine 
TGF-β, present in high amounts in tumor microenvironments such as MM, they observed that TGF-β 
reduces Satb1 levels and elicited higher PD-1 expression levels in activated T cells78. This suggests 
that Satb1 contributes to restrain PD-1 expression. Understanding the full spectrum of activities of 
the genomic organizer Satb1 in the process of T cell exhaustion could be required for further 
advances in preventing tumor-mediated T cell exhaustion and could also be an interesting approach 
to ameliorate iNKT cell-based immunotherapy. 
4. iNKT cell agonists or α-GalCer derivates. The identification and optimization of iNKT cell 
agonists or α-GalCer derivates which can superiorly promote Th1 anti-tumor responses without 
inducing iNKT cell anergy are also of high priority. The search for efficient iNKT agonists with 
functional differences, including optimized cytokine induction profiles, compared to α-GalCer should 
help to reduce anergy in the future and is currently intensively investigated (reviewed in79). For 
example, the C-glycoside analogue of α-GalCer (α-C-GalCer) elicits a strong Th1 cytokine iNKT cell 
response and increased the immunogenicity by as much as 1000-fold80. The novel 7DW8–5 analogue 
of α-GalCer also showed to be at least 100-fold more active at stimulating human and mouse iNKT 
cells81. Recently Huang et al. demonstrated that phenyl-glycolipids compared to α-GalCer could 
restimulate iNKT cells to secrete Th1/Th2 cytokines upon second exposure without inducing anergy44. 
Phenyl-glycolipids displayed greater binding avidity and stability for iNKT T cell receptors (TCRs) when 
complexed with CD1d, driving higher TCR signaling, Th1 polarization and greater anti-cancer 
potency44. Previous work performed by colleague Aspeslagh S. showed that NU-α-GalCer, is a much 
more potent glycolipid than α-GalCer in terms of IFN-γ and IL-12 production and thus enhanced a 
more favorable Th1 polarization of iNKT cells82. Additionally, she found PyrC-α-GalCer (carbamate 
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glycolipid) to induce a 12-fold increase of IL-12 production compared to α-GalCer and a 4-fold 
increase compared to NU-α-GalCer, as well as superior anti-tumor responses in the B16 melanoma 
model83. The results of these altered lipids represent an exciting new opportunity to optimize 
therapeutic approaches as performed in this PhD project. 
5. Loading of α-GalCer onto new delivery systems. A last approach that would be of great value 
to investigate and could lead to less anergy, allowing multiple injections and therefore a more 
prolonged response could be the loading of α-GalCer onto new delivery systems, such as liposomes , 
bacterial membranes, fusion proteins and (d)exosomes29,30. This could overcome a suboptimal 
activation due to an uncontrolled distribution of α-GalCer, what explains the low benefits of the 
currently used activation systems. Several experimental approaches can be and are currently 
developed to assist in targeting the delivery of α-GalCer to specific sites for more directed activation 
of iNKT cells. Nakamura et al. incorporated α-GalCer into stearylated octaarginine-modified 
liposomes (R8-Lip), a delivery system developed for vaccines84,85. Making use of α-GalCer/R8-
Liposomes, α-GalCer presentation on CD1d in APCs was enhanced resulting in an expansion of iNKT 
cells. Moreover, positive therapeutic effects were obtained against highly malignant B16 melanoma 
cells. They showed R8-Lip to be a potent delivery system and demonstrated that size control and R8-
modification in liposomal construction are promising techniques for achieving an efficient systemic 
administration of α-GalCer84. Similar results were obtained with unmethylated cytosine-
phosphorothioate-guanine oligodeoxynucleotides encapsulated in cationic liposomes (CpG-
liposomes)86. However, the effect on iNKT cell anergy was not yet investigated, similar liposome 
approaches are worthy to be further investigated. Another relatively simple and effective delivery 
method which could ameliorate both iNKT cell anergy and glycolipid toxicity, is the direct 
incorporation of glycolipids into bacterial membranes87. Further strategies for the improved delivery 
of glycolipid antigens could also be the use of specific-antibody/CD1d fusion proteins that are loaded 
ex vivo with α-GalCer. The administration of α-GalCer pulsed CD1d protein fused with an anti-HER2 
single chain antibody Fv fragment (scFv) induced a potent anti-tumor response in a mouse tumor 
model using HER2-expressing B16 melanoma cells. Importantly, repeated injections of this fusion 
protein led to sustained iNKT cell activation with reduced anergy induction88. The group of Thapa et 
al. avoided α-GalCer-induced anergy with poly-lactic acid based nanoparticles conjugated with α-
GalCer89. Recently, Gehrmann et al. reported that exosomes loaded with α-GalCer and ovalbumin 
activated iNKT cells, overcame anergy induction, and amplified tumor-specific adaptive immune30. 
Based on these interesting findings, our lab started to investigate if the use of dexosomes (exosomes 
originating from DCs) can be used as a delivery vehicle for α-GalCer to extend iNKT cell activation, 
reduce the subsequent anergy and increase anti-myeloma responses in the 5T33MM murine model. 
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Although this research is still in its infancy, the first in vivo results looks promising. More work is 
needed on optimizing the directed delivery of iNKT cell activators, which may allow the avoidance of 
anergy and result in the full therapeutic benefit without provoking unwanted toxic effects. 
Finally, a critical number of general issues need to be considered in immune-targeted cancer therapy 
and are thus also concerning the iNKT cell-based immunotherapeutic strategy in MM. The first is the 
time point of administration. The optimal therapeutic window should be at the beginning of the 
disease when the cancer is starting to develop and not aggressive yet (as performed in this project in 
the 5T33MM murine model and in newly diagnosed MM patients), or when patients are in minimal 
residual disease after responding well to conventional treatments. At this point, patients are not 
immune compromised making them susceptible to immune stimulation. As seen in our 5T33MM 
murine model, iNKT cells are only responsive in a low tumor burden setting. Secondly, the expression 
of immune checkpoint receptors and the presence of their cognate ligands on tumor cells or other 
immune cells within the tumor microenvironment is also an important point to mention. A number 
of studies namely demonstrated a better efficacy with immune checkpoint blockade in patients who 
had high levels of CTLA-4 and PD-1 on immune cells in the tumor microenvironment and high 
expression of CTLA-4 and PD-L1 ligands on the tumor cells 90–93. Furthermore, neo-antigens created 
by the multiple somatic mutations positively correlated with a response to PD-1 inhibitors in non-
small cell lung cancer and CTLA-4 inhibitors in melanoma94,95. The main challenge here will be the 
development of diagnostic tools that will enable to stratify and select the appropriate patient 
population; and the designing of biomarker strategies that would give the potential to predict the 
response to therapy to maximize treatment efficacy. Finally, it is also evident that the successful 
deployment of immunotherapy such as the iNKT cell-based immunotherapeutic strategy will require 
a combined approach, in which specific targeting of MM cells is paired with tactics reversing the 
hyporesponsive anergic milieu. Meaningful synergistic effects and long-term survival benefits are 
anticipated with such strategies. However, precautions should be considered so that these 
combinations are well tolerated. 
In conclusion, our data contribute to the understanding of iNKT cell biology in MM and has given us 
more insights in the concept of anergy impeding iNKT cell-based immunotherapy. Pursuing the above 
mentioned approaches, noting and addressing their limitations, will lead to the improvement of iNKT 
cell-based immunotherapy which will be beneficial for the therapy of MM patients. 
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was me dit niet gelukt. Dr. Louis Boon ook u anti-PD(L)1 antilichamen waren onmisbaar tijdens mn 
onderzoek. Een Haematologica paper om trots op te zijn mede dankzij u! Nathalie, alors pour toi se 
sera un petit mots en français: je te dis un grand merci du fond du coeur pour tout ce que tu as fait 
pour moi à Lille. Ton professionnalisme dans le domaine de la cytométrie est d’une qualité excellente 
et ta joie de vivre, ton enthousiasme faisait de toi un personne avec qui il était agréable de travailler. 
J’aimais bien venir te rendre visite à Lille! Merci Prof. Dr. Xavier Leleu pour les multiples échantillons 
de patients que vous m’avez procurés. Cela a haussé la qualité de ma recherche. Emeline, Samy, 
Elisabeth merci d’avoir été les chouettes collègues de Lille, qui n’hésitaient pas à m’aider de temps 
en temps. 
Wat zou ik zonder al mijn vrienden zijn die er altijd al voor me geweest zijn. Jullie wisten me te 
motiveren, op te krikken wanneer nodig en wisten ontspannende momenten in te lassen wanneer ik 
er even tussenuit moest. Béa, Mabi & Elise mijn luisterende oren waar ik altijd tot vervelens toe mag 
tegen klagen, mijn grootste geheimen aan kan vertellen, mee op reis kan gaan en voor alles bij 
terecht kan. Echte hartsvriendinnen die me steunen door dik en dun! Reinhilde, Jo, Katrien en 
Cardoen ook jullie hebben jullie steentje bijgedragen en zijn onmisbaar voor me geworden. Ook een 
bijzondere dankuwel aan de Duveltjes, mijn vrienden van het middelbaar waar plezier en vertier 




gegaan het laatste jaar maar toch blijven jullie me nauw aan het hart liggen. Elisah, Sam, Lieselot, 
Michiel en Wietje die “het jongske” graag bemoederen of de rol van grote broer/zus met plezier op 
zich nemen. Klimvriendjes, dankzij jullie heb ik er ook een nieuwe hobby bij. Wekelijks verleg ik mn 
grenzen en kan ik alles van me afzetten door te klimmen. Het schrikt mij niet meer af om buiten mn 
comfort zone te komen. Een muur of rotswand beklauteren, een uitdaging aangaan, grenzen 
verleggen, allemaal geen probleem meer voor deze rostie en dat heb ik grotendeels aan jullie te 
danken! Ik kan altijd op jullie rekenen en jullie zijn er altijd om me een schouderklopje te bezorgen 
wanneer nodig. Benjamin, Vincent, Eron, Elien en Charlotte, de topvrienden van Maarten, wat ben ik 
blij jullie te hebben leren kennen want nu heb ik er extra fantastische vrienden bij! 
Liefste maman et papa. Que dire à part... “merci merci merci et je vous aime tellement”. Van kleins 
af aan hebben jullie me ondergedompeld in een taalbad van Frans en Nederlands waardoor ik nu de 
grote troef bezit om zonder enige moeite van het ene taaltje naar het andere te huppelen. Ik ben 
jullie daar altijd al zo dankbaar voor geweest. Bedankt om van jongs af aan ook altijd meer in mij te 
hebben geloofd dan ik zelf kon. Ik weet hoe nauw het jullie aan het hart lag om mij en de broers die 
studeerkansen te gunnen en hoe gedreven jullie waren om ons hierin zoveel mogelijk te steunen. Ik 
kan enkel maar concluderen dat ik zonder jullie nooit zover zou geraakt zijn. Het feit dat ik mn 
doctoraat kan afleggen heb ik voor een groot deel aan jullie te danken. Ik hoop dat jullie uitermate 
trots op me zijn maar vooral ook op jullie zelf. Zie dit als een kers op de taart na een jarenlange 
opvoeding als ouders. Niels en Jens, mn petje en mn jetje, ook jullie hebben jullie grote zus elk op 
een eigenwijze manier weten te steunen wanneer het nodig was. Ik ben een fiere grote zus!!! Thanks 
bro’s en liefjes!! Nonkel Eric en tantemie Cindy ook jullie zijn onmisbaar in dit dankwoord. Dank u 
voor alles en om er altijd zo voor me te zijn. Bedankt ook aan mijn schoonouders te wege Marijke en 
Stephane, schoonzusje Elien en vriend Yannis en schoongrootouders om altijd zo lief en gastvrij te 
zijn voor mij. Wat ben ik een gelukzak met zo een schoonfamilie! Ik doe mn best om een zo goed 
mogelijk liefje te zijn voor jullie Maarten alsook een top tante Méré voor Estée!  
En tot slot, liefje Maarten, plots werd je de belangrijkste persoon in mn leven, terwijl we elkaar 
voordien al regelmatig kruisten tijdens het klimmen. Best wel grappig hoe het allemaal gelopen is! 
Onze vrienden met hun multipele koppelpogingen... daar hadden we toch niet te veel van gemerkt. 
Uiteindelijk vonden we zelf onze weg naar elkaar. Wat een eer om het liefje te mogen zijn van zo een 
sterke klimmer (of zeg ik nu beter alpinist) en daarenboven intelligente, behulpzame, luisterende, 
ongelooflijke lieve jongen met nog zoveel andere ontelbare kwaliteiten! Ik heb het je niet altijd even 
makkelijk gemaakt het afgelopen jaar en ik wil je zo hard bedanken om het te hebben volgehouden 
met mij ;-). Je weet lijk geen ander hoe me te steunen, te troosten, te motiveren en nieuwe 




vangen wanneer je het nodig hebt. Het is misschien cliché maar je bent mn rots in de branding, de 
perfecte persoon die ik nodig heb aan mn zijde. Laten we nu samen de wereld verder ontdekken en 












Als student krijgt gij kennis voorgeschoteld. En die is af. Klaar. En gedrukt.  
 Maar als jonge onderzoeker begint gij kennis te vergaren. Rommelig en sukkelachtig. 
Soms zijt gij vermoeid, soms niet in vorm. En ge denkt voortdurend: “ik ben aan het prutsen, 
ik ben daar niet voor gemaakt, mijn onderzoek moet zijn gelijk al die colleges die ge gekregen 
hebt” – Even systematisch, even smetteloos.  
 Totdat ge beseft dat dát ook maar een façade is. Totdat ge beseft dat uw Proffen 
vroeger en uw collega’s nu, ook maar aan het prutsen zijn. ’t is pas achteraf dat we voor de 
buitenwereld een orde forceren, dat we ons gepruts wegschrapen en doen alsof er vanaf het 
begin af aan logica in zat. 
 
 
 Soms denk ik: “ ’t is spijtig dat er op zuiver onderzoek altijd vlekken van ’t gewone 
leven moeten zitten. Maar nu weet ik dat het ’t misschien wel juist het tegendeel is. Dat 
zuiver onderzoek niet meer is dan een paar vlekjes op de rest van de wereld.” 
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